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Abstract
CATheter Infections in CHildren (CATCH): a randomised
controlled trial and economic evaluation comparing
impregnated and standard central venous catheters
in children
Katie Harron,1 Quen Mok,2 Kerry Dwan,3 Colin H Ridyard,4
Tracy Moitt,3 Michael Millar,5 Padmanabhan Ramnarayan,2
Shane M Tibby,6 Berit Muller-Pebody,7 Dyfrig A Hughes,4
Carrol Gamble3 and Ruth E Gilbert1*
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Background: Impregnated central venous catheters (CVCs) are recommended for adults to reduce
bloodstream infection (BSI) but not for children.
Objective: To determine the effectiveness of impregnated compared with standard CVCs for reducing BSI
in children admitted for intensive care.
Design: Multicentre randomised controlled trial, cost-effectiveness analysis from a NHS perspective and a
generalisability analysis and cost impact analysis.
Setting: 14 English paediatric intensive care units (PICUs) in England.
Participants: Children aged < 16 years admitted to a PICU and expected to require a CVC for ≥ 3 days.
Interventions: Heparin-bonded, antibiotic-impregnated (rifampicin and minocycline) or standard
polyurethane CVCs, allocated randomly (1 : 1 : 1). The intervention was blinded to all but inserting clinicians.
Main outcome measure: Time to first BSI sampled between 48 hours after randomisation and 48 hours
after CVC removal. The following data were used in the trial: trial case report forms; hospital
administrative data for 6 months pre and post randomisation; and national-linked PICU audit and
laboratory data.
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Results: In total, 1859 children were randomised, of whom 501 were randomised prospectively and 1358
were randomised as an emergency; of these, 984 subsequently provided deferred consent for follow-up.
Clinical effectiveness – BSIs occurred in 3.59% (18/502) of children randomised to standard CVCs, 1.44%
(7/486) of children randomised to antibiotic CVCs and 3.42% (17/497) of children randomised to heparin
CVCs. Primary analyses comparing impregnated (antibiotic and heparin CVCs) with standard CVCs showed
no effect of impregnated CVCs [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.37 to 1.34].
Secondary analyses showed that antibiotic CVCs were superior to standard CVCs (HR 0.43, 95% CI 0.20
to 0.96) but heparin CVCs were not (HR 1.04, 95% CI 0.53 to 2.03). Time to thrombosis, mortality by
30 days and minocycline/rifampicin resistance did not differ by CVC. Cost-effectiveness – heparin CVCs
were not clinically effective and therefore were not cost-effective. The incremental cost of antibiotic
CVCs compared with standard CVCs over a 6-month time horizon was £1160 (95% CI –£4743 to £6962),
with an incremental cost-effectiveness ratio of £54,057 per BSI avoided. There was considerable
uncertainty in costs: antibiotic CVCs had a probability of 0.35 of being dominant. Based on index hospital
stay costs only, antibiotic CVCs were associated with a saving of £97,543 per BSI averted. The estimated
value of health-care resources associated with each BSI was £10,975 (95% CI –£2801 to £24,751).
Generalisability and cost-impact – the baseline risk of BSI in 2012 for PICUs in England was 4.58 (95% CI
4.42 to 4.74) per 1000 bed-days. An estimated 232 BSIs could have been averted in 2012 using antibiotic
CVCs. The additional cost of purchasing antibiotic CVCs for all children who require them (£36 per CVC)
would be less than the value of resources associated with managing BSIs in PICUs with standard BSI rates
of > 1.2 per 1000 CVC-days.
Conclusions: The primary outcome did not differ between impregnated and standard CVCs. However,
antibiotic-impregnated CVCs significantly reduced the risk of BSI compared with standard and heparin
CVCs. Adoption of antibiotic-impregnated CVCs could be beneficial even for PICUs with low BSI rates,
although uncertainty remains whether or not they represent value for money to the NHS. Limitations –
inserting clinicians were not blinded to allocation and a lower than expected event rate meant that there
was limited power for head-to-head comparisons of each type of impregnation. Future work – adoption of
impregnated CVCs in PICUs should be considered and could be monitored through linkage of electronic
health-care data and clinical data on CVC use with laboratory surveillance data on BSI.
Trial registration: ClinicalTrials.gov NCT01029717.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 20, No. 18. See the NIHR Journals Library website
for further project information.
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Glossary
Bundled Healthcare Resource Group Healthcare Resource Group referring to a patient pathway of care
such as a ward stay.
Unbundled Healthcare Resource Group A high-cost or specialist service Healthcare Resource Group in
addition to a patient pathway of care.
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Plain English summary
Children who are admitted to hospital for intensive care often need to have medicines given directly intotheir veins, through a small plastic tube called a central venous catheter (CVC). CVCs avoid the need
for repeated injections, but their disadvantage is an increased risk of bloodstream infection (BSI), which can
result in prolonged treatment and time in hospital.
In adults, CVCs coated with medicine to kill bacteria (antibiotics) or prevent clots (heparin) help reduce the
risk of BSI. However, we do not know if coating the much narrower CVCs used for children would work
in the same way. The only way to find out which type of CVC (standard non-coated, antibiotic coated or
heparin coated) works best was to carry out a randomised controlled trial.
Children aged < 16 years who needed a CVC for intensive care treatment participated within 14 hospitals
in England. Consent was provided for all participants in the trial. Each child had an equal chance of
receiving one of the three CVC types.
Bloodstream infection occurred in 4% of children with standard CVCs and 2% of those with impregnated
CVCs. Rates of BSI were lowest in the antibiotic CVC group (1%) but these children had slightly higher
health-care costs for the 6 months after trial participation. Although doubt remains whether or not
antibiotic CVCs would result in cost savings for the NHS in England, our results suggest that using
antibiotic CVCs could help reduce BSI rates for children in intensive care.
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Scientific summary
Background
Bloodstream infection (BSI) is an important cause of adverse clinical outcomes and costs to the NHS in
the UK. Paediatric intensive care units (PICUs) have one of the highest reported rates of hospital-acquired
BSI of any clinical specialty.
Nine systematic reviews, two cost-effectiveness analyses and at least 48 randomised controlled trials
(RCTs; 11,586 patients) have demonstrated substantial benefits of impregnated central venous catheters
(CVCs) for reducing catheter-related BSI (CR-BSI) in adults. The best evidence to date shows that
antibiotic-impregnated or heparin-bonded CVCs are most effective, producing similar reductions in risk of
CR-BSI (70–80%). However, there is a lack of child-specific evidence for impregnated CVCs and they are
not recommended for children in UK or US guidance. We compared both types of impregnated CVC
(antibiotic and heparin) with standard CVCs to determine their effectiveness in children. Secondary
analyses were conducted to investigate the effectiveness of each type of impregnation.
Objectives
1. To determine the clinical effectiveness of impregnated compared with standard CVCs for reducing BSI
in children admitted for intensive care.
2. To determine the cost-effectiveness of impregnated CVCs from a NHS perspective.
3. To inform purchasing by assessing the generalisability and the cost impact of adopting impregnated
CVCs for all children who need them.
Randomised controlled trial: clinical effectiveness
Methods
We conducted a three-arm RCT to compare the effect of heparin-bonded, antibiotic-impregnated and
standard polyurethane CVCs on BSI in children requiring intensive care. The RCT is registered at
ClinicalTrials.gov (reference number NCT01029717).
Design, study population and intervention
Children admitted to 14 PICUs in England between December 2010 and November 2012 were
randomised to heparin-bonded, antibiotic-impregnated or standard CVCs manufactured by Cook Medical
Incorporated (Bloomington, IN, USA).
Children aged < 16 years were eligible if they were admitted or being prepared for admission to a
participating PICU and were expected to require a CVC for ≥ 3 days. For children admitted to a PICU
following elective surgery, we sought prospective parental consent during preoperative assessment.
For children who required a CVC as an emergency, we sought parental consent after randomisation and
stabilisation (deferred consent) to avoid delaying treatment.
Randomisation and masking
Children were randomised at the bedside or in theatre immediately before CVC insertion. Randomisation
sequences were computer generated in a 1 : 1 : 1 ratio, stratified by method of consent, site and envelope
storage location within the site.
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The clinician responsible for inserting the CVC was not blinded to CVC allocation (because of different
colour strips for impregnated CVCs) but, as the CVCs looked identical whilst in situ, allocation was
concealed from patients, their parents and PICU personnel responsible for their care.
Comparisons and end points
The primary analysis in the trial compared antibiotic or heparin CVCs with standard CVCs. Secondary
analyses consisted of three-way comparisons between standard, antibiotic and heparin CVCs.
The primary outcome was time to the first BSI based on blood cultures taken between 48 hours after
randomisation and 48 hours after CVC removal (or prior to death). All blood culture samples were clinically
indicated, defined by recorded evidence of infection (one or more of temperature instability, change in
inotrope requirements, haemodynamic instability or poor perfusion) or removal of the CVC because of
suspected infection. Any positive blood culture was accepted for a non-skin organism, but for skin
organisms two or more positive cultures within 48 hours of each other were required.
Secondary BSI-related outcomes were:
1. CR-BSI: the same organisms cultured from blood and the CVC tip between 48 hours after
randomisation and 48 hours after CVC removal; or differential positivity of cultures from multiple CVC
lumens on two or more occasions; or BSI and exit site infection or BSI and CVC removed for
suspected infection
2. rate of BSI per 1000 CVC-days: number of BSIs between randomisation and CVC removal
3. time to a composite measure of BSI consisting of the primary outcome or a negative blood culture
combined with a positive 16S polymerase chain reaction result for bacterial ribosomal ribonucleic acid,
removal of the CVC because of suspected infection or a start of antibiotics or change in type of
antibiotics on the same or next day.
We also compared time to CVC removal, CVC thrombosis, PICU discharge, hospital discharge and
mortality within 30 days. Safety analyses compared CVC-related adverse events, mortality and antibiotic
resistance to minocycline (> 0.5 µg/ml) or rifampicin (> 1.0 µg/ml).
Sample size
In total, 1200 children were required to achieve 80% power to detect a relative risk of 0.5 at a 5% level of
significance, based on an estimated BSI rate of 10% and allowing for 5% loss to follow-up.
Statistical analysis
Outcome data were analysed according to the intention-to-treat principle. Safety analyses included the
subset of children for whom CVC insertion was attempted, grouped by CVC actually received or, if
insertion was not successful, the type used in the attempt.
The statistical analysis plan was developed prior to analysis and is available in Appendix 1. Time-to-event
outcomes were analysed using Kaplan–Meier curves and the log-rank test. Cox regression was used to
adjust the primary analysis of time to BSI for the use of prospective or deferred consent and suspected
infection at baseline. Poisson regression was used to analyse the rate of BSI. All analyses were conducted
using SAS software (version 9.2; SAS Institute Inc., Cary, NC, USA).
Results
Study population
In total, 1859 children were randomised, of whom 501 children were randomised prospectively and 1358
were randomised as an emergency; of those randomised as an emergency, 984 subsequently provided
deferred consent for follow-up.
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Baseline characteristics
In total, 58% of the children were aged < 12 months at admission and 33% were aged < 3 months.
One-third had surgery prior to admission to the PICU and half had cardiovascular problems as their primary
diagnosis at admission. CVC insertion took place in theatre for 437 out of 493 (89%) in the prospective
consent (elective) group but in only 34 out of 917 (4%) of the deferred consent (emergency) group.
End points
Primary outcome
Bloodstream infection was recorded for 42 children [standard group 18/502 (3.59%); antibiotic group
7/486 (1.44%); heparin group 17/497 (3.42%)]. There was no significant difference in the primary
outcome of time to first BSI comparing any impregnated CVC with the standard CVC [hazard ratio (HR)
0.71, 95% confidence interval (CI) 0.37 to 1.34; p= 0.29]. BSI risk was reduced for antibiotic compared
with standard CVCs (HR 0.43, 95% CI 0.20 to 0.96; p= 0.04) and for antibiotic compared with heparin
CVCs (HR 0.42, 95% CI 0.19 to 0.93; p= 0.03) but not for heparin compared with standard CVCs
(HR 1.04, 95% CI 0.53 to 2.03; p= 0.90). The risk difference in BSI comparing any impregnated CVC with
standard CVCs was –1.14 (95% CI –3.04 to 0.75) (heparin vs. standard CVCs –0.17, 95% CI –2.45 to
2.12; antibiotic vs. standard CVCs –2.15, 95% CI –4.09 to –0.20; antibiotic vs. heparin CVCs –1.98,
95% CI –3.90 to –0.06).
Secondary outcomes
For CR-BSI there was no significant difference between any impregnated CVC and standard CVCs (p= 0.13)
but the risk of CR-BSI was significantly lower for antibiotic CVCs than for standard CVCs (p= 0.03). There
was no significant difference in the risk of CR-BSI between antibiotic CVCs and heparin CVCs (p= 0.09) or
between heparin CVCs and standard CVCs (p= 0.68). The BSI rate per 1000 CVC-days was lowest in the
antibiotic group. The composite measure of BSI or culture-negative infection did not differ by CVC. No
other secondary outcomes were associated with type of CVC.
Safety
No CVC-related adverse events (31 events) or mortality (148 events) were attributed to type of CVC. Only 12
out of 42 children with the primary outcome BSI had minocycline and rifampicin resistance reported using
Etest® strips [see www.biomerieux-diagnostics.com/etest (accessed 20 November 2015)]; 8 out of 12 were
resistant, in each case to both antibiotics (3/5 standard group; 2/2 antibiotic group; 3/5 heparin group).
Cost-effectiveness
We determined the cost-effectiveness of type of CVC per BSI averted using individual-level data on
hospital use captured for study participants.
Methods
Resource use and costs
We assumed that inpatient hospital costs would capture the main cost drivers and the greatest proportion
of direct medical costs. The time horizon aimed to include costs associated with managing BSI and was
defined as 6 months post randomisation (or death).
Resource use was evaluated using:
i. trial case report forms (CRFs) recording admission and transfer/discharge dates for PICUs, high-dependency
units (HDUs) and paediatric wards within participating hospitals
ii. Hospital Episode Statistics (HES) containing Healthcare Resource Groups (HRGs) for admissions to NHS
hospitals in England
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iii. the Paediatric Intensive Care Audit Network (PICANet), containing length of stay and HRGs for HDU
and PICU admissions
iv. Hospital Patient Administration Systems (PASs) of participating hospitals, capturing length of stay and
HRGs in PICUs and wards
The primary cost analysis was based on CRFs and PASs, with 6-month costs taken from HES, supplemented
with HDU and intensive care unit (ICU) data from PICANet. Total individual patient costs were calculated
from the sum of their bundled (ward) HRGs coded from the national tariff and their unbundled (ICU/HDU)
codes taken from the national schedule.
Incremental analysis
The cost-effectiveness of each type of CVC was evaluated by (1) ranking type of CVC according to
decreasing effectiveness and (2) eliminating ineffective or dominated interventions (those that are less
effective but more costly than others). The incremental cost-effectiveness ratio (ICER) for the remaining
CVCs was calculated as the difference in adjusted total costs divided by the difference in risk of BSI.
A cost-effectiveness acceptability curve was generated, using bootstrapping to account for the joint
uncertainty in costs and outcomes.
Value of health-care resources associated with bloodstream infection
The value of health-care resources associated with BSI was estimated using generalised linear regression to
model total post-randomisation costs, adjusting for significant prespecified baseline variables.
All analyses were performed using Stata version 10 (StataCorp LP, College Station, TX, USA).
Results
The average post-randomisation stay in the PICU was 10.5 days (95% CI 9.2 to 11.9 days) for standard
CVCs, 10.8 days (95% CI 9.3 to 12.5 days) for antibiotic CVCs and 9.9 days (95% CI 8.6 to 11.4 days) for
heparin CVCs. There were no significant differences in length of stay by CVC in PICUs (p= 0.61), HDUs
(p= 0.73) or wards (p= 0.54).
The mean 6-month unadjusted costs per patient were £44,503 (95% CI £40,554 to £48,776) for standard
CVCs, £45,663 (95% CI £41,600 to £49,994) for antibiotic CVCs and £42,065 (95% CI £38,220 to
£46,246) for heparin CVCs. Costs were not significantly different by CVC type (p= 0.46). The 6-month
incremental costs were positive (£1160, 95% CI –£4743 to £6962) for antibiotic CVCs and negative
(–£2439, 95% CI –£8164 to £3359) for heparin CVCs compared with standard CVCs.
As heparin CVCs were shown not to be clinically effective compared with standard CVCs, the incremental
analysis was limited to antibiotic CVCs compared with standard CVCs. The ICER for the 6-month time
frame was £54,057 per BSI averted for antibiotic CVCs compared with standard CVCs, with a probability
of 0.35 of antibiotic CVCs being cost saving or dominant.
Costs were very sensitive to the time horizon of analysis. Limiting the analysis to costs associated with
the index stay only resulted in antibiotic CVCs dominating standard CVCs with a saving of £97,543 per
BSI averted. The costs of antibiotic and standard CVCs became equal when the time horizon of analysis
was 122 days.
The value of health-care resources associated with each BSI averted (adjusted cost per BSI estimated from
the regression analysis) was £10,975 (95% CI –£2801 to £24,751).
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Generalisability and cost impact
The generalisability and cost impact analysis aimed to inform the adoption of antibiotic CVCs for all
children who need them during admission to PICUs in England.
Methods
Generalisability analysis
We determined the generalisability of the CATCH findings to the baseline risk of BSI in children with a
CVC across PICUs in England. Rates of BSI in all children requiring a CVC in the PICU were estimated from
a data linkage study using detailed information from PICANet and national laboratory surveillance data
co-ordinated by Public Health England. Rates of BSI per 1000 bed-days were modelled using multilevel
Poisson regression, adjusting for significant patient risk factors (p< 0.05).
Cost impact analysis
The baseline risk was defined as the number of BSIs per 1000 bed-days in children using standard CVCs in
English PICUs during 2012. We estimated the BSI rate using antibiotic CVCs by applying the rate ratio
from the trial to the baseline BSI rate, assuming that, irrespective of baseline risk, the relative effect of
impregnated CVCs would be the same in all children. The number of BSIs averted using antibiotic CVCs
was estimated by applying the respective BSI rates to the total number of bed-days in 2012. We estimated
the number of admissions requiring CVCs from responses to a PICU survey on the percentage of
emergency and elective admissions receiving CVCs in 2012.
We determined the budget and cost impacts of adopting antibiotic-impregnated CVCs by synthesising the
following evidence: (1) the estimated risk of BSI using standard CVCs (derived from the data linkage
study); (2) the number of BSIs potentially averted by using antibiotic-impregnated CVCs (based on the
relative treatment effect in the trial); (3) the additional £36 associated with purchasing each impregnated
CVC for all children expected to require one (numbers of CVCs based on PICU survey data); and (4) the
value of the health-care resources associated with each averted BSI (from the trial economic analysis).
Results
The additional cost of purchasing antibiotic CVCs for all children in English PICUs in 2012 corresponded to
an estimated budget impact of £317,916 (8831 CVCs). Based on 2012 BSI rates, the cost impact of
managing BSIs occuring with standard compared with antibiotic CVCs in all PICUs was £2.5M per year
(95% uncertainty interval –£66,544 to £5,557,451). The BSI rate using standard CVCs was 4.58 (95% CI 4.42
to 4.74) per 1000 estimated CVC-days in 2012. Applying the rate ratio gave an estimated 232 BSIs averted
using antibiotic CVCs. The additional costs of antibiotic CVCs would be less than the value of resources
associated with managing BSIs in PICUs with a standard BSI rate > 1.2 per 1000 CVC-days.
Conclusions
Implications for practice
The primary outcome, time to BSI, did not differ between impregnated and standard CVCs. Secondary
analyses showed that antibiotic CVCs reduced the risk of BSI compared with standard or heparin CVCs.
Therefore, use of impregnated CVCs for children admitted to PICUs could result in clinically important
reductions in BSI rates. The benefits of antibiotic-impregnated CVCs apply even for PICUs with low BSI
rates, although uncertainty remains whether or not they are cost-effective for the NHS.
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Recommendations for research
l Adoption of impregnated CVCs in PICUs should be considered. Implementation strategies could be
monitored through linkage of electronic health-care data and clinical data on CVC use with laboratory
surveillance data on BSI.
l Further trials comparing antibiotic-impregnated or heparin-bonded CVCs with standard CVCs for
children or adults in intensive care are not recommended.
l The NHS should work with industry to evaluate different types of impregnation for specific patient
groups (e.g. neonates or patients requiring long-term CVCs).
l Use of linked administrative data should be considered for future trials to determine the generalisability
of interventions when the event rate is likely to change substantially over the lifetime of the trial and
to monitor implementation of effective interventions.
Trial registration
This trial is registered as ClinicalTrials.gov NCT01029717.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Use in practice
Central venous catheters (CVCs) are widely used for patients of all ages who need intensive or
high-dependency care to provide venous access for resuscitation, drug delivery, intravenous feeding,
monitoring and blood sampling. CVCs are associated with an increased risk of bloodstream infection (BSI),
which is hypothesised to be caused by organisms tracking along the CVC from the skin or from the
external parts of the CVC to colonise the CVC tubing and tip.1–5
Risk factors for BSI include catheter dwell time, the frequency of ‘breaching’ the line for medication or
sampling, multiple compared with single-lumen CVCs and infusion of lipid solution as part of parenteral
nutrition.6–10 The risk of BSI is reduced by strict adherence to aseptic procedures during CVC insertion and
whenever the CVC is breached.11–13 To help ensure staff follow aseptic procedures, audited checklists
(called CVC bundles) have been introduced in several countries.14–19
In this report we focus on children who need a CVC as part of their intensive care treatment. Paediatric
intensive care units (PICUs) have one of the highest reported rates of hospital-acquired BSI of any clinical
specialty20–23 and BSI is an important cause of adverse clinical outcome and health-care costs in critically ill
children.21,24–26 We estimate that approximately 60% of the 16,000 children admitted to 23 PICUs each
year in England require insertion of a CVC as part of their acute care.27 We do not include CVCs used for
very preterm babies in neonatal intensive care or long-term CVCs, which are widely used to administer
medication or parenteral nutrition for children with conditions such as cancer, cystic fibrosis, renal failure
or short gut syndrome.
Rationale
Central venous catheter impregnation with anti-infective substances has been used for over 25 years.28
Recent systematic review evidence from 48 randomised controlled trials (RCTs) and cost-effectiveness
analyses including 11,586 patients demonstrated substantial benefits of impregnated compared with
standard CVCs for catheter-related BSI (CR-BSI).2,5,28–30 One of the most recent systematic reviews included
a meta-analysis of direct and indirect comparisons of different types of impregnated and standard CVCs.28
Heparin-bonded or antibiotic-impregnated CVCs were found to be the most effective options, being
associated with similar reductions (70–80%) in the risk of CR-BSI. Heparin bonding acts by reducing
thrombus formation and bacterial adherence to thrombi, but the bonding agent, benzalkonium chloride,
also has anti-infective properties. Antibiotic-impregnated CVCs act by preventing biofilm formation and
thereby prevent bacterial colonisation.
Despite the large number of RCTs and the substantial reductions seen in the risk of BSI in adults,
impregnated CVCs have not been recommended for children in US or UK guidelines and their use in UK
practice has been limited.3,15,31,32 A recent survey showed that impregnated CVCs had been adopted for
some or all children by less than half of British PICUs surveyed.32 Lack of implementation in PICUs relates
to (1) gaps in the evidence relating to children; (2) concerns about the quality of previous trials; and
(3) uncertainty about the generalisability of RCT findings to settings where improved infection control
strategies have been associated with steep declines in BSI rates.33,34
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In children, there is a lack of evidence on the most effective type of CVC and on the expected effect size.
According to the network meta-analysis by Wang et al.,28 heparin-bonded and antibiotic-impregnated
CVCs are the most effective options, having similar effects compared with standard CVCs. However,
there is a lack of evidence on which type of CVCs would be most effective as there have been no
adequately powered, direct ‘head-to-head’ comparisons of these options.28 In the UK, the additional
costs of heparin-bonded or antibiotic-impregnated CVCs are similar and so the decision on which type
to adopt depends on their relative benefits and adverse effects. Only one of the eight RCTs comparing
antibiotic-impregnated CVCs with standard CVCs (n= 2073 patients) included children and this study
was terminated early because of a lower than expected event rate.35–42 As CVCs for children are much
narrower than adult CVCs and the risk of thrombus formation, bacterial adhesion and infection is much
higher, it is hypothesised that the relative effect of antibiotic-impregnated compared with standard CVCs
may differ in children and adults. Evidence is stronger for the benefits of heparin-bonded CVCs, as two of
the three RCTs comparing heparin-bonded CVCs with standard CVCs (n= 472) included children.43–45
Several systematic reviews have raised concerns that the poor quality of previous studies means that the
benefits of impregnated CVCs may have been overestimated.5,29,46,47 First, few trials have reported good
concealment of treatment allocation or blinding of clinicians to the intervention and many have failed to
account for losses or withdrawals, all factors that could lead to overestimation of the effect.5,29 Second, all
previous trials relied on CR-BSI as the primary outcome measure, which requires positive cultures from the
blood and catheter tip. This measure is highly susceptible to bias, as the tip can be easily contaminated
during removal and residual antibiotic in the catheter tip may inhibit culture in the laboratory. Aside from
the potential biases in measuring CR-BSI, impregnated CVCs may impact on all BSIs after CVC insertion,
not just on CR-BSIs, and on the risks of mortality, complications and increased length of stay associated
with BSI.
Few trials have determined the effect of impregnated CVCs on all BSIs in PICU in the context of ongoing
reductions in BSI rates associated with the introduction of CVC care bundles.11,13,14,33,48 Neither of the two
trials of heparin-bonded CVCs in children and few of the trials of antibiotic-impregnated CVCs in adults
have been conducted in the context of these strenuous efforts to reduce BSI. It is not known whether or
not the relatively large reductions in relative risk (RR) and absolute risk seen in trials predating CVC care
bundles would be sustained in PICUs where rates of infection have already been reduced by improved
CVC care.34 Even though a UK cost-effectiveness analysis estimated that impregnated CVCs would be
cost-effective given baseline rates of CR-BSI as low as 0.2%,29 there remains the question of whether or
not the relative effect of impregnation would be less given improved catheter care.
Risks and benefits
Prevention of BSI is undoubtedly a clinically important outcome. Although evidence on attributable mortality
varies, BSI is clearly associated with a longer stay in hospital and more intensive support.20,21,24–26,49 For
children in intensive care, CR-BSI has been associated with an additional 9–21 days’ stay in hospital
(6.5–15 days in PICU).24–26 In adults, the additional acute health-care costs attributable to a BSI are an
estimated £9148 per patient and could range between £2500 and £71,000.29 The few studies of the costs
of BSIs in PICU patients have found a difference of US$33,039–39,219 in PICU direct costs between
infected and uninfected patients.21,25 However, quantifying the effects of BSI are complicated by the
time-dependent exposure: BSI increases hospital stay; increased length of stay is a risk factor for BSI.50
Estimates of the attributable length of stay are subject to this time-dependent bias, leading to potentially
overestimated BSI costs in previous studies.51,52 On the other hand, no study has taken into account the
long-term costs associated with BSI in children.
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Potential adverse effects of CVCs are rare. Heparin bonding could theoretically trigger an allergic response,
leading to heparin-induced thrombocytopenia, although no case has been reported to the manufacturers.
Antibiotic impregnation could potentially lead to antibiotic resistance, although a systematic review
showed no increased risk of resistant organisms isolated from blood cultures.1
Overview of aims and research questions
From a policy perspective, there could potentially be significant gains in terms of children’s health and
health-care costs across the NHS if impregnated CVCs could be confirmed to substantially reduce rates of
BSI. We compared both types of impregnated CVC previously shown to be most effective (antibiotic and
heparin) with standard CVCs to determine the effectiveness of CVC impregnation in children. Secondary
analyses were conducted to evaluate the effectiveness of each type of CVC.
We aimed to inform NHS policy regarding impregnated CVCs for intensive care of children by undertaking
a large pragmatic RCT to determine (1) clinical effectiveness; (2) cost-effectiveness of impregnated
compared with standard CVCs; and (3) the generalisability and cost impact of adopting impregnated CVCs
for all children who need them.
The main objectives and data sources for the three parts of the study were:
1. Clinical effectiveness:
¢ to determine the effectiveness of impregnated compared with standard CVCs for reducing BSI in
children admitted to intensive care
¢ to determine which type of CVC is most effective, based on three-way comparisons of measures of
BSI, mortality and adverse events
¢ data source: clinical outcomes captured on case report forms (CRFs) in the RCT.
2. Cost-effectiveness:
¢ to determine the cost-effectiveness of impregnated compared with standard CVCs for reducing
BSIs, based on incremental acute health-care costs per BSI avoided
¢ data sources: clinical outcomes captured on CRFs in the RCT and records of health-care use
captured by linkage of RCT data with hospital administrative data.
3. Generalisability and cost impact:
¢ to estimate the net cost impact to NHS PICUs given a policy to adopt impregnated CVCs for all
children who need them
¢ data sources: national data on PICU admissions (Paediatric Intensive Care Audit Network; PICANet)
linked with infection surveillance data collated by Public Health England (PHE) and costs from the
economic evaluation.
The specific objectives, methods and results for each of the three phases of the study are reported in
Chapters 2–5. We discuss the implications of our findings for policy and recommendations for future
research in Chapter 6.
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3

Chapter 2 Clinical effectiveness: methods
Trial design
We conducted a parallel, three-arm RCT.53 Children admitted to 14 PICUs in England between
December 2010 and November 2012 were randomised to CVCs impregnated with antibiotics or heparin
or to standard CVCs in a ratio of 1 : 1 : 1.
Setting and participants
Children aged < 16 years were eligible if they were admitted to a participating PICU or were being
prepared for PICU admission by an emergency retrieval team and were expected to require a CVC for
≥ 3 days. Children who had already participated in the trial were ineligible.
Interventions
We used polyurethane CVCs manufactured by Cook Medical Incorporated (Bloomington, IN, USA).
Sizes used were French gauge 4 (double lumen), 5 or 7 (triple lumen). Both types of impregnation involve
internal and external surfaces. Cook Medical Inc. reports a concentration of 503 μg/cm of minocycline
and 480 µg/cm of rifampicin for their antibiotic-impregnated CVC, which reduces biofilm formation.54
Heparin bonding reduces thrombus and thereby biofilm formation and uses benzalkonium chloride as an
anti-infective bonding agent.5,55
Randomisation and consent
For children admitted to the PICU following elective surgery, we sought prospective parental consent
during preoperative assessment. Randomisation took place in theatre or in the anaesthetic room prior to
entry into theatre. For children who required a CVC as an emergency, we sought parental consent after
randomisation and stabilisation (deferred consent) to avoid delaying treatment, which was usually within
48 hours of randomisation. Children who required a CVC as part of their emergency care or resuscitation
were randomised at the bedside in the PICU or at another hospital, where they were randomised by the
PICU retrieval team prior to transfer to the PICU. Further details are given in the protocol [see www.nets.
nihr.ac.uk/projects/hta/081347 (accessed 20 November 2015)].
At randomisation, the clinician or research nurse opened a pressure-sealed, sequentially numbered opaque
envelope containing the CVC allocation. Randomisation sequences were computer generated by an
independent statistician in random blocks of three and six, stratified by method of consent (deferred or
prospective), site and envelope storage location within the site to facilitate easy access to envelopes
(e.g. for insertion in theatre and in the PICU).
Parents consented to the use of their child’s data for the trial, to follow-up using routinely recorded clinical
data and to 0.5ml of blood being collected whenever a blood culture was clinically required.56 Samples
were sent for polymerase chain reaction (PCR) testing for 16S ribosomal ribonucleic acid (rRNA) of bacterial
ribosome protein to detect bacterial infection.
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
We also sought consent to link data from PICANet57 to the child’s study data to categorise the primary
reason for admission and the Paediatric Index of Mortality (PIM2)58 score on admission and to link to
administrative hospital data for the economic analyses and death registration data from the Office for
National Statistics (ONS) [see www.ons.gov.uk (accessed 4 January 2016)] to determine mortality after
discharge from the PICU.
Blinding
Central venous catheter allocation was not blinded to the clinician responsible for inserting the CVC
(because of the different colour strips for antibiotic and heparin CVCs) but, as the CVCs looked identical
whilst in situ, allocation was concealed from patients, their parents and PICU personnel responsible for
their care. Labels identifying the type of CVC were held securely in a locked drawer in case unblinding was
required. Participant inclusion in analyses and occurrence of outcome events were established prior to
release of the randomisation sequence for analysis.
Comparisons and outcomes
The primary analysis for the trial compared antibiotic or heparin CVCs with standard CVCs. Secondary
analyses compared antibiotic with standard CVCs, heparin with standard CVCs and antibiotic with
heparin CVCs.
The primary outcome was time to the first BSI based on blood cultures taken between 48 hours after
randomisation and 48 hours after CVC removal (or prior to death). We used time to event analyses as the
risk of BSI increases the longer a CVC is in place. This time interval was intended to capture BSIs related
to the type of CVC. All blood culture samples were clinically indicated, defined by removal of the CVC
because of suspected infection or other recorded evidence of infection (one or more of temperature
instability, change in inotrope requirements, haemodynamic instability or poor perfusion). Any positive
blood culture was accepted for a non-skin organism, but for skin organisms two or more positive cultures
of the same organism were required within 48 hours of each other. A clinical committee reviewed all
primary outcomes involving positive cultures.
We conducted a sensitivity analysis for potentially missing microbiology data by assuming that children
with a record of clinical indication but no sample taken in the primary outcome time window did actually
experience the primary outcome.
The main secondary outcomes were:
l CR-BSI: based on the same organisms cultured from blood and the CVC tip between 48 hours after
randomisation and 48 hours after CVC removal; or differential positivity of cultures from multiple CVC
lumens on two or more occasions; or BSI and exit site infection or BSI and CVC removed for
suspected infection
l rate of BSI per 1000 CVC-days, based on one or more BSI between randomisation and CVC removal
l time to a composite measure of BSI consisting of the primary outcome or a negative blood culture
combined with (1) a positive 16S PCR result for bacterial rRNA; (2) removal of the CVC because of
suspected infection; or (3) start of antibiotics or change in type of antibiotics on the same or next day.
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Other secondary outcomes were:
l time to CVC thrombosis (defined by two episodes within 5 days of each other of difficulty flushing the
CVC or drawing back blood from the CVC, one episode of swollen limb, CVC removal because of
thrombosis or a positive ultrasound indicating thrombosis)
l time to CVC removal
l mortality by 30 days
l length of PICU admission
l length of hospital stay (up to 6 months post randomisation)
l type of bacteria or fungi isolated from the BSI included in the primary outcome.
CVC-related outcomes evaluated in the safety analyses were:
l CVC-related adverse events (unexplained thrombocytopenia after insertion of the CVC, exit site
infection, hypersensitivity, trauma from line insertion, line displacement, line breakage/mechanical
problem/manufacture complication)
l mortality recorded up until hospital discharge
l antibiotic resistance to minocycline (> 0.5 µg/ml) or rifampicin (> 1.0 µg/ml).
Antibiotic resistance outcomes were based on Etest® strips [see www.biomerieux-diagnostics.com/etest
(accessed 20 November 2015)] applied to organisms isolated from the BSI included in the primary
outcome. Incomplete laboratory testing and reporting prevented analysis of resistance in cultures from the
CVC tip (as specified in the protocol).
Sample size
We based the sample size calculation for the primary analysis on a RR. We assumed that detection of a RR
of 0.5 in patients with a baseline risk of 10% would change policy. We assumed that the RR would remain
relatively constant across baseline risks whereas the absolute risk difference would be more variable.
A total of 1200 children were required in a 2 : 1 ratio (impregnated : standard) to achieve 80% power to
detect a RR of 0.5 at a 5% level of significance, based on an estimated BSI rate of 10% and allowing for
5% loss to follow-up. A lower than expected BSI rate of 5% would have 62% power to detect a RR of 0.5
or 80% power for a RR of 0.32.
The Independent Data and Safety Monitoring Committee (IDSMC) recommended continuation of the study
after (1) reviewing the first 209 children; (2) an interim analysis of 650 children using the Peto–Haybittle
stopping rule for the primary outcome; and (3) recruitment had reached the original target of 1200 pre
schedule in June 2012, before exhausting available funding (see Acknowledgements, Trial Oversight
Committees and Table 23).
Statistical methods
Outcome data were analysed according to the intention-to-treat principle, meaning that children who
were consented and randomised were analysed according to the type of CVC randomised, regardless of
whether or not CVC insertion was attempted or the type of CVC received. Safety analyses included the
subset of children for whom CVC insertion was attempted, grouped by CVC actually received.
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The statistical analysis plan was developed prior to analysis and is available in Appendix 1. A 5% level of
statistical significance and 95% confidence intervals (CIs) were used throughout. Absolute risk differences
were calculated for proportions. Time-to-event outcomes were analysed using Kaplan–Meier curves and
the log-rank test. Cox regression was used to adjust the primary analysis of time to BSI for the use of
prospective or deferred consent and suspected infection at baseline. Poisson regression was used to
analyse the secondary outcome of rate of BSIs (defined as the total number of BSIs per 1000 CVC-days
occurring between randomisation and CVC removal). All analyses were conducted using SAS software
version 9.3 (SAS Institute Inc., Cary, NC, USA).
Post hoc analyses evaluated competing risks from death or time to first BSI, using cumulative incidence
curves. We applied Gray’s test to detect whether or not there was a difference between impregnated and
standard CVCs for the primary outcome.59 This analysis was conducted using R statistical software
(The R Foundation for Statistical Computing, Vienna, Austria).
Study oversight and role of funders
The Research Ethics Committee for South West England approved the study protocol. The manufacturer
Cook supplied CVCs to participating units at a 20% discounted price. Neither the manufacturer nor
the funder (the National Institute for Health Research) had any role in the design of the study, the
collection or interpretation of the data or the reporting of the results. The CATCH trial is registered with
ClinicalTrials.gov (NCT01029717). The protocol is available at www.nets.nihr.ac.uk/projects/hta/081347
(accessed 20 November 2015) and the statistical analysis plan is provided in Appendix 1.
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Chapter 3 Clinical effectiveness: results
Study population
In total, 1859 children were randomised, of whom 501 children were randomised prospectively and 1358
were randomised as an emergency. Of those randomised as an emergency, 984 subsequently provided
deferred consent for inclusion in the analyses (Figure 1; see Appendix 2, Figures 11 and 12 for participant
flow by emergency/elective randomisation). Reasons for non-consent in the deferred consent group
included not approached [n= 180 (48%), mainly because of transfer to a non-participating unit or early
discharge from the PICU], no response [n= 17 (4.5%)] or consent refused [n= 177 (47%)]. Detailed
reasons for non-consent are reported elsewhere.60 Numbers enrolled by site and by month are provided in
Appendix 2 (see Table 24 and Figure 13).
Comparison of interventions
The intention-to-treat sample included 1485 children, of whom 1345 children received the allocated CVC.
Threats to validity because of protocol deviations are provided in Appendix 2 (see Table 26). Very few
children had a clinical indication but no blood culture taken in the primary outcome time window
(see Figure 1). Timings of samples for positive BSIs included in the primary and secondary outcomes are
provided in Table 1.
Baseline characteristics
Table 2 shows that baseline characteristics were similar between the randomised groups. Over half (58%)
of children were aged < 12 months at admission, with one-third aged < 3 months. One-third of children
had surgery prior to admission to the PICU and half of all children randomised had cardiovascular problems
as their primary diagnosis at admission.
During follow-up
Table 3 provides details of the CVC insertion and characteristics at 48 hours post randomisation. CVC
insertion took place in the operating room for 437 out of 493 (89%) in the prospective consent (elective)
group, but in only 34 out of 917 (4%) of the deferred consent (emergency) group.
Table 4 shows the number of arterial, peripheral and CVC samples taken by trial arm. Overall, 3583 blood
samples were taken and 1216 out of 1485 (81.9%) of children had a sample taken. Sampling was similar
by trial arm and site (see Appendix 2, Table 25).
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TABLE 1 Numbers of children included in the primary outcome, the rate of BSI and the rate of CR-BSI according to
time since randomisation
Randomisation 48 hours after randomisation to CVC removal 48 hours after CVC removal
Primary outcome of BSI
n= 40 n= 2
Rate of BSI per 1000 CVC-days
n= 10 n= 40
CR-BSI
n= 24 n= 1
Shading indicates time window for outcome measure.
TABLE 2 Baseline characteristics and clinical condition before randomisation
Variable
Standard Antibiotic Heparin
na % na % na %
Patient characteristics 502 100 486 100 497 100
Emergency (deferred consent) 333 66.3 320 65.8 331 66.6
Elective (prospective consent) 169 33.7 166 34.2 166 33.4
Male 285 56.8 291 59.9 277 55.7
Age
< 3 months 159 31.7 159 32.7 175 35.2
3–12 months 129 25.7 123 25.3 116 23.3
1–10 years 174 34.7 154 31.7 174 35.0
11+ years 40 8.0 50 10.3 32 6.4
Weight at admission
< 3 kg 41 8.2 38 7.8 56 11.3
3–10 kg 278 55.4 280 57.6 273 54.9
> 10 kg 183 36.5 166 34.2 168 33.8
Missing 0 0.0 2 0.4 0 0.0
Admitted for surgery 174 34.7 171 35.2 181 36.4
PICU assessment (from linked
PICANet data) 479 95.4 456 93.8 473 95.2
Primary reason for admission
Cardiovascular 235 49.1 233 51.1 250 52.9
Endocrine/metabolic 30 6.3 34 7.5 30 6.3
Infection 39 8.1 30 6.6 31 6.6
Cancer 9 1.9 6 1.3 8 1.7
Respiratory 102 21.3 86 18.9 84 17.8
Neurological 22 4.6 31 6.8 29 6.1
Trauma 18 3.8 10 2.2 18 3.8
Other 24 5.0 26 5.7 22 4.7
Unknown 0 0.0 0 0.0 1 0.2
continued
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
TABLE 2 Baseline characteristics and clinical condition before randomisation (continued )
Variable
Standard Antibiotic Heparin
na % na % na %
PIM2
< 1% 54 11.3 48 10.5 48 10.1
1 to < 5% 264 55.1 236 51.8 247 52.2
5 to < 15% 116 24.2 123 27.0 119 25.2
15 to < 30% 34 7.1 31 6.8 39 8.2
30%+ 11 2.3 18 3.9 20 4.2
Clinical condition at randomisation 502 100.0 486 100.0 497 100.0
< 72 hours before randomisation
Other CVC in situ 95 18.9 91 18.7 83 16.7
Anticoagulants received 50 10.0 59 12.1 61 12.3
Antibiotics received 286 57.0 276 56.8 284 57.1
Positive blood culture 40 8.0 25 5.1 36 7.2
At randomisation
Infection suspected 214 42.6 181 37.2 199 40.0
Immunocompromised 44 8.8 31 6.4 29 5.8
a n= number of participants by randomised CVC.
TABLE 3 Details of the intervention and characteristics at 48 hours post randomisation
Variable
Standard Antibiotic Heparin
na % na % na %
CVC details (inserted CVCs) 481 95.8 465 95.7 464 93.4
Deferred consent, CVC inserted 314 65.3 301 64.7 302 65.1
Inserted at same hospital
ICU 276 57.4 264 56.8 259 55.8
Theatre 5 1.0 4 0.9 7 1.5
Other 2 0.4 3 0.6 1 0.2
Inserted at other hospitalb
ICU 5 1.0 6 1.3 3 0.6
Theatre 3 0.6 8 1.7 7 1.5
Other 23 4.8 16 3.4 23 5.0
Missing 0 0.0 0 0.0 2 0.4
Prospective consent, CVC inserted 167 34.7 164 35.3 162 34.9
Inserted at same hospital
ICU 15 3.1 23 4.9 16 3.4
Theatre 152 31.6 141 30.3 144 31.0
Other 0 0.0 0 0.0 1 0.2
Missing 0 0.0 0 0.0 1 0.2
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TABLE 3 Details of the intervention and characteristics at 48 hours post randomisation (continued )
Variable
Standard Antibiotic Heparin
na % na % na %
Size of line
4 28 5.8 45 9.7 39 8.4
5 421 87.5 384 82.6 391 84.3
7 21 4.4 23 4.9 18 3.9
Missing 11 2.3 13 2.8 16 3.4
Triple-lumen CVC 450 93.6 421 90.5 422 90.9
CVC inserted into femoral vein 253 52.6 217 46.7 235 50.6
48 hours post randomisation 502 100.0 486 100.0 497 100.0
Number of devices in situ
< 4 160 31.9 169 34.8 185 37.2
≥ 4 340 67.7 311 64.0 311 62.6
Missing 2 0.4 6 1.2 1 0.2
Presence of an intrabody cavity devicec
Yes 404 80.5 381 78.4 380 76.5
No 96 19.1 100 20.6 116 23.3
Missing 2 0.4 5 1.0 1 0.2
ICU, intensive care unit.
a n= number of participants by randomised CVC.
b CVCs were inserted by the retrieval team prior to transfer to the PICU.
c Endotracheal tube, tracheotomy tube, intracranial pressure monitor, chest drain or peritoneal dialysis catheter.
TABLE 4 Samples taken in the primary outcome time window
Sample
Standard (n= 502) Antibiotic (n= 486) Heparin (n= 497)
n randomiseda/
n samplesb %
n randomiseda/
n samplesb %
n randomiseda/
n samplesb %
Samples clinically indicated and in the
primary outcome time window
213/328 42.4 190/269 39.1 190/326 38.2
Type of sample
Arterial 49/55 9.8 39/44 8.0 41/55 8.2
Peripheral 19/22 3.8 32/33 6.6 35/39 7.0
CVC 161/226 32.1 129/167 26.5 136/208 27.4
a n randomised= number of participants by randomised CVC.
b Columns do not sum to total as sample types recorded as ‘other’ or that were missing are excluded.
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Primary outcome
The number of blood samples contributing to the primary outcome is shown in Appendix 2 (see Figure 14).
Blood cultures were taken between 48 hours after randomisation and CVC removal for 40% of those
randomised (593/1485; see Figure 1). BSI was recorded for 42 children [standard 18/502 (3.6%); antibiotic
7/486 (1.4%); heparin 17/497 (3.4%)]. Gram-positive organisms accounted for the majority of BSIs (Table 5).
Figure 2 shows the Kaplan–Meier curve for the primary outcome of time to first BSI. There was no
significant difference in time to first BSI when comparing any impregnated CVC (antibiotic or heparin) with
standard CVCs (Table 6). However, the risk of BSI was significantly lower for antibiotic compared with
standard CVCs [hazard ratio (HR) 0.43, 95% CI 0.20 to 0.96] and for antibiotic compared with heparin
CVCs (HR 0.42, 95% CI 0.19 to 0.93). The direction of these results was robust to the sensitivity analysis
(see Appendix 2, Table 27). Regression analysis showed no significant effect of prespecified variables (type
of consent and suspected infection at randomisation) and the effect of type of CVC was similar after
adjusting for these variables (Table 7).
Competing risk analysis using Gray’s test indicated no difference between the treatments for either
competing risk (p-values of p= 0.29 for BSI and p= 0.89 for death; Table 8).
TABLE 5 Primary outcome (absolute measures) and type of organism isolated, according to CVC allocation
Outcome
Standard (n= 502) Antibiotic (n= 486) Heparin (n= 497)
na % na % na %
BSI 18 3.6 7 1.4 17 3.4
Median time to first BSI in days (IQR) 7.5 (4.5–11.2) 6.9 (6.0–8.0) 4.2 (3.1–8.4)
Organism type
Non-skin 15b 2.99 6 1.23 16 3.22
Skin 3 0.60 1 0.21 1 0.20
Organism groupc
Gram positived 10 1.99 3 0.62 10 2.01
Gram negative 6 1.20 4 0.82 5 1.01
Candida 2 0.40 0 0.00 3 0.60
IQR, interquartile range.
a n number of participants by randomised CVC unless otherwise stated.
b Includes one mixed BSI pathogen and skin organism.
c Subtotals add to more than the total in the heparin group because of multiple types of organisms isolated on the same
occasion in some patients.
d Includes skin bacteria.
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TABLE 6 Risk difference for first BSI and HR for time to first BSI according to CVC allocation
Analysis Comparison Risk difference (95% CI) HR (95% CI) p-value
Primary Any impregnated (n= 983) vs.
standard (n= 502) CVC
–1.14 (–3.04 to 0.75) 0.71 (0.37 to 1.34) 0.29
Secondary Antibiotic (n= 486) vs. standard
(n= 502) CVC
–2.15 (–4.09 to –0.20) 0.43 (0.20 to 0.96) 0.04
Heparin (n= 497) vs. standard
(n= 502) CVC
–0.17 (–2.45 to 2.12) 1.04 (0.53 to 2.03) 0.90
Antibiotic (n= 486) vs. heparin
(n= 497) CVC
–1.98 (–3.90 to –0.06) 0.42 (0.19 to 0.93) 0.03
Bold indicates differences that are significant at the 5% level.
TABLE 7 Regression results for the primary outcome
Analysis Variable (n with outcome)
Comparator
(n with outcome) HRa (95% CI) p-value
Primary Antibiotic or heparin CVC (24) Standard CVC (18) 0.71 (0.38 to 1.33) 0.29
Deferred consentb (30) Prospective consentb (12) 0.87 (0.40 to 1.90) 0.73
Suspected infection(18) No suspected infection (24) 0.69 (0.33 to 1.42) 0.31
Secondary Antibiotic CVC (7) Standard CVC (18) 0.40 (0.17 to 0.96) 0.04
Heparin CVC (17) Standard CVC (18) 1.05 (0.54 to 2.05) 0.89
Deferred consentb (30) Prospective consentb (12) 0.87 (0.40 to 1.90) 0.35
Suspected infection (18) No suspected infection (24) 0.68 (0.33 to 1.40) 0.30
Secondary Antibiotic CVC (7) Heparin CVC (17) 0.39 (0.16 to 0.95) 0.04
Deferred consentb (30) Prospective consentb (12) 0.85 (0.30 to 2.45) 0.76
Suspected infection (18) No suspected infection (24) 0.99 (0.40 to 2.43) 0.98
a HRs at p< 0.05 are in bold.
b Participants with prospective consent were admitted electively and participants with deferred consent were admitted as
an emergency.
TABLE 8 Competing risk analysis for primary outcome of time to first BSI
Outcome HR (95% CI) Gray’s test p-value
Time to first BSI (hours) 0.71 (0.39 to 1.31) 0.29
Time to death (hours) 1.08 (0.63 to 1.85) 0.89
CLINICAL EFFECTIVENESS: RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Secondary outcomes
No children had more than one BSI whilst the trial CVC was in situ. The relationship between BSI outcomes
and time since randomisation is shown in Table 1.
Overall, 25 (1.7%) children experienced a CR-BSI (Table 9). There was no significant difference between
any impregnated CVC and standard CVCs (p= 0.13), but the risk of CR-BSI was significantly lower for
antibiotic than for standard CVCs (p= 0.03). There was no significant difference between antibiotic and
heparin CVCs (p= 0.09) or between heparin and standard CVCs (p= 0.68).
The rate of BSI per 1000 CVC-days did not differ in the primary comparison between any impregnated and
standard CVCs (see Table 9). However, the rate of BSI was significantly lower for antibiotic compared with
standard (p= 0.04) and heparin (p= 0.03; Table 10) CVCs. There was no significant difference in the rate
of BSI between heparin and standard CVCs (p= 0.85).
A change in antibiotics on the same day as a negative blood culture or the next day made the largest
contribution to the composite measure of BSI (see Appendix 2, Table 28). Overall, 317 (21%) children
experienced the composite measure of BSI and this outcome did not differ by CVC type (see Table 10).
There was no difference in any other secondary outcome by CVC allocation (see Table 10). The types of
bacteria and fungi isolated from positive blood cultures are provided in Appendix 2 (see Table 29).
TABLE 9 Secondary outcomes (absolute measures) by CVC allocation
Outcome
Standard (n= 502) Antibiotic (n= 486) Heparin (n= 497)
na % na % na %
CR-BSI 12 2.4 3 0.6 10 2.0
Rate of BSI per 1000
CVC-days [number of
BSIs/(number of days
at risk/1000 days)]
(95% CI)
8.2 [21/2.547] (4.7 to 11.8) 3.3 [8/2.418] (1.0 to 5.6) 8.8 [21/2.391] (5.0 to 12.6)
Composite measure
of BSI
112 22.3 103 21.2 102 20.5
CVC thrombosis 125 24.9 126 25.9 105 21.1
Median time to CVC
removal in days (IQR)
4.28 (2.3–7.0) 4.3 (2.1–7.0) 4.20 (2.2–7.0)
Mortality by 30 days 42 8.4 39 8.0 28 5.6
Median time to PICU
discharge in days (IQR)
5.1 (2.8–10.0) 4.4 (2.2–9.3) 4.9 (2.3–8.9)
Median time to
hospital discharge in
days (IQR)
12.0 (6.4–25.6) 12.0 (6.7–22.7) 12.1 (6.4–22.5)
IQR, interquartile range.
a n= number of participants by randomised CVC who experienced the outcome.
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Safety analyses
More children in the cohort for the safety analyses were in the standard group (n= 533) than in the
antibiotic (n= 451) or heparin (n= 479) groups. As standard CVCs were the default option in the majority
of PICUs, more children received the allocated CVC in the standard arm (93%) than in the antibiotic (90%)
or heparin (89%) arms.
No serious adverse events (e.g. intervention causing death or prolonging hospitalisation) were reported.
CVC-related adverse events (i.e. unable to perform routine activity) were reported for 31 children (n= 21
mild, n= 8 moderate and n= 2 severe) (Table 11). No children had more than one adverse event and no
events were attributed to the type of CVC.
Of the 1463 children whose CVC insertion was attempted, 148 (10%) died before discharge from the
PICU (see Table 11). The majority of deaths were the result of related comorbidities at admission (see
Appendix 2, Table 30).
Testing for antibiotic resistance varied by centre. Only 12 of the 42 children with the primary outcome had
minocycline and rifampicin resistance reported using Etest strips; 8 out of 12 were resistant, in each case
to both antibiotics (3/5 standard group; 2/2 antibiotic group; 3/5 heparin group). Resistant organisms by
trial arm are provided in Appendix 2 (see Table 31).
Post hoc analyses
A total of 1573 valid PCR samples were taken from 715 (48%) of the children. Of these children, 11 (1.5%)
had a positive PCR result based on any detectable deoxyribonucleic acid (DNA) (12 samples) (Table 12).
Positive PCR results were observed for two (8.3%) children with the primary outcome compared with nine
(1.3%) children without the primary outcome. Values of the positive PCR results are provided in Appendix 2
(see Table 32).
TABLE 11 Safety analyses of CVC-related adverse events and mortality
Adverse event
Standard
(n= 533)
Antibiotic
(n= 451) Heparin (n= 479)
Total
(n= 1463)
na % na % na % na %
Unexplained thrombocytopenia 0 0.0 1 0.2 1 0.2 2 0.1
Exit site infection 1 0.2 0 0.0 0 0.0 1 0.1
Hypersensitivity 0 0.0 0 0.0 0 0.0 0 0.0
Trauma from line insertion 2 0.4 2 0.4 3 0.6 7 0.5
Line displacement 4 0.8 6 1.3 3 0.6 13b 0.9
Line breakage/mechanical problem/
manufacture complication
2 0.4 3 0.7 2 0.4 7b 0.5
Unclassifiable 0 0.0 1 0.2 0 0.0 1 0.1
Total 9 1.7 13 2.9 9 1.9 31 2.1
Mortality
Deathsc 66 12.4 44 9.8 38 7.9 148 10.1
Median time to death in
days (IQR)
15.3 (6.0–39.0) 9.0 (2.6–25.6) 14.8 (5.3–32.6)
IQR, interquartile range.
a n= number by type of CVC received or, if not inserted, type of CVC insertion attempted.
b One event reported as severe.
c Measured on CRF as an adverse event before discharge.
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TABLE 12 Polymerase chain reaction results for bacteria in blood samples taken during the primary outcome time
window by CVC type
Group
Sample taken from
child with primary
outcome n randomised n (%) with PCR sample n (%) with positive PCR result
Standard No 484 239 (49.4) 4 (1.7)
Yes 18 12 (66.7) 1 (8.3)
Antibiotic No 479 221 (46.1) 3 (1.4)
Yes 7 5 (71.4) 0 (0.0)
Heparin No 480 231 (48.1) 2 (0.9)
Yes 17 7 (41.2) 1 (14.3)
Total No 1443 691 (47.9) 9 (1.3)
Yes 42 24 (57.1) 2 (8.3)
1485 715 (48.1) 11 (1.5)
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Chapter 4 Cost-effectiveness analysis
Introduction
Central venous catheter infections are a substantial and preventable cause of iatrogenic morbidity,
mortality, excess length of stay and health-care costs. In the setting of the PICU, BSIs related to CVCs
have been reported to occur in 3–8% of all CVC insertions. As approximately two-thirds of the 16,000
admissions to English PICUs each year57 require CVCs, the overall impact represents a major burden to
patients and the NHS.20,21
Impregnated CVCs are nearly twice as expensive as standard CVCs, requiring decisions on their use to be
informed by evidence of their cost-effectiveness. However, current economic evaluations are limited in their
transferability to the PICU setting in the UK as they all relate to adult populations and, with one exception,29
apply to different health-care systems (Australia,61 Germany62 and the USA63–65). Although care pathways
and costs may differ in the UK setting, these studies consistently demonstrated antibiotic-impregnated CVCs
to be cost saving while yielding improved outcomes.
Hockenhull et al.29 modelled the cost-effectiveness of impregnated CVCs compared with standard CVCs in
adult patients. The cost of managing CR-BSIs, estimated as £9148, was taken from a systematic review
of economic studies. Based on a systematic review of RCTs, impregnated CVCs were estimated to reduce
the incidence of CR-BSIs from 3% to 1.4%. The incremental cost-effectiveness ratio (ICER) of £8530 saved
for each CR-BSI averted was calculated as the additional cost of the impregnated CVC less the expected
cost per patient of managing excess CR-BSIs divided by the absolute risk reduction. Although intuitively
simple, the model did not consider mortality effects or discriminate between different types of
impregnated CVCs and the authors recommended that decision-makers interpret the results with caution.
Halton et al.61 used a Markov decision model to compare the cost-effectiveness of a range of
antimicrobial-coated CVCs, including minocycline- and rifampicin-coated catheters, relative to uncoated
catheters in adult intensive care unit patients. Simulations suggested that antibiotic CVCs prevented
15 CR-BSIs per 1000 CVCs placed, with a corresponding gain of 1.6 quality-adjusted life-years (QALYs).
The model predicted that 32 intensive care unit (ICU) bed-days and 95 general ward bed-days would be
released, with a cost saving of AU$130,289 per 1000 CVCs.
Frank et al.62 performed a case–control analysis of resource use and costs among 30 adults who developed
a CR-BSI and 108 control subjects, each in an ICU setting. The marginal cost per infectious episode was
estimated as €231, but the calculation and meaning of the ICER presented for silver-impregnated CVCs
were unclear.
Marciante et al.63 developed a series of decision models with patient-level clinical trial data to determine whether
or not minocycline- and rifampin-impregnated CVCs are cost-effective in adults. Cost-effectiveness was
indeterminable for CVCs inserted for ≤ 1 week as no infections had occurred during this time. Antibiotic CVCs
were modelled to be cost-effective for longer periods of insertion, with expected savings of US$67 and gains of
0.009 QALYs per patient.
Shorr et al.64 presented another decision-analytic model based on a hypothetical cohort of 1000 adult
patients requiring a CVC. The incidence of CR-BSIs, excess lengths of ICU and ward stays and associated
costs were selected from published studies. Compared with standard CVCs, minocycline- and
rifampin-impregnated CVCs were estimated to reduce the incidence of CR-BSIs from 3.3% to 1.4%,
resulting in a saving of US$9605 for each CR-BSI averted.
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Veenstra et al.65 used data from RCTs, meta-analyses, and case–control studies within a decision-analytic
modelling framework to estimate the incremental cost-effectiveness of antiseptic-impregnated CVCs in a
hypothetical cohort of hospitalised patients at high risk for CR-BSIs. Modelling the use of chlorhexidine/
silver sulfadiazine-impregnated compared with standard CVCs resulted in a 2.2% decrease in the incidence
of CR-BSIs, a 0.33% decrease in the incidence of death and a saving of US$196 per CVC used.
An important limitation of these studies was that each analysis modelled the costs and consequences of
BSIs using data from disparate sources and as such relied heavily on assumptions relating to attribution
of hospital lengths of stay (the main cost driver) and mortality to BSIs. The only UK-based economic
evaluation considered an adult population and assumed that a patient with a CR-BSI spends 6 additional
days in the ICU and 5 additional days in a general medical ward.29 A recent study of 1339 cases of CR-BSI
sampled from a US paediatric population and matched to control subjects by propensity score revealed a
higher mean attributable length of stay of 19 days.66 Although this is comparable with the 21-day excess
length of stay estimated for paediatric haematology/oncology patients,67 these estimates are reliant on
retrospective observational data and are susceptible to bias.
Aim
We aimed to assess the cost-effectiveness of antibiotic, heparin and standard CVCs in an English PICU
setting using data from the CATCH RCT. Although the primary comparison showed no evidence that
impregnated CVCs (antibiotic or heparin) were more effective than standard CVCs, important differences
in secondary comparisons among the three CVCs suggested that an economic evaluation was warranted
to inform decisions on resource allocation. This would be especially relevant if one type of CVC were to
reduce total costs, be associated with shorter periods in the PICU or reduce the length of ward stays.
Methods
Although cost–utility analyses, based on QALYs, are more appropriate for informing decisions concerning
allocative efficiency, there are practical and methodological challenges in estimating utility values in
children, especially very young children in the PICU setting. These include difficulties in responding to
or understanding questions on health-related quality of life, whether for reasons of age, illness or
consciousness; the limitations of using proxy utilities; the low event rate for the primary end point; and the
inclusion of a wide range of clinical conditions. A cost-effectiveness analysis was therefore performed,
which allowed for an assessment of technical efficiency (i.e. determination of the most efficient CVC for
reducing the incidence of BSIs). The study methods were consistent with those used in other economic
evaluations of CVCs.62
Resource use
The perspective of the analysis was that of the NHS in England, with the expectation that the main
cost driver of inpatient hospital care would represent the greatest proportion of direct medical costs.
The principal cost components were PICU, high-dependency unit (HDU) and ward stays (including
readmissions), outpatient clinic visits, accident and emergency (A&E) admissions and the CVCs. The time
horizon of the base-case analysis was selected to include the costs associated with managing BSIs and
any sequelae within the 6-month period from randomisation. Shorter time horizons were examined in
sensitivity analyses.
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The measurement of resource use required complementary approaches using data collected as part of the
trial and as part of routine care. Patients’ use of hospital services was obtained from the following sources
(Figure 3):
1. The trial CRFs. Research nurses completed the relevant sections of the CRF to record the dates during
which patients were in neonatal intensive care units (NICUs) or PICUs, HDUs and paediatric wards
within the hospitals participating in the CATCH trial. Data recorded on CRFs were used for the dates of
hospital discharge, transfer to another hospital and CVC removal.
2. Hospital Episode Statistics (HES) data from the Health and Social Care Information Centre.68 HES data
contain details of all admissions to NHS hospitals in England and provide Healthcare Resource Groups
(HRGs) for the type of care patients receive at a ward level, outpatient visits and A&E admissions, but
do not provide details on ICU and HDU stays. HES data were used for estimating HRGs for ward stays,
outpatient and A&E attendances.
Incremental cost per BSI averted
(i) Base-case analysis based on deterministic analysis of unadjusted costs
Uncertainty analysis
(i) Joint uncertainty in costs and BSI based on bootstrapping
(ii) Sensitivity analysis of the time horizon
Dates: admission
and transfer/discharge
HRGs
Unit costs
Mean, 6-month total costs
Data from study CRF, cross-checked
against hospital patient administration 
systems and PICANet
Data from the Health and Social Care Information
Centre for ward, outpatient and A&E; data from
PICANet for HRGs relating to HDU and 
PICU admissions. Hospital patient administration 
systems to supplement missing data
Ward, outpatient and A&E costs based on the
2012–13 National Tariff; PICU, NICU and HDU 
based on the 2012–13 National Schedule of 
Reference Costs. Local bed-day rates applied for 
missing HRGs or unassignable National Tarrif HRGs
codes. Undiscounted CVC costs from the supplier
Rates of BSI based on the primary end point
FIGURE 3 Flow diagram of the methods employed for the economic evaluation.
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3. The PICANet data set.57 This data set includes all ICU length of stays for paediatric patients in the UK
and allows for the tracking over time of patients who have been transferred between ICUs in different
hospitals. PICANet data were used for the national schedule of reference costs HRGs for HDU and ICU
stays69 and for checking hospital admission, transfer and discharge dates.
4. Hospital Patient Administration Systems (PASs) of CATCH-participating hospitals. These were accessed
for patient lengths of stay on ICUs and wards and for relevant HRGs. These were used to supplement
data that were missing from other sources.
Unit costs
Healthcare Resource Groups were chosen as the main currency of the economic analysis as these most
closely reflect payments relating to patient stays. Cost codes based on the 2012–13 national tariff were
applied to ward, outpatient and A&E codes.70 These are bundled care packages, that is, they are
reimbursed at a national level according to the NHS Payment by Results scheme71 (see Appendix 3,
Table 33). The 2012–13 national schedule of reference costs69 was applied to PICU, NICU and HDU codes.
These are unbundled care packages as they are locally reimbursed services (Table 13). Obsolete national
tariff and schedule codes and hospital bed-day rates used between 2010 and 2012 were inflated using the
Consumer Price Index (4.3% for 2010–11 and 2.7% for 2011–12). The preferred Hospital Price Index was
available only for 2010–11, but was similar to the Consumer Price Index at 4.1%. The list prices of CVC
devices were obtained from the supplier (Cook Medical Inc.).
TABLE 13 Unit costs for intensive care and high-dependency care based on HRGs from the national schedule tariff
(2012–13)69
HRG code HRG name Primary description Secondary description
Cost per
day (£)
XB01Z Paediatric Critical
Care, Intensive Care,
ECMO/ECLS
Highly specialised intensive care
treatment, e.g. by ECMO
ECMO, ventricular assist devices and
other highly complex procedures
4391
XB02Z Paediatric Critical
Care, Intensive Care,
Advanced Enhanced
Unstable multisystem failure with
other complications
2409
XB03Z Paediatric Critical
Care, Intensive
Care, Advanced
Intensive nursing supervision at
all times, undergoing complex
monitoring and/or therapeutic
procedures and including
advanced respiratory support
Invasive ventilation with
multisystem failure
2017
XB04Z Paediatric Critical
Care, Intensive Care,
Basic Enhanced
Intensive ventilation with more than
one system failure
2110
XB05Z Paediatric Critical
Care, Intensive
Care, Basic
Continuous nursing supervision Invasive ventilation with single
system failure or non-invasive
ventilation with more than
one system failure
1743
XB06Z Paediatric Critical
Care, High
Dependency,
Advanced
Requiring closer observation and
monitoring than is usually
available on an ordinary
children’s ward, with higher than
usual staffing levels
Non-invasive ventilation (e.g. CPAP
and BIPAP by mask with intravenous
drugs)
1335
XB07Z Paediatric Critical
Care, High
Dependency
Close monitoring, oxygen by mask,
no invasive ventilation
886
COST-EFFECTIVENESS ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Cost analysis
Bundled national tariff costs were based on the hospital spell and incorporated excess ward-days, a market
forces factor and whether the case was elective or emergency. Tariff codes were obtained primarily from
HES data (see Appendix 3) or, when unavailable, PAS data. If bundled HRGs were missing from both of
these sources, ward costs were assigned from the ward bed-day rates supplied by hospital finance
departments (Table 14). Similarly, bed-day rates were applied to stays with unassignable national tariff
HRG codes (such as UZ01C and WA14Z) appearing in the HES and PAS data. These bed-day rates were
needed for < 1% of admissions.
TABLE 13 Unit costs for intensive care and high-dependency care based on HRGs from the national schedule tariff
(2012–13)69 (continued )
HRG code HRG name Primary description Secondary description
Cost per
day (£)
XB08Z Paediatric Critical
Care, Transportation
As paediatric critical care facilities are centralised in a small number of
hospitals providing expert specialist care, specialist transport teams are
required to deliver clinical management during transfer of patients
2799
XA01Z Neonatal Critical
Care, Intensive Care
Care provided for babies who
are the most unwell or unstable
and have the greatest needs in
relation to staff skills and staff to
patient ratios
Baby receives any form of
mechanical respiratory support via
a tracheal tube and/or parenteral
nutrition
1118
BIPAP; bilevel positive airway pressure; CPAP, continuous positive airway pressure; ECLS, extracorporeal life support;
ECMO, extracorporeal membrane oxygenation.
TABLE 14 Hospital ward bed-day rates as provided by hospital finance departments and adjusted for inflation
(UK pounds sterling, 2013)
Hospital HES hospital ID Market forces factora Ward rate (£)b
Birmingham Children’s Hospital RQ3 1.05 290
Bristol Royal Hospital for Children RA7 1.08 366
Evelina London Children’s Hospital (Guy’s and St Thomas’) RJ1 1.28 595c
Freeman Hospital RTD 1.04 595c
Alder Hey Children’s Hospital RBS 1.04 364d
Glenfield Hospital RWE 1.04 751
Great Ormond Street Hospital RP4 1.29 2157
Leeds General Infirmary RR8 1.05 542
Leicester Royal Infirmary RWE 1.04 751
Queen’s Medical Centre RX1 1.04 374
Royal Brompton Hospital RT3 1.25 370
Royal Victoria Infirmary RTD 1.25 342
Southampton General Hospital RHM 1.09 212
St Mary’s Hospital, London RYJ 1.24 394
a Used with HRGs only.
b Ward rate excludes ICU or HDU costs.
c Mean of series of wards provided by all hospitals except Alder Hey.
d Mean of series of wards provided by hospital.
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Unbundled, locally reimbursed costs were calculated from the national schedule ‘per day’ codes taken
from PICANet (see Table 13) or were assigned as XA01C in the cases in which neonatal critical care was
indicated in CRF data. In the 10% of cases in which unbundled codes were missing, CRF data were
consulted to determine whether the patient stay was in a PICU or a HDU. In addition, PICANet database
entries (such as patient note summaries) were examined for any evidence of advanced and/or enhanced
care. In the absence of any higher cost code indicators, a basic HDU code (XB07Z) or a basic ICU code
(XB05Z) was applied from the national schedule of reference costs.69
Baseline costs, relating to the 6 months preceding randomisation, were calculated from HES and PICANet
data on ward, PICU and HDU costs.
For the 6 months subsequent to randomisation, an adjustment was necessary to apportion costs given that
ward, PICU and HDU costs related to episodes of care could start prior to randomisation. Patients admitted
to hospital n days before randomisation and spending N days in hospital after randomisation had their
total costs calculated as:
Total cost= (N=n+N)×(ward cost+PICU cost+HDU cost)+ (outpatient costs+A&E costs+CVC costs): (1)
Patients’ use of health-care resources and total costs were calculated for the intention-to-treat population,
with summary statistics generated by intervention group.
Outcomes
The clinical outcome for the cost-effectiveness analysis was the presence of a first BSI defined by a positive
blood culture from a sample that was clinically indicated and taken more than 48 hours after CVC
insertion and up to 48 hours after CVC removal. The likelihood of a BSI was estimated using a logistic
regression analysis with intervention group as the explanatory variable.
Incremental analysis
The cost-effectiveness of each CVC was evaluated by (1) ranking CVCs according to decreasing
effectiveness and (2) eliminating dominated interventions (those that were less effective or ineffective) or
any extendedly dominated interventions. The ICER for the remaining CVCs was consequently calculated
according to the following equation:
ICER=Δcosts=ΔBSIs, (2)
where Δcosts is the difference in mean total costs between interventions and ΔBSIs is the difference in the
risk of BSIs between interventions.
Uncertainty analysis
Non-parametric bootstrapping (10,000 replicates) was used to calculate bias-adjusted 95% central ranges
for differences in costs and BSIs and their joint distributions. Uncertainty was represented using a
cost-effectiveness acceptability curve (CEAC), which presented the probability of CVCs being cost-effective
for given ceiling thresholds of costs per BSI averted.72
Uncertainty in total costs was further explored by adjusting for the contribution of independent baseline
factors to overall variability.73
The following predefined explanatory variables were tested for independent associations with total costs:
age group, body weight, 6-month pre-randomisation costs (all log-transformed), gender, pre-existing CVC
72 hours prior to randomisation, health status before PICU admission, reason for admission (cardiovascular,
endocrine or metabolic, infection, neurological, oncology, respiratory, trauma, other), suspected infection
at randomisation, immunocompromised, positive blood culture within 72 hours prior to randomisation,
numbers of devices in situ, intervention group and admission type (elective or emergency). Assumptions
were necessary to account for missing data with respect to some variables: patients were assumed to be
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healthy (n= 1), not immunocompromised (n= 19) and to have no positive blood cultures (n= 5). Missing
data for weight (n= 2) were imputed with the mean participant weight (11.95 kg). Missing reasons for
admission (n= 20) were cross-checked against PICANet, PAS and available HES data. All were correctly
assigned as cardiovascular patients.
Independent variables were tested in univariate analyses for their association with total costs, with risk factors
that were significant at the 5% level selected for the multivariable regression using a stepwise approach.
Given the non-normality of the cost data, generalised linear models were specified using a range of families
and links. Assessment of goodness of fit using the Akaike information criterion (AIC) and the modified Park
test was inconclusive, but the best-fitting link function, determined from the Pearson correlation, Pregibon link
and modified Hosmer and Lemeshow tests, was the identity link. Although the underlying true distributions of
costs are not normal, the analysis depends only on sample means and variances. Based on the comparatively
large sample size, the central limit theorem was assumed to guarantee near normality of sample means and
an ordinary least squares regression was considered appropriate.73
Bias-corrected CIs for costs and BSIs were estimated from bootstrapped data generated using the recycled
predictions method.74
Sensitivity analysis
The prespecified time horizon of 6 months in the base-case analysis was selected to capture longer-term
costs resulting from potential complications of BSIs but was somewhat arbitrary. The sensitivity of total
costs and the ICERs to the time horizon of analysis was therefore considered by limiting costs to those
incurred during the index hospitalisation (i.e. excluding any subsequent readmissions that may have
occurred during the 6 months) and by analysing their relationship with time, from 1 month (when all BSIs
had occurred) to 6 months.
Value of health-care resources associated with bloodstream infection
In an exploratory analysis, a variable representing the presence of a BSI was included in the cost regression
to estimate the value of the health-care resources associated with managing a BSI. To avoid collinearity,
the variable representing intervention group was omitted from this regression.
All analyses were performed using Stata version 10 (StataCorp LP, College Station, TX, USA) and the
economic evaluation was reported according to the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) statement.75
Results
Resource use and total costs
Complete cost data were available for all patients. In the 6 months preceding randomisation, the mean
costs (length of stay) of ICU/HDU admissions were £6026 (3.19 days) for the standard CVC group, £5188
(2.76 days) for the antibiotic CVC group and £6616 (3.47 days) for the heparin CVC group. The mean
total hospital costs for the corresponding period were £15,588, £16,933 and £16,722, respectively.
Neither ICU/HDU costs nor total hospital costs differed by intervention group.
Patients randomised to antibiotic-impregnated CVCs spent a mean of 10.8 days (95% CI 9.3 to 12.5) in
the PICU in the 6 months following randomisation compared with 9.9 days (95% CI 8.6 to 11.4) for those
in the heparin-bonded CVC group and 10.5 days (95% CI 9.2 to 11.9) for those in the standard CVC
group (Table 15). There were no significant differences between groups in length of stay in the PICU
(p= 0.70), HDU (p= 0.43) or ward (p= 0.52). The mean total hospital stay in the 6 months after
randomisation was 34.8 days (95% CI 31.2 to 38.5 days) for antibiotic CVCs, 31.4 days (95% CI 28.2 to
34.7 days) for heparin-bonded CVCs and 31.7 (95% CI 28.8 to 34.8 days) for standard CVCs. The six most
significant HRGs (of 349 in total) accounted for 50% of ward costs. These related to surgical correction of
congenital malformations, cardiac surgery or disorders of the lower respiratory tract.
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TABLE 15 Patient length of stay and count of dominant HRGs relating to inpatient stays from randomisation to
6 months (including readmissions) according to place and intensity of care and intervention group
Unit
Antibiotic Heparin Standard
Mean
(median) 95% CI
Mean
(median) 95% CI
Mean
(median) 95% CI
Days on ICU 10.79 (5.00) 9.28 to 12.48 9.91 (5.00) 8.57 to 11.44 10.50 (5.00) 9.17 to 11.93
Paediatric Critical Care,
Intensive Care, ECMO/
ECLS (XB01Z)
0.31 (0.00) 0.07 to 0.72 0.39 (0.00) 0.09 to 0.80 0.41 (0.00) 0.17 to 0.72
Paediatric Critical Care,
Intensive Care, Advanced
Enhanced (XB02Z)
0.16 (0.00) 0.09 to 0.26 0.12 (0.00) 0.09 to 0.15 0.16 (0.00) 0.10 to 0.26
Paediatric Critical Care,
Intensive Care, Advanced
(XB03Z)
0.77 (0.00) 0.51 to 1.05 0.62 (0.00) 0.43 to 0.83 0.65 (0.00) 0.46 to 0.87
Paediatric Critical Care,
Intensive Care, Basic
Enhanced (XB04Z)
2.30 (0.49) 1.92 to 2.72 2.69 (0.78) 2.09 to 3.44 2.76 (0.00) 2.14 to 3.54
Paediatric Critical Care,
Intensive Care, Basic
(XB05Z)
6.96 (2.00) 5.65 to 8.45 5.63 (2.00) 4.75 to 6.59 6.40 (2.95) 5.42 to 7.47
Neonatal Critical Care,
Intensive Care (XA01C)
0.29 (0.00) 0.10 to 0.55 0.46 (0.00) 0.13 to 1.03 0.11 (0.00) 0.04 to 0.20
Days on HDU 2.00 (0.59) 1.48 to 2.62 1.60 (0.59) 1.28 to 1.99 1.73 (0.00) 1.44 to 2.05
Paediatric Critical Care,
High Dependency,
Advanced (XB06Z)
1.28 (0.00) 0.94 to 1.70 1.09 (0.00) 0.80 to 1.45 1.22 (0.00) 0.98 to 1.49
Paediatric Critical Care,
High Dependency (XB07Z)
0.72 (0.00) 0.42 to 1.16 0.51 (0.00) 0.40 to 0.64 0.51 (0.00) 0.40 to 0.64
Days on ward 22.01 (9.13) 19.26 to 24.80 19.85 (9.00) 17.40 to 22.40 19.48 (8.57) 17.12 to 21.94
Total days in hospital 34.80 (20.00) 31.21 to 38.48 31.36 (17.00) 28.18 to 34.65 31.72 (17.97) 28.75 to 34.81
Count of non-PICU/-HDU inpatient HRGs
Complex Congenital
Surgery (EA24Z)
100 103 109
Intermediate
Congenital Surgery
(EA25Z)
68 70 72
Major Complex
Congenital Surgery
(EA23Z)
45 39 37
Cardiac Conditions
with Complication and
Comorbidity (PA23A)
109 102 74
Lower Respiratory Tract
Disorders without
Acute Bronchiolitis
with Length of
Stay ≥ 1 day with
Complication and
Comorbidity (PA14C)
95 78 105
Implantation of
Prosthetic Heart or
Ventricular Assist
Device (EA43Z)
2 2 4
Other inpatient HRGs 1103 1055 964
ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation.
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Total and disaggregated costs are presented in Table 16. The mean 6-month cost was £44,503
(median £28,952, range £1786–360,983, 95% CI £40,619 to £48,666) for standard CVCs, £45,663
(median £29,793, range £2189–442,365, 95% CI £41,647 to £50,009) for antibiotic-impregnated CVCs
and £42,065 (median £27,621, range £2638–382,431, 95% CI £38,322 to £46,110) for heparin CVCs
(Figure 4). These costs were not statistically significantly different between intervention groups (p= 0.46) or
when disaggregated according to bundled costs (p= 0.43) and unbundled costs (p= 0.73).
TABLE 16 Disaggregated and total costs (£) by intervention group from randomisation to the end of the 6-month
time frame
Unit
Antibiotic Heparin Standard
Mean
(median) 95% CI
Mean
(median) 95% CI
Mean
(median) 95% CI
Paediatric critical care, intensive care
ECMO/ECLS (XB01Z) 1358 (0) 310 to 3159 1703 (0) 386 to 3509 1796 (0) 723 to 3156
Advanced Enhanced
(XB02Z)
388 (0) 207 to 636 289 (0) 216 to 371 395 (0) 228 to 620
Advanced (XB03Z) 1545 (0) 1031 to 2124 1250 (0) 872 to 1674 1318 (0) 933 to 1752
Basic Enhanced
(XB04Z)
4861
(1023)
4060 to 5738 5675
(1646)
4418 to 7260 5822 (0) 4512 to 7460
Basic (XB05Z) 12,137
(3486)
9855 to 14,730 9822
(3486)
8274 to 11,489 11,159
(5133)
9440 to 13,025
Neonatal Critical
Care, Intensive
Care (XA01C)
325 (0) 113 to 613 517 (0) 142 to 1150 125 (0) 42 to 225
Paediatric critical care, high dependency
High Dependency,
Advanced (XB06Z)
1709 (0) 1254 to 2271 1450 (0) 1972 to 1940 1629 (0) 1301 to 1992
High Dependency
(XB07Z)
635 (0) 372 to 1025 454 (0) 354 to 567 456 (0) 356 to 566
Transportation
(XB08Z)
1158 (0) 1022 to 1293 1258 (0) 1109 to 1413 1208 (0) 1068 to 1353
Subtotal
(PICU/HDU/NICU)a
24,115
(12,201)
20,824 to 27,764 22,417
(11,903)
19,429 to 25,771 23,907
(12,495)
20,989 to 27,049
Inpatient stayb
Complex Congenital
Surgery (EA24Z)
3011 (0) 2445 to 3593 2908 (0) 2363 to 3481 3144 (0) 2565 to 3753
Intermediate
Congenital
Surgery (EA25Z)
2166 (0) 1670 to 2699 1934 (0) 1470 to 2440 2044 (0) 1583 to 2545
Major Complex
Congenital
Surgery (EA23Z)
1865 (0) 1315 to 2481 1915 (0) 1310 to 2603 1466 (0) 1013 to 1960
Cardiac Conditions
with Complication
and Comorbidity
(PA23A)
1277 (0) 818 to 1845 1173 (0) 831 to 1558 739 (0) 495 to 1025
continued
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TABLE 16 Disaggregated and total costs (£) by intervention group from randomisation to the end of the 6-month
time frame (continued )
Unit
Antibiotic Heparin Standard
Mean
(median) 95% CI
Mean
(median) 95% CI
Mean
(median) 95% CI
Lower Respiratory
Tract Disorders
without Acute
Bronchiolitis with
Length of Stay
≥ 1 day with
Complication and
Comorbidity
(PA14C)
858 (0) 593 to 1157 668 (0) 454 to 913 943 (0) 657 to 1268
Implantation of
Prosthetic Heart or
Ventricular Assist
Device (EA43Z)
273 (0) 0 to 684 298 (0) 0 to 762 548 (0) 103 to 1155
Other inpatient
HRG costs
10,316
(4017)
8616 to 12,231 8803
(3058)
7524 to 10,106 9930
(3259)
7860 to 12,409
Subtotal (inpatient) 19,766
(14122)
17,934 to 21,755 17,700
(13,716)
16,308 to 19,182 18,814
(13,748)
16,649 to 21,327
Other
A&E costc 89 (0) 76 to 104 85 (0) 73 to 99 91 (0) 78 to 104
Outpatient costc 1615
(883)
1412 to 1838 1784
(837)
1496 to 2109 1648
(881)
1453 to 1871
CVC costd 78.28 78 to 78 78.25 78 to 78 42.91 43 to 43
Total cost
(full 6 months)
45,663
(29,793)
41,647 to 50,009 42,065
(27,621)
38,322 to 46,110 44,503
(28,952)
40,619 to 48,666
ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation.
a National Schedule of Reference Costs 2012–13.69
b Top six (of 349) HRGs ranked by cost, together contributing 50% of overall inpatient costs.
c 2012–13 national tariff HRGs: < 1% taken from bed-day rates.
d Costs supplied by CVC provider (Cook Medical Inc.).
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FIGURE 4 Ranking of 6-month total costs by intervention group, indicating patients who experienced a BSI.
(a) Antibiotic CVCs; (b) heparin CVCs; and (c) standard CVCs.
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Incremental costs
Mean unadjusted costs over the 6-month time frame were not significantly different by CVC but tended to
be higher (by £1160, 95% CI –£4743 to £6962) for antibiotic CVCs than for standard CVCs and lower
(–£2439, 95% CI –£8164 to £3359) for heparin CVCs compared with standard CVCs.
Randomisation ensured that all variables tested for the cost regression were well balanced between
intervention groups. Only a small proportion (< 10%) of the residual variability in total cost could be
explained by the significant independent predictor variables: natural logarithm (ln) of age (in days), ln of
6-month pre-randomisation costs, health status before PICU admission, reason for admission, whether or
not immunocompromised and admission type (elective or emergency; Table 17). The adjusted incremental
costs associated with the antibiotic and heparin CVC groups in relation to the standard CVC group were
£1220 (95% CI –£4332 to £6773) and –£2399 (95% CI –£7914 to £3120), respectively, resulting in small
improvements in precision.
Value of health-care resources associated with bloodstream infection
Over 6 month, patients who had experienced a BSI (n= 42) experienced 6.5 more days (95% CI 1.4 to
11.6 days) in the PICU than those with no BSI (n= 1443) and 15.1 additional total days (95% CI 4.0
to 26.2 days) of hospitalisation. The unadjusted mean 6-month cost for patients with a BSI was £60,481
(95% CI £47,873 to £73,809) and for patients without a BSI was £43,578 (95% CI £41,185 to £45,970),
a difference of £17,263 (95% CI –£3076 to £31,450). The regression-derived adjusted difference in cost,
representing the value of the resources used to manage BSI, was £10,975 (95% CI –£2801 to £24,751)
(Table 18).
TABLE 17 Adjusted total (6-month) costs: results of the ordinary least squares regression of total costs based on
significant baseline variables
Variable Coefficient (£) 95% CI (£) p-value
Ln of pre-randomisation cost 1444 602 to 2287 < 0.001
Admission type 27,423 20,993 to 33,853 < 0.001
Intervention group (antibiotic) 1221 –4332 to 6773 0.67
Intervention group (heparin) –2399 –7917 to 3120 0.39
Prior health status (0= not healthy; 1= healthy) –9974 –15,807 to –4140 < 0.001
Reason for admission (endocrine/metabolic) –1921 –11,889 to 8048 0.71
Reason for admission (infection) –22,300 –32,609 to –11,992 < 0.001
Reason for admission (neurological) –21,854 –32,780 to –10,927 < 0.001
Reason for admission (oncology) 2641 –16,052 to 21,333 0.78
Reason for admission (other) –3510 –14,355 to 7335 0.53
Reason for admission (respiratory) –8289 –15,609 to –968 0.03
Reason for admission (trauma) –12,144 –26,764 to 2477 0.1
Compromised immunity (yes/no) 8476 –1246 to 18,198 0.09
Ln of age in days –236 –1300 to 828 0.66
Constant 24,086 13,255 to 34,916 < 0.001
BIC, Bayesian information criterion.
AIC= 24.25; BIC= 2.89 × 1012; R2= 0.092.
COST-EFFECTIVENESS ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
Outcomes
Seven of 486 children randomised to antibiotic CVCs experienced a BSI compared with 17 out of 497 in
the heparin CVC group and 18 out of 502 in the standard CVC group. A statistically significant absolute
risk difference was found only for antibiotic CVCs compared with standard CVCs (–2.15%, 95% CI
–4.09% to –0.20%). Compared with standard CVCs, the unadjusted odds of acquiring a BSI with an
antibiotic CVC was 0.39 (95% CI 0.16 to 0.95; p= 0.04) and with a heparin CVC was 0.95 (95% CI 0.49
to 1.87; p= 0.89).
Incremental and uncertainty analysis
As heparin CVCs were shown not to be clinically effective compared with standard CVCs there is no case
for an incremental analysis: a clinically ineffective intervention cannot be cost-effective according to the
same measure of BSI. The calculation of the ICER was therefore limited to the comparison between
antibiotic and standard CVCs, which resulted in an ICER of £54,057 per BSI averted (Table 19).
The CEAC yielded probabilities of 0.38, 0.49 and 0.62 of antibiotic CVCs being cost-effective at (arbitrary)
thresholds of £10,000, £50,000 and £100,000 per BSI averted respectively (Figure 5). The probability of
antibiotic CVCs dominating standard CVCs was estimated as 0.35.
Sensitivity analysis
The mean number of days in hospital during the index hospitalisation was substantially shorter (e.g. 22.1 days
for antibiotic CVCs) than the mean number of days in hospital during the 6 months from randomisation
(e.g. 34.8 days for antibiotic CVCs; Table 20 and see Table 15). Considering only the index hospitalisation,
total costs tended to be lower in the antibiotic CVC group (£33,073, 95% CI £30,047 to £36,337) and in
the heparin CVC group (£32,245, 95% CI £29,013 to £35,823) than in the standard CVC group (£35,165,
95% CI £31,864 to £38,670). The unadjusted incremental cost saving for antibiotic compared with standard
CVCs was –£2093 (95% CI –£6919 to £2583) and for heparin compared with standard CVCs was –£2920
(95% CI –£7833 to £2180).
TABLE 18 Value of health-care resources associated with managing a BSI: results of the ordinary least squares
regression for estimating the cost of BSI, with total costs as the dependent variable and univariately significant
baseline explanatory variables
Variable Coefficient (£) 95% CI (£) p-value
Ln of pre-randomisation cost 1439 598 to 2281 0.001
Admission type 27,341 20,916 to 33,767 < 0.001
Prior health status (0= not healthy; 1= healthy) –9593 –15,440 to –3745 0.001
Reason for admission (endocrine/metabolic) –2005 –11,968 to 7959 0.693
Reason for admission (infection) –22,585 –32,896 to –12,274 < 0.001
Reason for admission (neurological) –21,648 –32,559 to –10,736 < 0.001
Reason for admission (oncology) 2335 –16,347 to 21,017 0.806
Reason for admission (other) –2948 –13,789 to 7894 0.594
Reason for admission (respiratory) –8170 –15,484 to –856 0.029
Reason for admission (trauma) –12,412 –27,016 to 2192 0.096
Compromised immunity (yes/no) 7965 –1770 to 17,700 0.109
Ln of age (in days) –178 –1243 to 885 0.742
BSI (0= no; 1= yes) 10,975 –2801 to 24,751 0.118
Constant 23,064 12,759 to 33,369 < 0.001
R2= 0.092.
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TABLE 19 Incremental analysis of unadjusted costs (mean values with 95% central range)
Analysis Antibiotic Heparin Standard
Base-case analysis (6-month time horizon)
Total cost (£) 45,663 (41,647 to 50,009) 42,064 (38,322 to 46,110) 44,503 (40,619 to 48,666)
Incremental cost (vs. standard) (£) 1160 (–4743 to 6692) –2438 (–8164 to 3359) –
BSI (%) 1.44 (0.4 to 2.5) 3.42 (1.8 to 5.0) 3.59 (2.0 to 5.2)
Incremental BSI (vs. standard) (%) –2.15 (–4.1 to –0.2) –0.17 (–2.5 to 2.1) –
ICER (vs. standard) (£) 54,057 per BSI averted –a –
Sensitivity analysis (index hospitalisation)
Total cost (£) 33,073 (30,047 to 36,337) 32,245 (29,013 to 35,823) 35,165 (31,864 to 38,670)
Incremental cost (vs. standard) (£) –2093 (–6919 to 2583) –2920 (–7833 to 2180) –
BSI (%) 1.44 (0.4 to 2.5) 3.42 (1.8 to 5.0) 3.59 (2.0 to 5.2)
Incremental BSI (vs. standard) (%) –2.15 (–4.1 to –0.2) –0.17 (–2.5 to 2.1) –
ICER (vs. standard) (£) –97,543 per BSI avertedb –a –
a As heparin CVCs were not deemed to be clinically effective in reducing BSI rates, they cannot be cost-effective for the
same outcome measure.
b Cost saving.
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FIGURE 5 Cost-effectiveness acceptability curve based on a 6-month time horizon presenting the probabilities of
antibiotic and standard CVCs being cost-effective for given values of ceiling ratio expressed as cost per BSI averted.
COST-EFFECTIVENESS ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
Based only on the costs of the index stay, antibiotic CVCs dominated standard CVCs with a saving of
£97,543 per BSI averted (see Table 19).
An analysis of the cumulative mean costs over the course of the 6 months (Figure 6) shows that costs in
the heparin CVC group were lower overall, whereas costs in the antibiotic CVC group were variably cost
incurring and cost saving in comparison to costs in the standard CVC group.
The resulting ICER for antibiotic compared with standard CVCs fluctuated considerably (Figure 7), ranging
from £82,204 saved per BSI averted by day 50 post randomisation to being cost neutral by day 122 and to
the base-case cost of £54,057 per BSI averted by 6 months.
TABLE 20 Patient length of stay for hospitalisation episode from randomisation by intervention group
Unit
Antibiotic Heparin Standard
Mean 95% CI Mean 95% CI Mean 95% CI
Days on ICU 9.31 8.09 to 10.70 8.93 7.71 to 10.32 9.79 8.60 to 11.03
Days on HDU 1.70 1.25 to 2.25 1.39 1.09 to 1.76 1.51 1.24 to 1.80
Days on ward 11.13 9.19 to 13.18 10.32 8.59 to 12.18 10.79 9.03 to 12.70
Total days in hospital 22.14 19.48 to 24.89 20.65 18.27 to 23.16 22.09 19.76 to 24.51
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Chapter 5 Generalisability study
Introduction
The CATCH trial was the largest trial carried out in PICUs to date, recruiting 1485 children within 14 PICUs in 12
NHS trusts in England, corresponding to 5% of children admitted to all PICUs in England and Wales during the
trial period (2010–12). However, if antibiotic-impregnated CVCs were to be adopted, it is likely that these CVCs
would be bulk purchased and used for all children requiring CVCs in PICUs, not just children like those in the
trial. Those making decisions on whether or not to purchase antibiotic-impregnated CVCs therefore need to
take into account the generalisability of benefits to all children who need a CVC and the cost impact of
purchasing the more expensive impregnated CVCs.
In terms of generalisability, trial populations may have different characteristics and outcomes from the
characteristics and outcomes of those who receive the intervention in practice, for a variety of reasons.76
In the CATCH trial there were two specific reasons why those recruited might differ from those likely to
receive impregnated CVCs outside the trial setting. First, children recruited to the CATCH trial were
expected to require a CVC for ≥ 3 days and would therefore have a higher risk of BSI than those staying
for < 3 days. Second, the introduction of CVC care bundles and ongoing improvements in infection control
in recent years have been associated with rapidly decreasing rates of BSI over the past decade, meaning
that the background BSI rate may be lower now than it was at the start of the trial.33,34
In terms of budget impact, impregnated CVCs are approximately twice as expensive as standard CVCs.
However, the additional costs might be outweighed by the number of BSIs averted through using the
more effective CVCs and the associated reduction in the use of health-care resources.
We determined the generalisability of the CATCH trial findings by estimating risk-adjusted trends in the
rate of BSIs for children expected to require CVCs in PICUs, based on a data linkage study including
children not participating in the CATCH trial.77 We determined the budget and cost impacts of adopting
antibiotic-impregnated CVCs for all children requiring a CVC in the PICU by synthesising the following
evidence: (1) the estimated risk of BSI using standard CVCs (derived from the data linkage study); (2) the
number of BSIs potentially averted by using antibiotic-impregnated CVCs (based on the relative treatment
effect in the trial); (3) the additional costs associated with purchasing impregnated CVCs for all children
expected to require a CVC (numbers of CVCs based on PICU survey data); and (4) the value of the
health-care resources associated with each BSI (from the CATCH cost-effectiveness analysis).
Methods
Rate of bloodstream infections using standard central venous catheters
Data sources
There is no single data set from which the rate of BSIs in PICUs across the NHS can be estimated for children
requiring standard CVCs. Linkage between the national laboratory surveillance system co-ordinated by PHE
(LabBase2)78 and data from PICANet57 has provided an enhanced data set from which to estimate the
baseline rate of BSIs.
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Details of the data linkage study have been published elsewhere.77 Briefly, a combination of deterministic
linkage and a method called prior-informed imputation was used to identify PICANet admission records
that had a corresponding record of a BSI in LabBase2.79,80 A set of deterministic rules based on agreement
between NHS number, hospital number, first name, surname, date of birth and postcode was used to
identify unequivocal links. For the remaining records, match probabilities were calculated based on date of
birth, Soundex code for surname, sex and location (laboratory and hospital). Match probabilities were used
to inform imputation of values for uncertain links using prior-informed imputation.79,80 Five imputed data
sets were produced and analysed separately, with results combined using Rubin’s rules.81
The resulting linked data set captured approximately 71% of all children aged < 16 years admitted to
20 of the 25 PICUs in England and Wales between March 2003 and December 2012 and is broadly
representative of the whole PICU population.82 As some PICUs used impregnated CVCs for some patients,
we restricted the linked data set to children expected to require a standard CVC in a PICU in England.
Types of CVCs used for emergency and elective admissions at each PICU were derived from responses to
a PICU practice survey sent to a designated consultant at each PICU in 2009.32 When no response was
obtained or the PICU was not included in the survey, we assumed that standard CVCs were used.
Identifying children with central venous catheters
Central venous catheter use is not routinely captured for all admissions in PICANet, so we identified
admissions likely to have included use of a CVC using a statistical model. We estimated the probability
of CVC use for all admissions based on a subset of individual-level audit data in which CVC used was
recorded.82 Presence of a CVC was recorded for 2488 admissions as part of two audits: London’s Great
Ormond Street Hospital (January 2006–December 2010) and Cambridge’s Addenbrooke’s Hospital
(July 2009–December 2009). We used a multivariable logistic regression model to predict the probability of
CVC use for all admissions, based on potentially predictive variables recorded in PICANet (e.g. use of
vasoactive agents, length of stay and other clinical factors). The best-fitting predictive model was chosen
based on the Bayesian information criterion (BIC).
The internal validity of the model was assessed using bootstrapping, accounting for any model overfitting
from developing and testing the model in the same data set.83–85 The external validity was assessed
using aggregate data from a further two PICUs. We identified the subset of admissions most likely to have
required a CVC using a probability cut-off based on the Youden Index.86 Full details of the predictive
model are provided in Appendix 4.
Estimated BSI rates were based on the subset of admissions identified by the predictive model as most
likely to have received standard CVCs.
Case definition
We estimated CVC-days at risk of BSI by assuming that, for children expected to require a CVC, bed-days
in the PICU were equivalent to CVC-days, that is, CVCs were inserted at admission and removed at
discharge from the PICU. We defined an episode of BSI as any positive blood culture isolated from a blood
sample taken from 2 days after admission to 2 days after discharge from the PICU. Repeated samples with
positive cultures of the same organism within 14 days were treated as the same episode.
Statistical analysis
Rates of BSI per 1000 CVC-days were modelled using multilevel Poisson regression. We accounted for
clustering of admissions within PICUs by including a random effect for PICU. The appropriateness of the
Poisson model was verified using a goodness of fit test based on the deviance statistic. For comparisons
between units and over time, rates were adjusted for risk factors identified as being significant (p< 0.05).
Likelihood ratio tests were used to identify significant interactions between risk factors.
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We compared BSI rates between CATCH participants using a standard CVC and non-participating
admissions expected to require a standard CVC and non-participating admissions in the same PICUs but
not expected to require a CVC. For non-participating PICUs, the trial period was defined as the period
between December 2010 (when the first PICU began recruiting) and December 2012 (when the last PICU
stopped recruiting).
Number of bloodstream infections averted using antibiotic central
venous catheters
We estimated the difference in the number of BSIs if antibiotic CVCs were used in place of standard CVCs.
We asked PICUs to provide the percentage of emergency and elective admissions receiving CVCs in a
second PICU practice survey conducted in 2012 (not published but a repeat of the first survey32). The
number of admissions requiring CVCs in all 23 PICUs in England was then estimated by applying these
percentages to the number of emergency and elective admissions within each PICU. The total number of
CVC-days was estimated by multiplying the number of CVCs required by the mean number of CVC-days
for children expected to require a CVC in PICANet.
We estimated the BSI rate using antibiotic CVCs in place of standard CVCs by applying the relative
treatment effect (rate ratio) from the trial to the BSI rate using standard CVCs.
We assumed that the relative treatment effect would be the same regardless of the baseline rate of BSIs,
that is, the effect would be the same for children who would have been ineligible for the trial because
they were expected to stay for < 3 days in the PICU. We reasoned that the biological mechanism through
which impregnated CVCs work is the same for low- and high-risk patients (impregnated CVCs reduce
the chance that bacteria track internally or externally along the CVC from the insertion site). RCTs of
impregnated CVCs show similar results for long- and short-term CVCs, suggesting that the effect is not
modified in groups with a different baseline risk or length of stay.2 In reality, 72% of children recruited in
the CATCH trial required a CVC for ≥ 3 days.
Budget impact: additional costs of antibiotic central venous catheters
Antibiotic CVCs are more expensive than standard CVCs: £73 compared with £42 for double-lumen CVCs
and £79 compared with £43 for triple-lumen CVCs. The total additional costs of antibiotic CVCs were
calculated by multiplying the number of CVCs required by the maximum additional cost per CVC, that is
£36. We assumed, conservatively, that any change in PICU length of stay, nursing or other resources
would not impact on hospital budgets. The budget impact was therefore based on the additional costs of
antibiotic CVCs only.
Cost impact: value of resources associated with managing
bloodstream infections
Assuming that any differences in costs between arms were the result of differences in the number of BSIs,
the cost impact analysis utilised the estimated difference in the 6-month risk-adjusted costs between
patients who had a BSI and those who did not (£10,975 per BSI, 95% CI –£2801 to £24,751)
(cost-effectiveness analysis; see Table 18).
The total number of BSIs potentially averted was estimated by applying the BSI rate assuming that all
children in 2012 had used either standard CVCs or antibiotic CVCs. The cost impact (total value of
resources associated with managing BSIs with standard CVCs) was calculated by multiplying the costs per
BSI by the estimated number of BSIs averted if antibiotic CVCs were used instead of standard CVCs.
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Sensitivity analysis
We estimated the budget and cost impacts based on best- and worst-case scenarios for the total number
of CVCs required and the excess number of BSIs for standard compared with antibiotic CVCs. We also
performed probabilistic sensitivity analysis using Monte Carlo simulation to reflect uncertainty in both costs
and number of BSIs. Values for each parameter were sampled from probability distributions based on
observed data and 5000 iterations were performed to provide a 95% uncertainty interval for the
cost impact.87
Results
Rate of bloodstream infections using standard central venous catheters
Of the 2488 admissions in the CVC audit data, 1431 (58%) required a CVC. The best-fitting prediction
model included length of stay, vasoactive agent, admission from ward, renal support and invasive
ventilation (see Appendix 4, Table 37). With a probability cut-off of 0.57, the sensitivity of the predictive
model for capturing admissions requiring a CVC was 61%, specificity was 82%, the positive predictive
value was 82% and the negative predictive value was 61%. The predictive model identified 80% of the
CATCH admissions as requiring a CVC.
Survey responses for the types of CVCs used prior to the CATCH trial were obtained for 18 of the
23 PICUs in England (see Appendix 4, Table 36). Only two PICUs reported not using standard CVCs for any
admissions (both used heparin CVCs). BSI rates were estimated based on linked data from the remaining
16 English PICUs.
Applying the predictive model to the 16 PICUs in the linked data set identified a subset of 21,381 admissions
most likely to have received a standard CVC between 2003 and 2012. The characteristics of these
admissions (based on PICANet data) are provided in Appendix 4 (see Table 38). Risk-adjusted rates of BSI
using standard CVCs decreased steadily between 2003 and 2012 and were greater for CATCH PICUs (5.27,
95% CI 5.06 to 5.49 per 1000 CVC-days in 2012) than for non-participating PICUs (2.09, 95% CI 1.60 to
2.58 per 1000 CVC-days in 2012) (Figure 8). Of the subset of admissions predicted to receive a CVC in 2012,
103 out of 3021 (3.4%) experienced a BSI, corresponding to an overall BSI rate using standard CVCs of
4.58 (95% CI 4.42 to 4.74) per 1000 CVC-days (Table 21). This was non-significantly lower than the rate
observed during the trial (8.24, 95% CI 4.7 to 11.8 per 1000 CVC-days; see Table 9), partially because of
the inclusion of all children with CVCs (not just those requiring CVCs for ≥ 3 days). Further explanations for
this difference are the potentially incomplete reporting of BSIs to the national infection surveillance system,
use of bed-days instead of CVC-days in the estimated rate and the increased frequency of sampling in trial
PICUs during the CATCH trial.
Number of bloodstream infections averted using antibiotic central
venous catheters
Survey responses indicated that, on average, 60% of emergency admissions and 50% of elective
admissions require a CVC (see Appendix 4, Table 36). The estimated number of children using CVCs in
2012 was 8831, corresponding to a total of 85,971 CVC-days (see Table 21). The rate ratio for BSIs for
antibiotic compared with standard CVCs was estimated as 0.40 (95% CI 0.17 to 0.97; see Table 10) in the
trial. The point estimate of the number of BSIs averted by switching from standard to antibiotic CVCs for
all children requiring CVCs in 2012 was therefore 232, with best- and worst-case scenarios of 332 and
11 respectively (Table 22).
Budget impact: additional costs of antibiotic central venous catheters
Based only on a CVC cost difference of £36, the additional cost of purchasing antibiotic CVCs for all
children in 2012 was 8831 × £36= £317,916.
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TABLE 21 Parameter estimates for the cost impact and sensitivity analyses
Variable Base case Source Sensitivity analysis
BSI rate using standard
CVCs in 2012 per 1000
CVC-days
4.58 (95% CI
4.42 to 4.74)
3021 admissions in 15 PICUs –
subset of admissions identified as
most likely to have received a
standard CVC by applying the
predictive model to the linked data
set. Admissions identified by survey
responses as receiving non-standard
(heparin or antibiotic) CVCs were
excluded
Random sample taken with
replacement from the linked data
set for the number of admissions
expected to require a CVC
Rate ratio 0.40 (95% CI
0.17 to 0.97)
Trial clinical effectiveness analyses
(see Table 10)
Log-normal distribution with
parameters (–0.913, 0.415)
Estimated BSI rate using
antibiotic CVCs in 2012
per 1000 CVC-days
1.83; worst case
4.29, best case
0.81
Rate ratio from the CATCH trial
applied to the estimated BSI rate
using standard CVCs for PICUs
in England
Derived from (i) the BSI rate using
standard CVCs and (ii) the rate
ratio
Number of admissions
requiring CVCs in 2012
8831 Average survey estimates for the
percentage of emergency (60%)
and elective (50%) admissions
requiring CVCs, applied to all
admissions in PICANet in 2012
(15,739 admissions in 23 PICUs)
Beta distributions with stated
parameters: emergency: beta
(60,40); elective: beta (50,50)
Number of CVC-days
in 2012
85,971 Average bed-days per admission in
the subset of admissions identified
as most likely to have received a
standard CVC by applying the
predictive model to the linked data
set, multiplied by the number of
admissions requiring a CVC in 2012
Random sample taken with
replacement from the linked data
set for admissions expected to
require a CVC
Number of BSIs averted
in 2012
232 BSI rate applied to CVC-days for
admissions requiring a CVC in 2012
Derived from (i) the number of
admissions requiring a CVC in
2012 and (ii) the estimated BSI rate
using antibiotic CVCs
Additional cost of
antibiotic CVCs
£36 Difference in costs between
standard (£43) and antibiotic (£79)
CVCs (conservative case assuming
triple-lumen CVCs used for all
children)
Fixed at £36
Costs associated with
managing each BSI
£10,975
(95% CI –£2801
to £24,751)
CATCH trial cost-effectiveness
analysis (see Table 18)
Normal distributions with
parameters (£10,975, £7,023)
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Cost impact: value of additional costs associated with managing BSI
Based on each BSI being associated with a mean cost of £10,975 (95% CI –£2801 to £24,751; see Table 18),
over 6 months the value of resources made available in 2012 through averting BSIs associated with standard
CVCs (i.e. the total costs of managing these BSIs) would have been 232 × £10,975= £2,541,397, with
best- and worst-case scenarios of –£648,606 and £5,731,401 based on CIs for both estimates. The
probabilistic sensitivity analysis provided a 95% uncertainty interval of –£66,544 to £5,557,451 for the total
resources made available through averting BSIs in 2012. There was a probability of 0.90 that the value of
resources made available would be more than the additional costs of purchasing antibiotic CVCs (Figure 9).
The estimated cost impact for a typical PICU with 350 admissions per year is shown for a range of BSI
rates in Table 22. Figure 10 shows that the cost of purchasing antibiotic CVCs for all children who require
them will be less than the cost of managing BSIs with standard CVCs for PICUs with BSI rates > 1.2 per
1000 bed-days. This break-even value is substantially lower than the BSI rate observed in the standard arm
of the trial (8.24, 95% CI 4.7 to11.8 per 1000 bed-days) or in the linked data set for PICUs in England
(4.58, 95% CI 4.42 to 4.74 per 1000 bed-days).
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FIGURE 9 Probability distribution for the value of resources made available by averting BSIs using antibiotic CVC in
all PICUs in England during 2012. In total, 90% of the distribution represented costs greater than the additional
cost of purchasing antibiotic CVCs.
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Chapter 6 Discussion
Introduction
We aimed to inform NHS policy regarding impregnated CVCs for the intensive care of children. To address
the question of whether or not impregnated CVCs should be adopted by PICUs in England and Wales,
we undertook a large pragmatic RCT to determine the clinical effectiveness and cost-effectiveness of
impregnated compared with standard CVCs. To determine the implications of adopting impregnated CVCs
for all children who need them, we conducted a generalisability and cost impact study, using linked data
from two national sources.
Clinical effectiveness
The primary analysis showed no evidence of a statistically significant difference in time to first BSI between
any impregnated CVCs (antibiotic-impregnated and heparin-bonded CVCs combined) and standard CVCs.
However, secondary analyses showed that antibiotic impregnation reduced the hazard of BSIs by 57%
compared with standard CVCs and by 58% compared with heparin-bonded CVCs. Antibiotic-impregnated
CVCs were associated with an absolute risk reduction of 2.15% compared with standard CVCs, meaning
that 47 children would need to be treated with an antibiotic-impregnated CVC instead of a standard CVC
to prevent one case of BSI.
Our choice of any BSI as a clinically important primary outcome and a recognised quality indicator is an
important strength of our study, avoiding the biases inherent in measuring CR-BSI.2,46,88,89 CR-BSI requires
positive cultures from the blood and catheter tip and is highly susceptible to bias, as the tip can be
easily contaminated during removal and residual antibiotic in the catheter tip may inhibit culture in
the laboratory.55,88
A further strength of the study is the restriction to positive blood cultures that were clinically indicated.
This increased the clinical relevance of the primary outcome, but diminished the sensitivity of the study to
detect bacteraemia, as only 40% of children had a blood culture taken in the relevant time window.
A third strength is the representativeness of the study population in terms of children admitted to the
14 largest PICUs (of 23) across England. We were able to enrol a similar proportion of emergency
patients (two-thirds) as seen in practice, enabled by the inclusion of retrieved children and the use of
deferred consent.90
A potential limitation of the study is that clinicians inserting the CVCs could not be blinded to allocation.
However, we found no evidence of differential sampling by trial arm (see Figure 1). The number of children
who received their allocated CVC was slightly higher for those in the standard arm, probably reflecting the
fact that standard CVCs were the default CVC used in many units.32 A second limitation is that, because
of the lower than expected BSI rate in the standard arm of the trial, we had limited power to detect
differences in the primary outcome comparing impregnated with standard CVCs. This choice of primary
outcome was justified by the best available evidence to date – a systematic review and meta-analysis
of direct and indirect comparisons of different types of impregnated and standard CVCs28 – which showed
that heparin-bonded and antibiotic-impregnated CVCs resulted in similar reductions in the risk of CR-BSI
(70–80%). A third limitation is that resistance testing was not standardised across sites. This reflects local
laboratory administration and processing, which centralised testing of all positive cultures could have
mitigated. When reported, resistance occurred in all trial arms, predominantly in Gram-negative isolates, as
expected. The low rates are consistent with the previous lack of evidence for the emergence of resistance.1
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Few previous trials have reported the effectiveness of impregnated CVCs for any BSI.45 However, the
superiority of antibiotic-impregnated CVCs in children was consistent with the most recent systematic
review reporting a pooled odds ratio for CR-BSI of 0.18 (95% CI 0.08 to 0.34).28 Although our finding of
a clinically important reduction in any BSI with antibiotic-impregnated CVCs (HR 0.25, 95% CI 0.07 to
0.09; p= 0.04) was based on a secondary comparison and should be viewed as exploratory, this result
does add important evidence of the overall effectiveness of antibiotic-impregnated CVCs.
The finding that heparin CVCs were not effective for BSIs or CR-BSIs contradicts past evidence showing a
pooled odds ratio for CR-BSI for heparin-bonded compared with standard CVCs of 0.20 (95% CI 0.06
to 0.44).28 The difference in findings may reflect poor data quality in previous trials, highlighted by
systematic reviews. Only one of the three trials comparing heparin with standard CVCs reported adequate
concealment of randomisation, and this trial did not state whether or not clinicians were blinded to the
intervention.2 A further explanation for the discrepancy may be the low baseline event rate observed in the
CATCH trial, which was conducted after implementation of CVC care bundles in PICUs to improve aseptic
procedures during CVC insertion and maintenance.32 It is conceivable that heparin CVCs are most effective
in the context of high rates of surface colonisation, as they prevent thrombosis, which aids organism
adherence to the CVC. Finally, the pairwise comparisons used to determine the most effective type of
impregnation were not adequately powered to detect the anticipated small differences between antibiotic
and heparin CVCs. However, our results suggest that antibiotic-impregnated CVCs can achieve further
reductions in BSI rates, over and above that achieved by CVC care bundles.33,34
Cost-effectiveness
The ICER of antibiotic-impregnated CVCs compared with standard CVCs was £54,057 per BSI averted over
the 6 months after randomisation. Assuming that the health impact of a BSI is no greater (on average)
than a reduction of 1 year of full health (i.e. 1 QALY), then, at the cost-effectiveness threshold of £30,000
per QALY, antibiotic CVCs may not represent a cost-effective alternative to standard CVCs in a PICU
setting. However, there is considerable uncertainty surrounding this estimate, which is driven mainly by the
time horizon of analysis.
The sensitivity analysis in which costs were restricted to the index hospital stay resulted in antibiotic CVCs
dominating standard CVCs, with £97,543 saved for each BSI averted. Antibiotic CVCs therefore appear
highly cost-effective when considering events and costs accruing over comparable periods.
A secondary analysis of the CATCH trial indicated that heparin CVCs were not clinically effective, with a risk
difference for a first BSI of –0.17 (95% CI –2.45 to 2.12) compared with standard CVCs. It follows, therefore,
that heparin CVCs cannot be cost-effective by the same measure. Theoretically, a cost-minimisation analysis
might apply, to assess whether or not heparin CVCs are less costly overall than standard CVCs. However,
heparin CVCs are more expensive than standard CVCs (in terms of unit prices) and, as the only difference
among CVCs can be in BSI rates, any difference in total cost (which was not statistically significant) was
caused by random variation. A cost-minimisation analysis might therefore lead to an erroneous conclusion
that heparin CVCs are more cost-effective than standard CVCs.
Our economic evaluation benefits from being conducted alongside a pragmatic clinical trial, which is
representative of current practice in the UK PICU setting. The evaluation utilises data from a definitive
and unbiased comparison of impregnated and standard CVCs and was conducted robustly according to
accepted methods of trial-based economic evaluations.74 We used patient-level HES data to reflect the
reimbursement costs for hospitals and multiple data sources to measure hospital resource use to ensure
that cost data were complete.
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However, there are limitations that affect the strength of our findings. First, the CATCH trial was not
powered to determine cost differences between each of the three CVCs. As a consequence, the results
are susceptible to random variation in costs between trial arms. Although hypothesis testing may be
considered less relevant to decision making in the context of net benefits, the non-statistically significant
differences in costs between groups translated to uncertainty in the joint distribution of costs and benefits
such that, in the base-case analysis, antibiotic CVCs had a probability of 0.35 of dominating standard
CVCs.91 Mean total costs associated with heparin CVCs were lower than those for both antibiotic and
standard CVCs, despite their ineffectiveness in avoiding BSIs compared with standard CVCs. Being a rare
event, BSI costs were diluted compared with the overall costs relating to the intensive care of patients.
Second, the economic evaluation did not consider QALYs, which is the standard metric for informing
decisions on resource allocation. This was because the estimation of utilities in paediatric ICU populations
is empirically and conceptually challenging92,93 and because the main long-term consequence of BSIs, the
impact on neurological outcomes, is poorly measured in children and was not measured in this trial.
Short-term outcomes not considered in our economic analysis include mortality, antibiotic resistance and
other adverse events. However, antibiotic resistance to minocycline or rifampicin did not differ by CVC
allocation. There were no also no differences in 30-day mortality for antibiotic compared with standard
CVCs (HR 0.96, 95% CI 0.61 to 1.51) or for heparin compared with standard CVCs (HR 0.65, 95% CI
0.40 to 1.07) and no differences in adverse events (see Table 11).
Assumptions regarding the time horizon of analysis represent a third limitation. The base-case, 6-month
analysis was selected to include the costs of hospital readmissions in addition to the costs of the index
hospitalisation and transfers that may have occurred subsequently. This was intended to capture the costs
of managing any longer-term complications from BSIs, but, as the economic outcome was chosen to align
with the primary clinical outcome, the health impacts of these complications were not included in the
ICER. Consequently, as costs accrue over time with no corresponding change in the number of BSIs
(these all occurred within 30 days), the ICER continued to increase over time.
Our findings are consistent with those of other studies in terms of the estimation of the costs associated
with the management of BSIs. However, our ICER differs considerably and is inconclusive with regard to
determining the cost-effectiveness of antibiotic CVCs. Published economic evaluations, including those
that adopted a lifetime horizon of analysis, suggest dominance of antibiotic-impregnated CVCs over
standard CVCs. One explanation for this discrepancy is in the methods of analysis. A decision-analytic
model, based on a synthesis of data from various sources, is fundamentally different from a prospective
RCT, in which differences between intervention groups are less evident, particularly in the context of rare
events such as BSIs. In the evaluation by Hockenhull et al.,29 for instance, the incremental cost saving of
£138.20 per patient receiving an impregnated CVC was calculated as the additional cost of the antibiotic
CVC less the expected cost per patient of managing excess BSIs. The equivalent calculation based on
CATCH data for antibiotic CVCs results in a value of £200.08 saved for each antibiotic CVC used
[(£78.28 – £42.91) – (£10,975 × 2.15%)]. Extending this further to calculate the ICER gives a value of
£9326 saved per BSI averted (£200.08/2.15%), which differs appreciably from our base-case result [the
differences between the ICER stated and the ICER calculated from the numbers in the text is due to
rounding (difference in risk of BSI is 2.1453%)]. However, by analysing the data as a cohort study,
separating the apparent costs of BSIs from the total costs relating to each intervention group, biases are
likely to arise from assuming that the cost of managing BSIs is independent of CVC type.
In conclusion, the results of the cost-effectiveness analysis indicate that a policy of replacing standard CVCs
with antibiotic-impregnated CVCs in paediatric ICUs would be more beneficial in terms of fewer patients
developing BSIs. Given the low BSI rate, the variation in costs between arms and the sensitivity of analyses
to the specified time horizon, there remains considerable uncertainty whether or not use of antibiotic
CVCs represents a cost-effective use of NHS resources.
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Generalisability and cost impact
We explored the generalisability of the CATCH trial results and the cost impact of changing practice in
PICUs across England based on the trial results. In terms of generalisability, the observed rates of BSI using
standard CVCs declined steadily over the past decade, including the period when children were enrolled
into the CATCH trial.34,94 In addition, children participating in the CATCH trial had a higher risk of BSI than
all children receiving CVCs in practice, as they were expected to require a CVC for ≥ 3 days. This means
that children currently receiving CVCs in PICUs are likely to have a lower BSI risk than those participating
in the trial. This was reflected in the higher rate of BSIs observed in the standard arm of the trial (8.24
per 1000 bed-days) compared with linked administrative data from 16 PICUs in England for 2012 (4.58 per
1000 bed-days; see Figure 8).
In terms of budget impact, antibiotic CVCs are more expensive than standard CVCs. If adopted in PICUs,
antibiotic CVCs would likely be bulk purchased for all children (including those with a lower risk of BSI
than the risk for children participating in the trial). By estimating the number of BSIs potentially averted
using antibiotic CVCs for all children (including those with a low risk of BSI), we showed that the
additional cost of purchasing antibiotic CVCs is less than the value of resources associated with managing
excess BSIs associated with using standard CVCs. A limitation of this study was that estimated BSI rates
using standard CVCs relied on a predictive model for identifying children most likely to have required a
CVC. Another limitation was the possible error in estimating CVC-days: we assumed that, for children in
the linked data set likely to have required a CVC, the CVC would remain in place for the entire PICU stay.
There is no clear direction of bias as we may have over- or underestimated CVC-days, but our assumptions
are reasonable based on the subset of CATCH participants. Finally, we relied on survey responses to
estimate the number of CVCs required in PICUs, but we addressed this and the uncertainty in other
parameter estimates by performing sensitivity analyses.95,96
The generalisability of the RCT results can be assessed by accounting for differences in subgroup treatment
effects, for example by reweighting treatment effects based on population distributions.97,98 In the CATCH
trial, the event rate was low and there was limited power to assess variation in the treatment effect
according to the duration of CVC insertion. However, because of the nature of the intervention, we
assumed that the treatment effect would be constant across groups and would be the same in children
who were not enrolled into the trial, as there was no a priori reason for an interaction.
Our results suggest that the benefits of using impregnated CVCs apply even for PICUs with BSI rates as
low as 1.2 per 1000 CVC-days. These finding are consistent with systematic review evidence on the
cost-effectiveness of impregnated CVCs in adults, which indicates that implementation of impregnated
CVCs would be cost-effective for a range of RRs and for a baseline incidence of CR-BSIs as low as 0.2%.29
The CATCH trial is the first trial to assess the effectiveness of antibiotic-impregnated compared with
standard CVCs in children, and our results adds to the strong evidence of effectiveness in adults.
Furthermore, as our cost estimates consider only use of hospital resources, the true cost of BSIs and the
benefits of antibiotic CVCs may be even greater when longer-term outcomes of BSIs are taken into account.
Other conclusions
Deferred consent
There is a growing recognition of the need for better evidence in paediatric settings, as evidence in adults
cannot always be safely extrapolated to children.99,100 However, achieving informed consent in emergency
paediatric settings is complicated by the stressful situation and the need to avoid any delay in
treatment.56,101 As the CATCH trial was one of the first UK studies to use deferred consent in children,
there was a lack of evidence on which to make decisions about the design and conduct of this aspect of
the trial.102,103 Our experience of deferred consent in the CATCH trial could help to inform future studies.
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In the CATCH trial, deferred consent was obtained from 84% of families who were approached.60 The use
of deferred consent allowed us to recruit emergency admissions, reach the target sample size within the
available funding and provide results that are convincing to clinicians working in the emergency setting.
Participation in the CATCH trial after the intervention had taken place represented a minimal burden to
children (use of data already collected and follow-up data collection only). However, a proportion of
parents chose not to consent because of a perceived burden on the child. Ongoing in-depth research as
part of the CONseNt methods in paediatric Emergency and urgent Care Trials (CONNECT) study56,104 may
help to explain further the experiences and choices of parents of children involved in the CATCH trial.
One of the main concerns relating to deferred consent in the CATCH trial was whether or not the decision
to consent was related to the child’s outcome. The ethics committee recommended not approaching
families whose child had been discharged or transferred before the original approach for consent could be
made. Inclusion rates were also lower in the group of children who died. Although there were no deaths
related to the type of CVC in the CATCH trial, the low rate of consent for children who died could bias the
validity of comparisons between treatment arm and outcomes, including adverse events. We propose that,
in future, ethics committees allow use of linked administrative records without consent, when reasonable
efforts to obtain consent have been made or are not feasible or are considered to be harmful.60
There is still uncertainty about the most appropriate ways to approach bereaved parents of children
randomised in an emergency.105 Our experience in the CATCH trial highlights that further in-depth
research should be incorporated into the design of emergency trials involving populations with high
mortality rates.106,107
Co-enrolment
Another challenge to improving evidence in paediatric settings is the limited population of children who can
be recruited into trials. The CATCH trial was the largest RCT conducted in paediatric intensive care to date and
overlapped with the second largest RCT [the Control of Hypoglycaemia in Paediatric Intensive Care (CHiP)
trial],108 which recruited 1369 children in 13 centres. Allowing co-enrolment into several trials at the same time
can potentially enable efficient recruitment of children and has been successful in particular settings, for
example in evaluating treatments for acquired immune deficiency syndrome.88,90,109,110 Aside from statistical
concerns, perceived burden to the child, ethics requirements and stress of recruiting into multiple trials are
barriers to co-enrolment.111–114
Of five PICUs with the opportunity to recruit simultaneously to both the CATCH trial and the CHiP trial,
only two units decided to allow co-enrolment. Of the remaining three units, one delayed recruitment of
elective patients to the CATCH trial until the CHiP trial had closed, resulting in a loss of 6 recruiting weeks.
Reasons provided for not allowing co-enrolment related to concerns about jeopardising recruitment targets
for the earlier trial, asking too much of parents because of the overwhelming amounts of information
involved for two trials and the stressful situation of intensive care.112
On the other hand, we found that parents were accepting of co-enrolment: recruitment rates at the same
PICU were similar whether parents were approached for a single study (78% for CATCH, 51% for CHiP) or
both studies (82% for CATCH, 51% for CHiP). Concerns of the PICUs were therefore not supported by
evidence on parental decisions.115,116
Our experience with the CATCH trial highlighted that co-enrolment can be successful and acceptable, but
that barriers to co-enrolment remain. Decisions on the appropriateness of co-enrolment need to take into
account the potential impact on results, interaction between therapies, safety and internal and external
validity. Strategies that allow increasing research capacity whilst minimising burden on patients and parents
should continue to be developed.
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Administrative/electronic health-care data to support randomised
controlled trials
This study provides a convincing example of how administrative and electronic health-care data can be
used to support and enhance RCTs.117 It would not have been possible to provide such comprehensive
information relating to the use of impregnated CVCs without the use of administrative data, which
contributed to all three aspects of the study:
1. clinical effectiveness: trial participant data were linked with (i) mortality data from the ONS to allow
evaluation of deaths within 30 days of randomisation and (ii) PICANet data to ascertain the primary
diagnosis at admission and PIM2 score
2. cost-effectiveness: HES and PICANet data were used to estimate hospital, ICU and HDU costs up to
6 months after randomisation
3. generalisability and cost impact: PICANet data linked with national laboratory surveillance data were
used to estimate rates of BSI outside of the trial setting.
There are other areas in which administrative and electronic health-care data could be used to enhance
and support RCTs.117 First, in terms of capturing outcomes, we used administrative data up to 6 months
post randomisation. Ongoing linkage with administrative data could be useful to many RCTs for capturing
further long-term outcomes and safety measures.118
Second, the sample size calculation in the CATCH trial was based on audit data from several PICUs prior to
the trial. If PICANet and infection surveillance data had been linked prior to the study, even more accurate
event rates, taking into account the context of decreasing BSI rates, could have been calculated. Using
administrative data to identify variation in care across services and to aid site selection will lead to more
well-designed trials that are likely to meet targets and provide evidence more quickly.
Third, we used administrative data collected during the trial period to assess the generalisability of trial
participants and to identify the population for whom impregnated CVCs may be purchased. This could be
extended post trial by monitoring the scaling up of effective interventions and for the continued study of
the safety and efficacy of new medicines and devices.
Barriers to realising the full potential of integrating administrative data into RCTs include concerns about
data quality, regulatory compliance and ethical issues relating to consent for data linkage. Decisions on
the appropriateness of using administrative data should be made on a trial-by-trial basis. However,
administrative data provide an opportunity to efficiently investigate short- and long-term effectiveness in
real health-care settings, assess the broader impact of treatments across the NHS and provide evidence on
interventions to help implement improved treatments quickly for those who would benefit most. The
potential to improve quality and decrease the burden and cost of RCTs is particularly important in the
paediatric setting.99,119,120
Implications for practice
Although our primary outcome showed no difference between the different types of CVC, secondary
analyses demonstrated strong evidence of effectiveness of antibiotic-impregnated CVCs compared
with standard and heparin-bonded CVCs in children. Based on these results, we consider that use of
antibiotic-impregnated CVCs for children admitted to PICUs could result in clinically important reductions
in BSI rates. We expect that the benefits of antibiotic-impregnated CVCs would be likely to apply even for
PICUs with low BSI rates. At the cost-effectiveness threshold of £30,000 per QALY, antibiotic-impregnated
CVCs may not represent a cost-effective alternative to standard CVCs in a PICU setting. However, there is
considerable uncertainty surrounding this estimate, which is driven mainly by the time horizon of analysis.
Careful monitoring of implementation would help to build up further evidence.
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Recommendations for future research
Our research suggests that adoption of impregnated CVCs in PICUs should be considered. Implementation
could be monitored through continued linkage of electronic health-care data and information on PICU
practice. Such monitoring could allow routine feedback to PICUs and could be enhanced by routine
capture of CVC insertion and removal dates in hospital records.
We do not recommend any further trials of antibiotic-impregnated or heparin-bonded CVCs compared
with standard CVCs for children or adults in intensive care. However, further trials could be justified to
determine whether or not antibiotic CVCs would be similarly effective in preterm neonates (for whom
smaller line sizes are required, with potentially different mechanisms for BSI) or in those with long-term
CVCs (to determine whether or not the effect of impregnation remains for longer periods). The NHS
should work with industry to evaluate different types of impregnation for specific patient groups.
Use of linked administrative data should be considered for future trials to determine the generalisability of
interventions in contexts in which outcomes are likely to change substantially over the lifetime of the trial
and to monitor implementation of effective interventions.117
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53

Acknowledgements
We thank the children and families who participated in the CATCH trial and the principal investigatorsand research nurses at each study site (in order of number of patients recruited): Great Ormond
Street Hospital – Quen Mok, Twin Yen Lee and Samantha Riordan; Southampton General Hospital –
Iain Macintosh, Jenni McCorkell, Katie Stearn and Rosie Mitchell; Evelina London Children’s Hospital –
Shane Tibby, Julie Harris and Paul Wellman; Birmingham Children’s Hospital – Oliver Bagshaw, Jenna Spry,
Simon Laker and Nikki Holdback; Leeds General Infirmary – John Roche, Sian Cooper and Darren Hewett;
Alder Hey Children’s Hospital – Steve Kerr and Felicity Haigh; Bristol Royal Hospital for Children –
Michelle White, Margrid Schindler, Clare Traub and Nina Worrin; Glenfield Hospital – Raghu Ramaiah and
Rekha Patel; Royal Brompton Hospital – Duncan Macrae and Sarah Bacon; St Mary’s Hospital, London –
Mehrengise Cooper, Amina Abdulla and Amy Brewer; Royal Victoria Infirmary – Rachel Agbeko and
Christine Mackerness; Queen’s Medical Centre – Patrick Davies, Daniel Walsh and Lindsay Crate; Freeman
Hospital – Rachel Agbeko and Clare Simmister; and, Leicester Royal Infirmary – Raghu Ramaiah and
Rekha Patel. We thank Hazel Greig-Midlane for contributing a lay perspective to the design and conduct
of the study.
We also thank the Local Research Networks in England whose work and support was invaluable in
supporting the CATCH trial (see Trial oversight committees). We would also like to thank the British
Antibiotic and Silver-Impregnated Catheters (BASICS) data managers Susan Howlin and Lynsey Finnetty.
We would like to thank all of the staff in the participating hospitals who have collected data for PICANet
or responded to survey questionnaires. We are grateful to the UK Paediatric Intensive Care Society for its
continued support and to the members of the PICANet Steering Group and Clinical Advisory Group,
who are listed on the PICANet website [see www.picanet.org.uk/About/ (accessed 25 November 2015)].
We would like to acknowledge Nicola Panton who carried out the 16S analyses, Mark Wilks who
co-ordinated the collection and storage of relevant samples and Michaela Blundell who undertook quality
assurance checks.
We wish to acknowledge the contribution of Catrin Plumpton to the economic analysis. For work relating
to the generalisability study, we would like to acknowledge the input of Angie Wade and Harvey
Goldstein, who made substantial contributions to the data linkage study. We would also like to thank
Roger Parslow, Tom Fleming, Phil McShane and Lee Norman (PICANet) for facilitation of PICANet data
retrieval. We thank Dr Roger Parslow and The Healthcare Quality Improvement Partnership for contributing
data from the PICANet Audit. The PICANet Audit is commissioned by the Healthcare Quality Improvement
Partnership (HQIP) as part of the National Clinical Audit (NCA) Programme. HQIP is led by a consortium of
the Academy of Medical Royal Colleges, the Royal College of Nursing and National Voices. Its aim is to
promote quality improvement and in particular to increase the impact that clinical audit has on health-care
quality in England and Wales. HQIP holds the contract to manage and develop the NCA Programme,
comprising more than 30 clinical audits that cover care provided to people with a wide range of medical,
surgical and mental health conditions. The PICANet Audit is funded by NHS England, NHS Wales, NHS
Lothian/National Service Division NHS Scotland, the Royal Belfast Hospital for Sick Children, The National
Office of Clinical Audit, Republic of Ireland and Hospital Corporation of America® Healthcare. We also
thank Sue Howlin and Andrew McKay from the Medicines for Children Clinical Trials Unit for collating trial
data. Thanks also go to those contributing CVC audit data: John Hartley and Paul Lock (Great Ormond
Street Hospital), Jim Grey and Adrian Bigland (Birmingham Children’s Hospital), Rachel Agbeko (Newcastle
upon Tyne Hospitals NHS Foundation Trust) and Sarah Morley, Tim Peto and Anke Top (Cambridge
University Hospitals NHS Foundation Trust).
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
Trial oversight committees
We would like to thank all of the members of the trial oversight committees for their support and work
throughout the study and the recommendations in Table 23: Trial Steering Committee – Robert Tasker
(Chair), Stephen Playfor (Chair), Andy Vail, Derek Roebuck, Jim Gray and Hazel Greig-Midlane; IDSMC –
Paul Ewings (Chair), Mike Sharland, Neena Modi; and the Trial Management Group – Ruth Gilbert
(Chair and Chief Investigator), Carroll Gamble, Kerry Dwan, Tracy Moitt, Rachel Breen, Colin Ridyard,
Angie Wade, Dyfrig Hughes, Quen Mok, Liz Draper, Shane Tibby, Michael Millar, Oliver Bragshaw,
Padmanabhan Ramnarayan, Julia Harris and Darren Hewett.
All members of the Trial Management Group, the Trial Steering Committee and the IDSMC were invited to
comment on the final draft of the report.
Ethics
For PICANet, collection of personally identifiable data was approved by the National Information
Governance Board for Health and Social Care (formerly the Patient Information Advisory Group)
[see www.nigb.nhs.uk/s251/registerapp (accessed 25 November 2015)] and ethical approval was granted
by the Trent Medical Research Ethics Committee (reference number 05/MRE04/17). PICANet also has
specific permission from the National Research Ethics Service for linkage with PHE laboratory data on BSIs
using personal identifiers and to share PICANet data with PHE. An exemption under Section 251 of the
NHS Act 2006121 (previously Section 60 of the Health and Social Care Act 2001122) allows PHE to receive
patient-identifiable data from other organisations without patient consent to monitor infectious disease.
Specific permission for the PICANet–PHE linkage has been granted by the National Information
Governance Board for Health and Social Care.
Funding
This work was supported by funding from the National Institute for Health Research Health Technology
Assessment (NIHR HTA) programme (project number 08/13/47). The views and opinions expressed therein
are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS or
Department of Health. No funding was provided by the manufacturer (Cook Medical Inc.) of the CVCs,
although participating units could purchase CVCs at a discount of 20% during recruitment to the study.
Neither the funder nor the manufacturer had any involvement in the study design, interpretation of the
results or writing of the report.
TABLE 23 Trial oversight committee meetings and recommendations
Oversight committee Meeting dates Recommendations
IDSMC 26 October 2009, 26 March 2010,
10 February 2012, 14 June 2012
Trial to be continued
Trial Steering
Committee
26 October 2009, 26 March 2010,
12 March 2012, 2 August 2012
Support for continuing to recruit
past the target number
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
Contributions of authors
Katie Harron (research fellow), Dyfrig A Hughes (Professor of Pharmacoeconomics) and Ruth E Gilbert
(Professor of Clinical Epidemiology) prepared drafts of the report, which were reviewed and amended by
coauthors [Quen Mok (Consultant in Paediatric Intensive Care), Kerry Dwan (Statistician), Tracy Moitt
(senior trials manager), Michael Millar (Consultant in Infection), Padmanabhan Ramnarayan
(Consultant in Paediatric Intensive Care and Retrieval), Shane M Tibby (Consultant in Paediatric Intensive
Care), Berit Muller-Pebody (Consultant in Infection Control) and Carrol Gamble (Professor in
Medical Statistics)].
Statistical analyses were conducted by Kerry Dwan (research associate) and Carrol Gamble
(Professor of Medical Statistics).
Colin H Ridyard (research officer in Health Economics) performed the cost-effectiveness analyses.
Berit Muller-Pebody co-ordinated the linkage of PICANet data to laboratory surveillance data.
The end-point review for the primary outcome was carried out by Quen Mok (Consultant in Paediatric
Intensive Care), Michael Millar and Ruth E Gilbert (Professor of Clinical Epidemiology).
All authors were invited to comment on the final draft of the report.
Publications
Research articles
Harron K, Ramachandra G, Mok Q, Gilbert R. Consistency between guidelines and reported practice for
reducing the risk of catheter-related infection in British paediatric intensive care units. Intensive Care Med
2011;37:1641–7.
Goldstein H, Harron K, Wade A. The analysis of record-linked data using multiple imputation with data
value priors. Stat Med 2012;31:3481–93.
Harron K, Lee T, Ball T, Mok Q, Gamble C, Macrae D, et al. Making co-enrolment feasible for randomised
controlled trials in paediatric intensive care. PLOS ONE 2012;7:e41791.
Harron K, Goldstein H, Wade A, Muller-Pebody B, Parslow R, Gilbert R. Linkage, evaluation and analysis of
national electronic healthcare data: application to providing enhanced blood-stream infection surveillance
in paediatric intensive care. PLOS ONE 2013;8:e85278.
Harron K, Wade A, Muller-Pebody B, Goldstein H, Parslow R, Gray J, et al. Risk-adjusted monitoring
of blood-stream infection in paediatric intensive care: a data linkage study. Intensive Care Med
2013;39:1080–7.
Woolfall K, Frith L, Gamble C, Young B. How experience makes a difference: practitioners’ views on the
use of deferred consent in paediatric and neonatal emergency care trials. BMC Med Ethics 2013;14:45.
Harron K, Mok Q, Parslow R, Muller-Pebody B, Gilbert R, Ramnarayan P. Risk of bloodstream infection
in children admitted to paediatric intensive care units in England and Wales following emergency
inter-hospital transfer. Intensive Care Med 2014;40:1916–23.
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
Harron K, Wade A, Gilbert R, Muller-Pebody B, Goldstein H. Evaluating bias due to data linkage error in
electronic healthcare records. BMC Med Res Methodol 2014;14:36.
Harron K, Parslow R, Mok Q, Tibby S, Wade A, Muller-Pebody B, et al. Monitoring quality of care through
linkage of administrative data: national trends in bloodstream infection in UK paediatric intensive care units
2003–2012. Crit Care Med 2015;43:1070–8.
Harron K, Woolfall K, Dwan K, Gamble C, Mok Q, Ramnarayan P, et al. Deferred consent for randomized
controlled trials in emergency care settings. Pediatrics 2015;136:e1316–22.
Woolfall K, Frith L, Gamble C, Gilbert R, Mok Q, Young B, et al. How parents and practitioners experience
research without prior consent (deferred consent) for emergency research involving children with life
threatening conditions: a mixed method study. BMJ Open 2015;5:e008522.
Gilbert RE, Mok Q, Dwan K, Harron K, Moitt T, Millar M, et al. Impregnated central venous catheters for
prevention of bloodstream infection in children (the CATCH trial): a randomised controlled trial [published
online ahead of print March 3 2016]. Lancet 2016. http://dx.doi.org/10.1016/S0140-6736(16)00340-8
Harron K, Mok Q, Hughes D, Muller-Pebody B, Parslow R, Ramnarayan P, et al. Generalisability and cost-impact
of antibiotic-impregnated central venous catheters for reducing the risk of bloodstream infection in paediatric
intensive care units in England. PLOS ONE 2016; in press.
Letters and editorials
Mok Q, Gilbert R. Interventions to reduce central venous catheter-associated infections in children: which
ones are beneficial? Intensive Care Med 2011;37:566–8.
Harron K, Wade A, Muller-Pebody B, Goldstein H, Gilbert R. Opening the black box of record linkage.
J Epidemiol Community Health 2012;66:1198.
Gilbert R, Harron K, Mok Q, Gamble C. Impregnated central venous catheters should be readily used to
reduce risk of bloodstream infection. BMJ 2013;347:f7169.
Harron K, Gilbert R. Research: increasing value, reducing waste. Lancet 2014;383:1124.
Harron K, Gamble C, Gilbert R. E-health data to support and enhance randomised controlled trials in the
United Kingdom. Clin Trials 2015;12:180–2.
Data sharing statement
All available data can be obtained, subject to data sharing agreements, from the Medicines for Children
Clinical Trials Unit.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
References
1. Falagas ME, Fragoulis K, Bliziotis IA, Chatzinikolaou I. Rifampicin-impregnated central venous
catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemoth 2007;59:359–69.
http://dx.doi.org/10.1093/jac/dkl522
2. Gilbert R, Harden M. Effectiveness of impregnated central venous catheters for catheter related
blood stream infection: a systematic review. Curr Opin Infect Dis 2008;21:235–45. http://dx.doi.org/
10.1097/QCO.0b013e3282ffd6e0
3. O’Grady N, Alexander M, Dellinger E, Gerberding J, Heard S, Maki D, et al. Guidelines for the
prevention of intravascular catheter-related infections. Am Acad Pediatr Policy 2002;110:e51–74.
http://dx.doi.org/10.1067/mic.2002.129427
4. Pellowe C, Pratt R, Loveday H, Harper P, Robinson N, Jones S. The epic project. Updating the
evidence-base for national evidence-based guidelines for preventing healthcare-associated
infections in NHS hospitals in England: a report with recommendations. J Hosp Infect 2005;5:10.
http://dx.doi.org/10.1016/j.jhin.2004.11.007
5. Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis,
prevention, and management. Lancet Infect Dis 2007;7:645–57. http://dx.doi.org/10.1016/
S1473-3099(07)70235-9
6. Costello J, Graham D, Morrow D, Potter-Bynoe G, Sandora T, Laussen P. Risk factors for central
line-associated bloodstream infection in a pediatric cardiac intensive care unit. Pediatr Crit Care
Med 2009;10:453–9. http://dx.doi.org/10.1097/PCC.0b013e318198b19a
7. Mello M, Albuquerque M, Lacerda H, Souza W, Correia J, Britto M. Risk factors for healthcare-
associated infection in pediatric intensive care units: a systematic review. Cad Saude Publica
2009;25:373–91. http://dx.doi.org/10.1590/S0102-311X2009001500004
8. Milstone AM, Sengupta A. Do prolonged peripherally inserted central venous catheter dwell times
increase the risk of bloodstream infection? Infect Control Hosp Epidemiol 2010;31:1184–7.
http://dx.doi.org/10.1086/656589
9. Niedner MF, Huskins WC, Colantuoni E, Muschelli J, Harris JM II, Rice TB, et al. Epidemiology of
central line-associated bloodstream infections in the pediatric intensive care unit. Infect Control
Hosp Epidemiol 2011;32:1200. http://dx.doi.org/10.1086/662621
10. Wylie MC, Graham DA, Potter-Bynoe G, Kleinman ME, Randolph AG, Costello JM, et al.
Risk factors for central line-associated bloodstream infection in pediatric intensive care units.
Infect Control Hosp Epidemiol 2010;31:1049–56. http://dx.doi.org/10.1086/656246
11. Bhutta A, Gilliam C, Honeycutt M, Schexnayder S, Green J, Moss M, et al. Reduction of
bloodstream infections associated with catheters in paediatric intensive care unit: stepwise
approach. BMJ 2007;334:362–5. http://dx.doi.org/10.1136/bmj.39064.457025.DE
12. Miller MR, Griswold M, Harris JM II, Yenokyan G, Huskins WC, Moss M, et al. Decreasing PICU
catheter-associated bloodstream infections: NACHRI’s quality transformation efforts. Pediatrics
2010;125:206–13. http://dx.doi.org/10.1542/peds.2009-1382
13. Pronovost P, Goeschel C, Colantuoni E, Watson S, Lubomski L, Berenholtz S, et al. Sustaining
reductions in catheter related bloodstream infections in Michigan intensive care units:
observational study. BMJ 2010;340:c309. http://dx.doi.org/10.1136/bmj.c309
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
14. Bion J, Richardson A, Hibbert P, Beer J, Abrusci T, McCutcheon M, et al. ‘Matching Michigan’:
a 2-year stepped interventional programme to minimise central venous catheter-blood stream
infections in intensive care units in England. BMJ Qual Saf 2012;22:110–23. http://dx.doi.org/
10.1136/bmjqs-2012-001325
15. Department of Health (DH). Saving Lives: Reducing Infection, Delivering Clean and Safe Care.
London: DH; 2007.
16. Jeong IS, Park SM, Lee JM, Song JY, Lee SJ. Effect of central line bundle on central line-associated
bloodstream infections in intensive care units. Am J Infect Control 2013;41:710–16. http://dx.doi.org/
10.1016/j.ajic.2012.10.010
17. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to
decrease catheter-related bloodstream infections in the ICU. New Engl J Med 2006;355:2725–32.
http://dx.doi.org/10.1056/NEJMoa061115
18. Reddy KK, Samuel A, Smiley KA, Weber S, Hon H. Reducing central line-associated bloodstream
infections in three ICUs at a tertiary care hospital in the United Arab Emirates. Jt Comm J Qual
Patient Saf 2014;40:559.
19. Zuschneid I, Schwab F, Geffers C, Rüden H, Gastmeier P. Reducing central venous catheter-associated
primary bloodstream infections in intensive care units is possible: data from the German nosocomial
infection surveillance system. Infect Control Hosp Epidemiol 2003;24:501–5. http://dx.doi.org/
10.1086/502236
20. Abou Elella R, Najm H, Balkhy H, Bullard L, Kabbani M. Impact of bloodstream infection on the
outcome of children undergoing cardiac surgery. Pediatr Cardiol 2010;31:483–9. http://dx.doi.org/
10.1007/s00246-009-9624-x
21. Elward AM, Hollenbeak CS, Warren DK, Fraser VJ. Attributable cost of nosocomial primary
bloodstream infection in pediatric intensive care unit patients. Pediatrics 2005;115:868–72.
http://dx.doi.org/10.1542/peds.2004-0256
22. Lakshmi KS, Jayashree M, Singhi S, Ray P. Study of nosocomial primary bloodstream infections in
a pediatric intensive care unit. J Trop Pediatr 2007;53:87–92. http://dx.doi.org/10.1093/tropej/
fml073
23. Yogaraj JS, Elward AM, Fraser VJ. Rate, risk factors, and outcomes of nosocomial primary
bloodstream infection in pediatric intensive care unit patients. Pediatrics 2002;110:481–5.
http://dx.doi.org/10.1542/peds.110.3.481
24. Dominguez TE, Chalom R, Costarino ATJ. The impact of adverse patient occurrences on hospital
costs in the pediatric intensive care unit. Crit Care Med 2001;29:169–74. http://dx.doi.org/
10.1097/00003246-200101000-00033
25. Nowak JE, Brilli RJ, Lake MR, Sparling KW, Butcher J, Schulte M, et al. Reducing catheter-associated
bloodstream infections in the pediatric intensive care unit: business case for quality improvement.
Pediatr Crit Care Med 2010;11:579–87. http://dx.doi.org/10.1097/PCC.0b013e3181d90569
26. Slonim AD, Kurtines HC, Sprague BM, Singh N. The costs associated with nosocomial
bloodstream infections in the pediatric intensive care unit. Pediatr Crit Care Med 2001;2:170–4.
http://dx.doi.org/10.1097/00130478-200104000-00012
27. Health Protection Agency. English National Point Prevalence Survey on Healthcare-Associated
Infections and Antimicrobial Use: 2011. URL: www.gov.uk/government/publications/
healthcare-associated-infections-hcai-point-prevalence-survey-england (accessed 6 October 2014).
28. Wang H, Huang T, Jing J, Jin J, Wang P, Yang M, et al. Effectiveness of different central venous
catheters for catheter-related infections: a network meta-analysis. J Hosp Infect 2010;76:1–11.
http://dx.doi.org/10.1016/j.jhin.2010.04.025
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
29. Hockenhull J, Dwan K, Boland A, Smith G, Bagust A, Dündar Y, et al. The clinical effectiveness
and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing
bloodstream infections: a systematic review and economic evaluation. Health Technol Asses
2008;12(12).
30. Lai NM, Chaiyakunapruk N, Lai NA, O’Riordan E, Pau WSC, Saint S. Catheter impregnation,
coating or bonding for reducing central venous catheter-related infections in adults. Cochrane
Database Syst Rev 2013;6:CD007878. http://dx.doi.org/10.1002/14651858.cd007878.pub2
31. Gilbert R, Harron K, Mok Q, Gamble C. Impregnated central venous catheters should be readily
used to reduce risk of bloodstream infection. BMJ 2013;347:f7169. http://dx.doi.org/10.1136/
bmj.f7169
32. Harron K, Ramachandra G, Mok Q, Gilbert R. Consistency between guidelines and reported
practice for reducing the risk of catheter-related infection in British paediatric intensive care units.
Intensive Care Med 2011;37:1641–7. http://dx.doi.org/10.1007/s00134-011-2343-9
33. Harron K, Wade A, Muller-Pebody B, Goldstein H, Parslow R, Gray J, et al. Risk-adjusted
monitoring of blood-stream infection in paediatric intensive care: a data linkage study. Intensive
Care Med 2013;39:1080–7. http://dx.doi.org/10.1007/s00134-013-2841-z
34. Harron K, Parslow R, Mok Q, Tibby S, Wade A, Muller-Pebody B, et al. Monitoring quality of care
through linkage of administrative data: national trends in bloodstream infection in UK paediatric
intensive care units 2003–2012. Crit Care Med 2015;43:1070–8. http://dx.doi.org/10.1097/
CCM.0000000000000941
35. Chatzinikolaou I, Finkel K, Hanna H, Boktour M, Foringer J, Ho T, et al. Antibiotic-coated
hemodialysis catheters for the prevention of vascular catheter–related infections: a prospective,
randomized study. Am J Med 2003;115:352–7. http://dx.doi.org/10.1016/S0002-9343(03)
00367-X
36. Cox EG, Knoderer CA, Jennings A, Brown JW, Rodefeld MD, Walker SG, et al. A randomized,
controlled trial of catheter-related infectious event rates using antibiotic-impregnated catheters
versus conventional catheters in pediatric cardiovascular surgery patients. J Ped Infect Dis
2013;2:67–70. http://dx.doi.org/10.1093/jpids/pis066
37. Darouiche RO, Berger DH, Khardori N, Robertson CS, Wall MJ Jr, Metzler MH, et al. Comparison
of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized
controlled trial. Ann Surg 2005;242:193. http://dx.doi.org/10.1097/01.sla.0000171874.29934.61
38. Hanna H, Benjamin R, Chatzinikolaou I, Alakech B, Richardson D, Mansfield P, et al. Long-term
silicone central venous catheters impregnated with minocycline and rifampin decrease rates of
catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial.
J Clin Oncol 2004;22:3163–71. http://dx.doi.org/10.1200/JCO.2004.04.124
39. León C, Ruiz-Santana S, Rello J, Maria V, Vallés J, Álvarez-Lerma F, et al. Benefits of minocycline
and rifampin-impregnated central venous catheters. Intensive Care Med 2004;30:1891–9.
http://dx.doi.org/10.1007/s00134-004-2378-2
40. Marik PE, Abraham G, Careau P, Varon J, Fromm RE. The ex vivo antimicrobial activity and
colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med
1999;27:1128–31. http://dx.doi.org/10.1097/00003246-199906000-00034
41. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al. Central venous catheters
coated with minocycline and rifampin for the prevention of catheter-related colonization and
bloodstream infections: a randomized, double-blind trial. Ann Intern Med 1997;127:267–74.
http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00002
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
42. Yücel N, Lefering R, Maegele M, Max M, Rossaint R, Koch A, et al. Reduced colonization and
infection with miconazole–rifampicin modified central venous catheters: a randomized controlled
clinical trial. J Antimicrob Chemoth 2004;54:1109–15. http://dx.doi.org/10.1093/jac/dkh483
43. Abdelkefi A, Achour W, Ben Othman T, Ladeb S, Torjman L, Lakhal A, et al. Use of heparin-coated
central venous lines to prevent catheter-related bloodstream infection. J Support Oncol
2007;5:273–8.
44. Appelgren P, Ransjo U, Bindslev L, Espersen F, Larm O. Surface heparinization of central venous
catheters reduces microbial colonization in vitro and in vivo: results from a prospective,
randomized trial. Crit Care Med 1996;24:1482–9. http://dx.doi.org/10.1097/00003246-
199609000-00009
45. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and
infective complications in critically ill children. Intensive Care Med 2000;26:967–72. http://dx.doi.
org/10.1007/s001340051289
46. Geffers C, Zuschneid I, Eckmanns T, Rüden H, Gastmeier P. The relationship between
methodological trial quality and the effects of impregnated central venous catheters. Intensive
Care Med 2003;29:403–9.
47. Niel-Weise B, Stijnen T, Van den Broek P. Anti-infective-treated central venous catheters for total
parenteral nutrition or chemotherapy: a systematic review. J Hosp Infect 2008;69:114–23.
http://dx.doi.org/10.1016/j.jhin.2008.02.020
48. Mok Q, Gilbert R. Interventions to reduce central venous catheter-associated infections in
children: which ones are beneficial? Intensive Care Med 2011;37:566–8. http://dx.doi.org/
10.1007/s00134-011-2135-2
49. Mermel L. Prevention of intravascular catheter-related infections. Ann Intern Med 2000;132:391–402.
http://dx.doi.org/10.7326/0003-4819-132-5-200003070-00009
50. Barnett AG, Batra R, Graves N, Edgeworth J, Robotham J, Cooper B. Using a longitudinal model
to estimate the effect of methicillin-resistant Staphylococcus aureus infection on length of stay in
an intensive care unit. Am J Epidemiol 2009;170:1186–94. http://dx.doi.org/10.1093/aje/kwp249
51. Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of
health care-associated infections: mind your p’s and q’s. Clin Infect Dis 2010;50:1017–21.
http://dx.doi.org/10.1086/651110
52. Halton K, Graves N. Economic evaluation and catheter-related bloodstream infections. Emerging
infectious diseases 2007;13:815–23. http://dx.doi.org/10.3201/eid1306.070048
53. Gilbert RE, Mok Q, Dwan K, Harron K, Moitt T, Millar M, et al. Impregnated central venous
catheters for prevention of bloodstream infection in children (the CATCH trial): a randomised
controlled trial [published online ahead of print March 3 2016]. Lancet 2016. http://dx.doi.org/
10.1016/S0140-6736(16)00340-8
54. Cook Incorporated. Cook Spectrum® Central Venous Catheter Minocycline/Rifampin Antibiotic
Impregnated Power Injectable. Bjaeverskov, Denmark: William Cook Europe; 2013.
55. Mermel LA, Stolz SM, Maki DG. Surface antimicrobial activity of heparin-bonded and antiseptic-
impregnated vascular catheters. J Infect Dis 1993;167:920–4. http://dx.doi.org/10.1093/infdis/
167.4.920
56. Woolfall K, Frith L, Gamble C, Young B. How experience makes a difference: practitioners’ views
on the use of deferred consent in paediatric and neonatal emergency care trials. BMC Med Ethics
2013;14:45. http://dx.doi.org/10.1186/1472-6939-14-45
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
57. PICANet. Paediatric Intensive Care Audit Network: A Decade of Data. Leeds: University of
Leeds; 2014.
58. Slater A, Shann F, Pearson G. PIM2: a revised version of the Paediatric Index of Mortality.
Intensive Care Med 2003;29:278–85.
59. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk.
Ann Stat 1988;16:1141–54. http://dx.doi.org/10.1214/aos/1176350951
60. Harron K, Woolfall K, Dwan K, Gamble C, Mok Q, Ramnarayan P, et al. Deferred consent for
randomized controlled trials in emergency care settings. Pediatrics 2015;136:e1316–22.
http://dx.doi.org/10.1542/peds.2015-0512
61. Halton KA, Cook DA, Whitby M, Paterson DL, Graves N. Cost effectiveness of antimicrobial
catheters in the intensive care unit: addressing uncertainty in the decision. Crit Care 2009;13:R35.
http://dx.doi.org/10.1186/cc7744
62. Frank U, Chojnacki T, Dettenkofer M, Daschner FD. Cost-effectiveness of an antiseptic-impregnated
central venous catheter in the ICU. Intensive Care Med 2003;29:139.
63. Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous
catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use.
Am J Infect Control 2003;31:1–8. http://dx.doi.org/10.1067/mic.2003.35
64. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters: potential
financial implications. Chest 2003;124:275–84. http://dx.doi.org/10.1016/S0012-3692(15)
36021-9
65. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous
catheters for the prevention of catheter-related bloodstream infection. JAMA 1999;282:554–60.
http://dx.doi.org/10.1001/jama.282.6.554
66. Goudie A, Dynan L, Brady PW, Rettiganti M. Attributable cost and length of stay for central
line-associated bloodstream infections. Pediatrics 2014;133:e1525–32. http://dx.doi.org/10.1542/
peds.2013-3795
67. Wilson MZ, Rafferty C, Deeter D, Comito MA, Hollenbeak CS. Attributable costs of central
line-associated bloodstream infections in a pediatric hematology/oncology population. Am J Infect
Control 2014;42:1157–60. http://dx.doi.org/10.1016/j.ajic.2014.07.025
68. Health & Social Care Information Centre. Data Linkage & Extract Service. URL: www.hscic.gov.uk/
dles (accessed 8 June 2014).
69. Department of Health. National Schedule of Reference Costs 2012–13. URL: www.gov.uk/
government/publications/nhs-reference-costs-2012-to-2013 (accessed 8 June 2014).
70. Department of Health. PbR Tariff Information Spreadsheet for 2012 to 2013. URL: www.gov.uk/
government/publications/confirmation-of-payment-by-results-pbr-arrangements-for-2012–13
(accessed 8 June 2014).
71. Department of Health. A Simple Guide to Payment by Results. November 2012. URL: www.gov.uk/
government/uploads/system/uploads/attachment_data/file/213150/PbR-Simple-Guide-FINAL.pdf
(accessed 11 December 2015).
72. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness
acceptability curves. Health Econ 2001;10:779–87. http://dx.doi.org/10.1002/hec.635
73. Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing
healthcare resources and costs. Health Econ 2011;20:897–916. http://dx.doi.org/10.1002/hec.1653
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
74. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford: Oxford
University Press; 2007.
75. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013;346:f1049.
http://dx.doi.org/10.1136/bmj.f1049
76. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short
term)? Evidence for a ‘trial effect’. J Clin Epidemiol 2001;54:217–24. http://dx.doi.org/10.1016/
S0895-4356(00)00305-X
77. Harron K, Goldstein H, Wade A, Muller-Pebody B, Parslow R, Gilbert R. Linkage, evaluation and
analysis of national electronic healthcare data: application to providing enhanced blood-stream
infection surveillance in paediatric intensive care. PLOS ONE 2013;8:e85278. http://dx.doi.org/
10.1371/journal.pone.0085278
78. Wilson J, Elgohari S, Livermore DM, Cookson B, Johnson A, Lamagni T, et al. Trends among
pathogens reported as causing bacteraemia in England, 2004–2008. Clin Microbiol Infect
2011;17:451–8. http://dx.doi.org/10.1111/j.1469-0691.2010.03262.x
79. Goldstein H, Harron K, Wade A. The analysis of record-linked data using multiple imputation with
data value priors. Stat Med 2012;31:3481–93. http://dx.doi.org/10.1002/sim.5508
80. Harron K, Wade A, Gilbert R, Muller-Pebody B, Goldstein H. Evaluating bias due to data linkage
error in electronic healthcare records. BMC Med Res Methodol 2014;14:36. http://dx.doi.org/
10.1186/1471-2288-14-36
81. Rubin D.Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley; 1987.
http://dx.doi.org/10.1002/9780470316696
82. Harron K. Evaluating Data Linkage Techniques for the Analysis of Bloodstream Infection in
Paediatric Intensive Care. PhD thesis. London: University College London; 2014.
83. Steyerberg EW, Harrell FE Jr, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, Habbema JDF.
Internal validation of predictive models: efficiency of some procedures for logistic regression
analysis. J Clin Epidemiol 2001;54:774–81. http://dx.doi.org/10.1016/S0895-4356(01)00341-9
84. Steyerberg EW, Eijkemans MJC, Harrell FE, Habbema JDF. Prognostic modeling with logistic
regression analysis: in search of a sensible strategy in small data sets. Med Decis Making
2001;21:45–56. http://dx.doi.org/10.1177/0272989X0102100106
85. Harrell F, Lee KL, Mark DB. Tutorial in biostatistics multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and measuring and reducing errors.
Stat Med 1996;15:361–87. http://dx.doi.org/10.1002/(SICI)1097-0258(19960229)15:4<361::
AID-SIM168>3.0.CO;2-4
86. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point.
Biom J 2005;47:458–72. http://dx.doi.org/10.1002/bimj.200410135
87. O’Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, et al. Incorporation of
uncertainty in health economic modelling studies. Pharmacoeconomics 2005;23:529–36.
http://dx.doi.org/10.2165/00019053-200523060-00001
88. Angus DC, Mira JP, Vincent JL. Improving clinical trials in the critically ill. Crit Care Med
2010;38:527. http://dx.doi.org/10.1097/CCM.0b013e3181c0259d
89. Schierholz J, Fleck C, Beuth J, Pulverer G. The antimicrobial efficacy of a new central venous
catheter with long-term broad-spectrum activity. J Antimicrob Chemoth 2000;46:45–50.
http://dx.doi.org/10.1093/jac/46.1.45
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
90. Dondorp AM, Fanello CI, Hendriksen ICE, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate
versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT):
an open-label, randomised trial. Lancet 2010;376:1647–57. http://dx.doi.org/10.1016/
S0140-6736(10)61924-1
91. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation
of health care technologies. J Health Econ 1999;18:341–64. http://dx.doi.org/10.1016/
S0167-6296(98)00039-3
92. Kerren R, Pati S, Feudtner C. The generation gap; difference between children and adults
pertinent to economic evaluations of health interventions. Pharmacoeconomics 2004;22:71–81.
93. Tarride JE, Burke N, Bischof M, Hopkins RB, Goeree L, Campbell K, et al. A review of health
utilities across conditions common in paediatric and adult populations. Health Qual Life Outcomes
2010;8:12. http://dx.doi.org/10.1186/1477-7525-8-12
94. Harron K, Mok Q, Parslow R, Muller-Pebody B, Gilbert R, Ramnarayan P. Risk of bloodstream
infection in children admitted to paediatric intensive care units in England and Wales following
emergency inter-hospital transfer. Intensive Care Med 2014;40:1916–23. http://dx.doi.org/
10.1007/s00134-014-3516-0
95. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter
uncertainty. Value Health 2005;8:1–2. http://dx.doi.org/10.1111/j.1524-4733.2005.08101.x
96. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity
analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339–47.
http://dx.doi.org/10.1002/hec.985
97. Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target populations:
the ACTG 320 Trial. Am J Epidemiol 2010;172:107–15. http://dx.doi.org/10.1093/aje/kwq084
98. Stuart EA, Cole SR, Bradshaw CP, Leaf PJ. The use of propensity scores to assess the
generalizability of results from randomized trials. J R Stat Soc Ser A Stat Soc 2011;174:369–86.
http://dx.doi.org/10.1111/j.1467-985X.2010.00673.x
99. Junker A, Klassen T. Improving standards for paediatric clinical trials. Paediatr Child Health
2011;16:539–40.
100. Hartling L, Wittmeier KDM, Caldwell P, van der Lee H, Klassen TP, Craig JC, et al. StaR Child
Health: developing evidence-based guidance for the design, conduct, and reporting of pediatric
trials. Pediatrics 2012;129:S112–17. http://dx.doi.org/10.1542/peds.2012-0055C
101. Gamble C, Nadel S, Snape D, McKay A, Hickey H, Williamson P, et al. What parents of children
who have received emergency care think about deferring consent in randomised trials of
emergency treatments: postal survey. PLOS ONE 2012;7:e35982. http://dx.doi.org/10.1371/
journal.pone.0035982
102. Molyneux S, Njue M, Boga M, Akello L, Olupot-Olupot P, Engoru C, et al. ‘The words will pass
with the blowing wind’: Staff and parent views of the deferred consent process, with prior assent,
used in an emergency fluids trial in two African hospitals. PLOS ONE 2013;8:e54894.
http://dx.doi.org/10.1371/journal.pone.0054894
103. Brierley J, Larcher V. Emergency research in children: options for ethical recruitment. J Med Ethics
2011;37:429–32. http://dx.doi.org/10.1136/jme.2010.040667
104. Woolfall K, Young B, Frith L, Appleton R, Iyer A, Messahel S, et al. Doing challenging research
studies in a patient-centred way: a qualitative study to inform a randomised controlled trial in
the paediatric emergency care setting. BMJ Open 2014;4:e005045. http://dx.doi.org/10.1136/
bmjopen-2014-005045
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
105. Jansen T, Kompanje EJ, Druml C, Menon D, Wiedermann C, Bakker J. Deferred consent in
emergency intensive care research: what if the patient dies early? Use the data or not? Intensive
Care Med 2007;33:894–900. http://dx.doi.org/10.1007/s00134-007-0580-8
106. Davies H, Shakur H, Padkin A, Roberts I, Slowther A-M, Perkins GD. Guide to the design and
review of emergency research when it is proposed that consent and consultation be waived.
Emerg Med J 2014;31:794–5. http://dx.doi.org/10.1136/emermed-2014-203675
107. Maitland K, Molyneux S, Boga M, Kiguli S, Lang T. Use of deferred consent for severely ill children
in a multi-centre Phase III trial. Trials 2011;12:90. http://dx.doi.org/10.1186/1745-6215-12-90
108. Macrae D, Grieve R, Allen E, Sadique Z, Morris K, Pappachan J, et al. A randomized trial of
hyperglycemic control in pediatric intensive care. New Engl J Med 2014;370:107–18.
http://dx.doi.org/10.1056/NEJMoa1302564
109. Ellenberg SS, Finkelstein DM, Schoenfeld DA. Statistical issues arising in AIDS clinical trials.
JAMA 1992;87:562–9.
110. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al. Mortality after
fluid bolus in African children with severe infection. New Engl J Med 2011;364:2483–95.
http://dx.doi.org/10.1056/NEJMoa1101549
111. Cook DJ, Blythe D, Rischbieth A, Hebert PC, Zytaruk N, Menon K, et al. Enrollment of intensive
care unit patients into clinical studies: A trinational survey of researchers’ experiences, beliefs, and
practices. Crit Care Med 2008;36:2100–5. http://dx.doi.org/10.1097/CCM.0b013e31817c00b0
112. Harron K, Lee T, Ball T, Mok Q, Gamble C, Macrae D, et al. Making co-enrolment feasible for
randomised controlled trials in paediatric intensive care. PLOS ONE 2012;7:e41791. http://dx.doi.
org/10.1371/journal.pone.0041791
113. Myles PS, Williamson E, Oakley J, Forbes A. Ethical and scientific considerations for patient enrollment
into concurrent clinical trials. Trials 2014;15:470. http://dx.doi.org/10.1186/1745-6215-15-470
114. Shilling V, Williamson PR, Hickey H, Sowden E, Beresford MW, Smyth RL, et al. Communication
about children’s clinical trials as observed and experienced: qualitative study of parents and
practitioners. PLOS ONE 2011;6:e21604. http://dx.doi.org/10.1371/journal.pone.0021604
115. Burgess E, Singhal N, Amin H, McMillan D, Devrome H, Fenton A. Consent for clinical research in
the neonatal intensive care unit: a retrospective survey and a prospective study. Arch Dis Child
Fetal Neonatal Ed 2003;88:F280. http://dx.doi.org/10.1136/fn.88.4.F280
116. Morley C, Lau R, Davis P, Morse C. What do parents think about enrolling their premature babies
in several research studies? Arch Dis Child Fetal Neonatal Ed 2005;90:F225. http://dx.doi.org/
10.1136/adc.2004.061986
117. Harron K, Gamble C, Gilbert R. E-health data to support and enhance randomised controlled
trials in the UK. Clinical Trials 2015;12:180–2. http://dx.doi.org/10.1177/1740774514562030
118. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the
West of Scotland Coronary Prevention Study. New Engl J Med 2007;357:1477–86. http://dx.doi.org/
10.1056/NEJMoa065994
119. Rawlins M. A New Pathway for the Regulation and Governance of Health Research. The Academy
of Medical Sciences; 30 January 2011. URL: www.acmedsci.ac.uk/p47prid88.html (accessed
15 June 2012).
120. Stephenson T. The medicines for children agenda in the UK. Br J Clin Pharmacol 2006;61:716–19.
http://dx.doi.org/10.1111/j.1365-2125.2006.02676.x
121. Great Britain. NHS Act 2006. London: The Stationery Office; 2006.
122. Great Britain. Health and Social Care Act 2001. London: The Stationery Office; 2001.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
66
Appendix 1 Statistical analysis plan
Form prepared: 06/12/2013 v1.1 for CATCH Study  
 
 
 
 
 
 
 
CATheter Infections in CHildren  
 
 
 
Statistical Analysis Plan 
 
 
 
 ORIGINATED BY 
Name  
Title  
Date  
Protocol Version 
and Date 
 
  
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
Form prepared: 06/12/2013 v1.1 for CATCH Study  
Change Control 
Updated 
SAP 
version 
no. 
Section 
number 
changed 
Description of change Date 
changed 
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1.1 13 and 
14 
Comments from Paul Ewings addressed 06/12/20
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KD 
1.2 Append
ix D 
Organisms added to the appendix  21/02/20
14 
KD 
1.3 Section 
5.2 
 
 
 
Section 
5.2 
 
 
Section 
7.1, 13 
 
 
 
 
 
Section 
11 
 
 
 
 
 
 
Section 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 
14.10 
 
 
 
Section 
Data for ‘primary reason for admission based on ICD 
10 code, categorised as Infection, Renal, Cancer, 
Respiratory, Neurological, Circulatory, Other’ will 
now be obtained from PICANET data. 
 
PIMS2 score has been added using PICANET data. 
 
 
 
Clarification on timepoint for primary outcome. Date 
of randomisation and date of insertion are used 
interchangeably. Version 1 of the SAP does state 
that the time to event analysis will be calculated from 
date of randomisation. This has been clarified in the 
SAP in all relevant sections.  
 
Per protocol analyses have been removed as this 
was never stated in the protocol.  
Clarification has been made on the definition of 
elective and emergency patients. 
 
Protocol deviations will not be signed off as a per 
protocol analysis is not being undertaken 
Adverse events will be grouped into fewer groups. 
Clarification has been made to reporting of the two 
outcomes thrombosis and unexplained 
thrombocytopenia: ‘to avoid double counting of 
unexplained thrombocytopenia will be presented as 
an adverse event and thrombosis will be presented 
as a secondary outcome as the outcome is time to 
event. 
 
Clarification has been added to the secondary 
outcome ‘length of time in PICU’ that this is for the 
first stay in PICU only as stated in appendix E.  Also, 
CICU and NICU will be treated as PICU 
 
For the secondary outcome ‘Time to a composite 
15/05/20
14 
KD 
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14.3 
 
 
 
 
 
 
 
Append
ix E 
 
 
 
measure of clinically indicated blood stream infection 
based on the primary outcome or high bacterial DNA 
load or culture negative bloodstream infection based 
on clinical criteria’, antibiotics need to be grouped as 
they are included on CRFs as free text so often 
misspelt. This grouping has been added to the 
appendix. 
 
Clarification has been added to the appendix for the 
time between the two events of flushing or difficulty 
drawing back blood, this should be up to 5 days. 
1.4 Section 
13 
 
 
Section 
14.2 
 
 
 
Append
ix F 
Clarification has been added regarding the process 
when times are not available and details on 
censoring. 
 
Clarification has been added regarding the process 
when times are not available and details on 
censoring. 
 
 
Antibiotics were grouped by a clinical member of the 
TMG 
12/08/20
14 
KD 
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6.6 Antibiotic resistance        78  
6.7 Positive CVC tip culture       78  
6.8 Exit site infection        78  
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8 Description of compliance with treatment     81
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10 Unblinding of randomised treatments      81  
11 Patient groups for analysis        81  
12 Protocol deviations         82  
12.1 Adverse reactions/events       82  
13 Analysis of primary efficacy outcome      82  
13.1 Analyses of missing data       84  
13.2 Sampling frequency        85  
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Form prepared: 06/12/2013 v1.1 for CATCH Study  
14 Analysis of secondary efficacy outcomes     85  
14.1 Rate of blood stream infection during CVC insertion per 1000 CVC days 85  
14.2 Time to CVC thrombosis       85  
14.3 Time to a composite measure of blood stream infection based on the primary 
outcome or high bacterial DNA load or culture negative bloodstream infection based 
on clinical criteria         86  
14.4 A CVC related blood stream infection     86  
14.5 Mortality by 30 days        87  
14.6 Type of bacteria and fungi isolated from positive blood cultures  87  
14.7 Resistance to minocycline or rifampicin of blood culture or CVC tip isolates
            87  
14.8 Unexplained thrombocytopenia after insertion of CVC- detected by routine 
laboratory monitoring         87  
14.9 Time to randomised CVC removal      87  
14.10 Length of stay requiring PICU      88  
14.11 Total length of hospital stay for current episode (for up to 6 month post 
randomisation)         88  
14.12 Cost effectiveness of heparin bonded vs. antibiotic-impregnated vs. standard 
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15 Setting results in context of previous research     88  
16 References          89  
Approval and agreement         90  
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2 Introduction 
This Statistical Analysis Plan (SAP) provides a detailed and comprehensive 
description of the pre-planned final full analysis for the study “CATCH”.  
 
This study is carried out in accordance with the World Medical Association 
Declaration of Helsinki (1964) and the Tokyo (1975), Venice (1983), Hong Kong 
(1989) and South Africa (1996) amendments and will be conducted in compliance 
with the protocol, Clinical Trials Research Centre (CTRC) Clinical Trials Unit (CTU) 
Standard Operating Procedures (SOPs) and EU Directive 2001/20/EC, transposed 
into UK law as the UK Statutory Instrument 2004 No 1031: Medicines for Human 
Use (Clinical Trials) Regulations 2004. 
 
These analyses will be performed by the trial statistician. The analysis results will be 
described in a statistical analysis report, to be used as the basis of the primary 
research publications according to the study publication plan specified within the 
study protocol.  
 
All analyses will be performed with standard statistical software (SAS version 9 or 
later). The finalised analysis datasets, programs and outputs will be archived 
following Good Clinical Practice guidelines and SOP IS006 Study Closedown and 
Archiving. The testing and validation of the statistical analysis programs will be 
performed following SOP ST001: Statistical Analysis and Reporting - v.2.0.    
 
3 Study design and objectives 
This study is designed as a prospective, parallel, controlled, multicentre, randomised 
clinical trial comparing the effectiveness of heparin bonded or antibiotic impregnated 
CVCs with standard CVCs for preventing hospital acquired blood stream infection in 
children (aged less than 16 years) admitted to PICU, who require insertion of a CVC 
for at least 3 days.  
The primary objective of this trial is to determine the effectiveness of heparin bonded 
or antibiotic impregnated CVCs (combined) compared with standard CVCs for 
preventing hospital acquired blood stream infection  
 
Secondary objectives are: 
a. To determine the cost effectiveness of heparin bonded or antibiotic 
impregnated CVCs compared with standard CVCs, based on the primary 
outcome and costs of acute care from the perspective of the NHS. 
b. To determine the effectiveness of type of CVC in 3-way comparisons of 
heparin bonded versus antibiotic impregnated versus standard CVCs for 
preventing hospital acquired blood stream infection, based on culture, 
quantitative bacterial DNA, and clinical measures of infection. 
c. To determine the effect of type of CVC on clinical measures of care (duration 
of CVC insertion, duration of antibiotic use, and duration of stay). 
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d. To determine the effect of type of CVC on mortality at 30 days. 
e. To identify adverse effects of CVC type on pathogen selection, antibiotic 
resistance, clinical evidence of CVC thrombosis and thrombocytopenia. 
The null hypothesis is that there is no difference in time to first blood stream infection 
between the standard and impregnated (antibiotic and heparin combined) groups. 
The alternative hypothesis is that there is a difference between the two groups.
Randomisation 
Randomisation lists were generated in STATA using simple block randomisation with 
random variable block length and a 1:1:1 ratio of treatment allocation. 
Randomisation was stratified by elective and emergency participants and centre with 
further stratification within centre to permit multiple cvc allocation/storage sites. 
The randomisation numbers are 9 digits long.   
Digits 1 to 4 indicate the UK CRN number;  
Digit 5 indicates whether a participant is elective (0) or emergency (1);  
Digit 6 indicates the place where the cvc is stored and  
Digits 7 to 9 are sequential numbers within place and site. 
Treatment allocation could not be blinded to the clinician responsible for randomising 
a patient and inserting the CVC but was concealed from patients, their parents and 
PICU personnel responsible for their care.
 
There was an interim analysis of the primary outcome mid-way (650 patients 
randomised and consented and entered onto the database) through the trial, using 
Peto-Haybittle stopping rules. 
3.1 Sample size calculations 
Sample size calculations were undertaken using NQuery Advisor software.  
At a sample size of 1200, we would have 80% power to detect a relative risk of 0.5 at 
a 5% level of significance given a baseline risk of 10%, using a Fisher s exact test. 
At the lower expected baseline event rate of 5%, there would be 80% power to 
detect a relative risk of 0.32 (absolute risk difference 3.4% ) whereas at a baseline 
event rate of 15% there would be 80% power to detect a relative risk of 0.6 (absolute 
risk difference of 6%). The power to detect these effects would be similar for survival 
analyses. Explicit power calculations have not been given for the survival analysis to 
avoid making potentially erroneous assumptions about the distribution of infection 
times in the standard arm based on the limited information available at present. 
3.2 Interim analysis 
The interim analysis of the primary outcome was completed mid-way (approximately 
half of the patients randomised and consented and entered onto the database), 
through the trial, using Peto-Haybittle stopping rules.  This was completed under 
version 2.0 of the SOP as version 3.0 of the SOP was released later (30/06/2012).  
Details can be found in the IDSMC report dated 22/05/2012. 
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
Form prepared: 06/12/2013 v1.1 for CATCH Study  
4 Inclusion / Exclusion Criteria 
4.1 Inclusion Criteria  
Patients with the following characteristics will be eligible for inclusion in the trial: 
a. Less than 16 years of age; 
b. Admitted to or being prepared for admission to an intensive care unit participating 
in the trial; 
c. Require insertion of a CVC as part of good clinical management; 
d. Require one of the CVC sizes available to the trial; 
e. Expected to require a CVC for at least 3 days; 
f. Appropriate consent obtained (prospective consent for elective surgical patients, 
deferred consent for emergency admission patients). 
4.2 Exclusion Criteria  
Patients with the following characteristics will be excluded from the trial: 
a. Patients previously enrolled in the CATCH trial; 
b. Patients with a known allergy or hypersensitivity to tetracyclines (including 
minocycline), rifampicin or heparin; 
c. Patients known to be pregnant; 
d. Patients with a history of heparin induced thrombocytopenia; 
e. Patients are in a randomised controlled trial that excludes participation in CATCH 
5 Description of study population 
5.1 Representativeness of study sample and patient throughput 
Details will be presented on: 
• the number of patients, both elective and emergency who were randomised, 
• those emergency patients who were randomised but did not provide deferred 
consent,  
• those who received the randomised allocation,  
• those who did not receive the randomised allocation,  
• those randomised but where CVC insertion was not attempted,  
• those where CVC insertion was attempted but the CVC was not inserted, 
• those who withdrew from the study after randomisation and  
• those who were lost to follow-up  
 
will be summarised in a CONSORT flow diagram (Appendix A) ( ).  Due to the 
nature of the trial, information could not be collected regarding eligible emergency 
participants who were not randomised. Therefore, this information is not presented 
for elective patients. 
5.2 Baseline comparability of randomised groups 
Baseline characteristics will be descriptively summarised (numbers and 
percentages). Table columns will be:  Standard; impregnated (heparin or antibiotic); 
antibiotic; heparin; and total. This table will be produced across all sites and by site. 
Variable to be included in the table are:  
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Descriptor Form 
Baseline characteristics 
Number of patients randomised 1, 2 and 3 
Elective/ emergency 1 and 3 
Age, categorised as <3 months, 3 months-<1 year, 1-10 years and 11+ 
years. A median and interquartile range will also be calculated. 
 
Gender (male/female) 4 
Weight, categorised as <3kgs, 3-10kgs, >10kgs. A median and 
interquartile range will also be calculated. 
4 
Electives - Type of surgery, categorised as cardiac/other. 4 
Source of admission to PICU, categorised as: 
 Elective, same hospital or  
Emergency, Same hospital or Other hospital – retrieved by: Specialist 
retrieval  team, Other 
4 
Disease characteristics 
Pre-existing CVC at time of randomisation or within 72 hours prior to 
time of randomisation (Yes/ No) 
1 or 3 and 
4 
Health status BEFORE the acute problem precipitated PICU admission: 
(Healthy/ Not Healthy). 
4 
Anticoagulant medication within 72 prior to randomisation: (yes/no). 4 
Antibiotics 72 hours prior to randomisation: (yes/no). 4 
Primary reason for admission based on ICD 10 code, categorised as 
Infection, Renal, Cancer, Respiratory, Neurological, Circulatory, Other. 
PICANET 
data 
PIMS2 score (<1%, 1-5%, 5-15%, 15-30%, 30%+) PICANET 
data 
Positive blood culture within 72 hours prior to time of randomisation 
(yes/no). 
4 
Suspected infection at time of randomisation (yes/no).  4 
Immune compromised (yes/no). 4 
Description of interventions 
Where the CVC was inserted, stratified by elective and emergency and 
then same hospital and other hospital and then: ICU 
(PICU/NICU/CICU); other ward (HDU or other ward); theatre; other 
/A&E 
1 or 3 
Size of line: (4, 5 or 7)  1 or 3 
Number of lumens (triple or double lumen) 1 or 3 
Site: (femoral or other) 1 or 3 
Sterile procedures used split by elective and emergency: yes/no 1 or 3 
 
Descriptor Form 
48 hours post randomisation 
Other devices in situ in addition to CVC: 
Less than 4 
Greater than or equal to 4 
4 
5.3 Loss to follow-up 
The number lost to follow up within each treatment group will be reported and the 
reasons where known will be provided.  
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Reasons for loss to follow up are: transferred to a site not participating in CATCH; 
deferred consent not obtained. For deaths – see follow up assessments (section 6). 
6 Follow up assessments  
Where CVC insertion was successful, patients will be followed up to 48 hours after 
CVC removal.  For those where insertion was attempted but not successful, patients 
will be followed up to 48 hours after attempted insertion. 
6.1 Blood culture samples 
Blood culture samples may be taken from CVC lumens, peripheral veins, or if 
necessary, from the arterial line (although this is discouraged). To differentiate 
potential contaminants or line infection from blood stream infection the best 
approach to sampling is in the following diminishing order of preference 
a. take both a peripheral blood sample and a CVC culture at the same time 
b. Take a peripheral blood culture; 
c. Take a CVC culture – from all available lumens of the randomised CVC; 
d. Take a CVC culture – from all available lumens of any other CVC; 
e. Take an arterial line culture (high risk of contamination). 
A minimum of 0.5ml of blood should be taken for any blood culture. For CVC 
cultures, a minimum of 0.5ml of blood will be taken from each lumen and 
inoculated into separate culture bottles (note total volume is 1ml for neonates in 
whom double lumen CVCs are used). Sampling from multiple lumens will be 
used because sampling from one lumen reduces sensitivity for catheter related 
bloodstream infection. 
 
Blood culture contributes to definitions of: 
• Time to first blood stream infection (7.1) 
• Rate of blood stream infection during CVC insertion per 1000 CVC days 
(7.2.1) 
• Time to a composite measure of clinically indicated blood stream 
infection (7.2.3) 
• A CVC related blood stream infection (7.2.4) 
• Type of bacteria and fungi isolated from positive blood cultures (7.2.6) 
• Resistance to minocycline or rifampicin of blood culture or CVC tip 
isolates (7.2.7) 
6.2 Clinically indicated  
Clinically indicated means blood cultures taken because infection is 
suspected by the clinician either due to a change in the patient’s condition (e.g. 
pyrexia, change in oxygen or inotrope requirements, hypotension, poor 
perfusion), or removal of the CVC line due to suspected infection, or a high 
likelihood of infection due to their risk status. Guidelines will be developed to 
improve standardisation of practice, but not to dictate what must ultimately be a 
clinical judgement of signs of infection. Blood cultures will be taken routinely at 
CVC removal, to allow comparison of isolate with the CVC tip culture. This 
culture will be counted as ‘clinically indicated’ if the line was removed for 
suspected infection or if there were signs of infection at the CVC exit site . 
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Clinically indicated contributes to definitions of:  
• Time to first blood stream infection (7.1) 
• Rate of blood stream infection during CVC insertion per 1000 CVC days 
(7.3.2) 
• Time to a composite measure of clinically indicated blood stream 
infection (7.2.3) 
6.3 Positive blood culture 
Positive blood culture will be defined as: 
a. one or more positive blood cultures with a non-skin organism from a 
sample taken from any vascular site; or 
b. the same skin organism isolated from 2 or more positive blood cultures 
(from any vascular site) within 48 hours of each other. One or more of the 
samples must be taken 48 hrs after CVC insertion or within 48 hours after 
removal. A review committee will independently classify multiple cultures 
according to same or different organisms based on species and antibiogram 
as to whether it is the same BSI or not. 
 
Positive blood culture contributes to definitions of:  
• Time to first blood stream infection (7.1) 
• Rate of blood stream infection during CVC insertion per 1000 CVC days 
(7.2.1) 
• Time to a composite measure of clinically indicated blood stream 
infection (7.2.3) 
• A CVC related blood stream infection (7.2.4) 
• Resistance to minocycline or rifampicin of blood culture or CVC tip 
isolates (7.2.7) 
6.4 High bacterial DNA load indicative of blood stream infection 
High bacterial DNA load indicative of blood stream infection will be defined 
as more than 0.25 pg of bacterial DNA per microlitre of whole blood detected 
from one or more sites taken more than 48 hours after CVC insertion and 
before 48 hours after CVC removal.  High bacterial DNA load indicative of CVC 
related blood stream infection will be defined by differential results for high 
bacterial load from multiple lumens (i.e. not all above or below 0.25 
pg/microlitre. Note that this may be influenced in advances in methodology 
since the protocol was approved). Analysis of bacterial DNA load will be based 
on a minimum sample of 0.2ml from each lumen taken at the same time as the 
blood culture, placed in separate EDTA bottles for each lumen, and frozen at -
20ºC till batching within 1 month of sampling. The rationale for using 
quantitative PCR measures of bacterial DNA is because most children in PICU 
will be on antibiotic treatment, which reduces the sensitivity of blood culture. 
PCR appears to be more sensitive than culture for detecting blood stream 
infection. 
 
High bacterial DNA load indicative of blood stream infection contributes to the 
definition of:  
• Time to a composite measure of clinically indicated blood stream 
infection (7.2.3) 
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6.5 Culture negative infection 
Culture negative infection will be defined by a change in antibiotic treatment on 
the same or subsequent day after a blood culture sample more than 48 hours 
after CVC insertion or up until 48 hr after CVC removal in the presence of 
negative blood cultures, and 1 or more clinical signs of infection and at least one 
other sign (clinical or laboratory). The signs of infection include the following: 
clinical signs – temperature >38oC or temperature instability, haemodynamic 
instability (hypotension, mottled, poor perfusion, capillary refill>3s); or laboratory 
signs - C-reactive protein rising above normal range; white blood cell count 
(falling below 2 x 109/l or above 10 x 109/l or showing a rising trend). 
 
Culture negative infection contributes to definitions of:  
· Time to a composite measure of clinically indicated blood stream 
infection (7.2.3) 
6.6 Antibiotic resistance 
Antibiotic resistance will be recorded as an adverse event if resistance is 
detected to minocycline or rifampicin using standard E tests on isolates from 
blood or the CVC tip. All microbiology laboratories supporting PICUs involved in 
the trial will be asked to use E strips to test for minocycline or rifampicin 
resistance in any isolates from blood cultures or CVC tips. 
 
Antibiotic resistance contributes to the definition of:  
· Resistance to minocycline or rifampicin of blood culture or CVC tip 
isolates (07.2.7) 
 
6.7 Positive CVC tip culture 
Positive CVC tip culture will be based on any sized tip of the catheter, 
removed using a sterile procedure, and cultured according to standard 
methods. A positive culture will be considered a secondary outcome only if the 
blood culture is positive for the same isolate and positive blood culture sample 
was taken within 7 days prior to the CVC removal. This is because CVCs are 
easily contaminated during removal. 
 
Positive CVC tip culture contributes to definitions of:  
· A CVC related blood stream infection (7.2.4) 
· Resistance to minocycline or rifampicin of blood culture or CVC tip 
isolates (7.2.7) 
 
6.8 Exit site infection 
Exit site infection will be defined by erythema extending 0.5cm or more for 
infants, 1cm for older children and 2cm for adolescents from the exit site of the 
CVC, or pus at the exit site.  
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Exit site infection is listed within the Adverse Events (Section 12.1) and also 
contributes to the definition of:  
• Time to first blood stream infection (7.1) 
• A CVC related blood stream infection (7.2.4) 
 
7 Study Outcomes  
7.1 Primary Outcome  
The primary outcome will be time to first blood stream infection defined by a positive 
blood culture from a sample that was clinically indicated and taken more than 48 
hours after randomisation and up to 48 hours after CVC removal. 
7.2 Secondary Outcomes  
7.2.1 Rate of blood stream infection during CVC insertion per 1000 CVC days. 
Where blood stream infection is defined as per primary outcome but without any 
criteria around the timing of the sample and the CVC must be in situ. 
Second episode of blood stream infection (defined as per primary outcome) will be 
defined by a positive blood culture (see definition above) of a different isolate (in 
terms of species and antibiogram) from a sample taken whilst the cvc is in situ. Any 
positive blood cultures of the same isolate will be regarded as the same episode 
regardless of time since the first sample.   
 
7.2.2 Time to CVC thrombosis - defined clinically by (any one or more of the 
following):  
a. 2 records of difficulty drawing back blood from one or more lumen;  
b. 2 or more episodes of flushing to unblock;  
c.  an episode of swollen limb;  
d.  positive ultrasound;  
e.  removal of CVC because of clinical evidence of a blocked CVC. 
7.2.3 Time to a composite measure of clinically indicated blood stream infection 
based on the primary outcome or high bacterial DNA load or culture negative 
bloodstream infection based on clinical criteria defined as :  
a. Primary outcome as defined above 
b. Any of the clinical indicators of infection (Section 6.2) and blood culture 
taken and  
i. High bacterial DNA load from a PCR positive result or  
ii. change in antibiotic on same day or next day or 
iii. CVC removal for infection 
7.2.4 A CVC related blood stream infection will be defined by: 
a. the same isolate (species and antibiogram) from the CVC tip and from 
a blood culture sample taken from any site more than 48 hours after 
CVC insertion and within 48 hours following CVC removal; 
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b. differential positivity of the same isolate in blood cultures taken from 
multiple CVC lumens (i.e. not all positive or negative at the same 
sampling or the same skin commensal isolated from the same lumen 
but not all lumens on multiple occasions). 
c. OR positive BSI AND CVC removed for infection 
d. OR positive BSI AND CVC exit site infection 
 
7.2.5 Mortality by 30 days 
7.2.6 Type of bacteria and fungi isolated from positive blood cultures 
7.2.7 Resistance to minocycline or rifampicin of blood culture or CVC tip isolates 
7.2.8 Unexplained thrombocytopenia after insertion of CVC- detected by routine 
laboratory monitoring 
7.2.9 Time to randomised CVC removal 
7.2.10 Length of stay requiring PICU 
7.2.11 Total length of hospital stay for current episode (for up to 6 month 
postrandomisation) 
7.2.12 Cost effectiveness of heparin bonded vs. antibiotic-impregnated vs. standard 
CVC 
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8 Description of compliance with treatment 
The number of patients where CVC insertion was attempted but was not successful, 
where insertion was not attempted after randomisation and for those that received a 
CVC other than the randomised CVC will be reported in the CONSORT flow diagram 
(Appendix A). 
 
9 Trial monitoring 
There have been two IDSMC meetings, one in February 2012 to investigate the 
control group event rate and the other in June 2012 for the interim analysis of the 
primary outcome for 650 patients randomised, consented and entered onto the 
database.  The recommendation from both of these meetings was to continue 
recruitment.  
 
10 Unblinding of randomised treatments 
The number of patients who were unblinded prior to database lock will be reported 
for each treatment group along with the reasons as to why they were unblinded. 
 
Checks were made on the order of patients being randomised and records were kept 
of any unblinding requests that were made by sites. 
 
11 Patient groups for analysis 
The principle of intention-to-treat, as far as is practically possible, will be the main 
strategy of the analysis adopted for the primary outcome and all the secondary 
outcomes. These analyses will be conducted on all patients randomised to the 
treatment groups, regardless of whether CVC insertion was attempted or not. 
 
The membership of the analysis set for each outcome will be determined and 
documented.  Reasons for participant exclusion will be given prior to blinding being 
broken and the randomisation lists being requested. Reasons may include missing 
data or loss to follow up.  
 
The safety analysis data set will contain all participants that were randomised and 
had CVC insertion attempted.  Patients will be included in the treatment group that 
they actually received (the CVC that was actually inserted or the CVC that was 
attempted if no CVC was inserted).
 
Patients to be excluded from populations will be defined in template ST001TEM04 
(Protocol deviations and population exclusions template) and will be agreed and 
approved prior to any release of randomisation codes. 
 
Patients will be classified as elective/emergency based on consent given i.e. 
deferred/prospective. 
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12 Protocol deviations 
Any protocol deviations will be tabulated and the frequency of these deviations 
presented by site and in total, and by treatment group.  
 
Protocol deviations have been defined in the draft monitoring plan (Appendix B). The 
monitoring plan also defines whether each deviation is considered major or minor. 
 
Description of safety outcomes 
12.1 Adverse reactions/events 
All related adverse events (AEs) or adverse reactions (ARs) and serious adverse 
events (SAEs) reported by the clinical investigator (as in Section 10.4 of the protocol) 
will be presented, identified by treatment group. The number (and percentage) of 
patients experiencing each AE/SAE will be presented for each treatment arm 
categorised by severity. For each patient, only the maximum severity experienced of 
each type of AE will be displayed. The number (and percentage) of occurrences of 
each AE/SAE will also be presented for each treatment arm. No formal statistical 
testing will be undertaken.  
 
Any adverse events entered in free text will be assessed by a team of clinical 
professionals and summarised as below. 
 
• Thrombosis 
• Exit site infection  
• Antibiotic resistance 
• Low platelets/hypersensitivity 
• Line displacement (falling out/tip displaced) 
• Trauma from line insertion  
• Line breakage/mechanical problem 
• Mortality  
 
To avoid double counting of unexplained thrombocytopenia will be presented as an 
adverse event and thrombosis will be presented as a secondary outcome as the 
outcome is time to event. 
 
13 Analysis of primary efficacy outcome  
The primary efficacy outcome is time to first blood stream infection defined by a 
positive blood culture from a sample that was clinically indicated and taken more 
than 48 hours after CVC insertion and up to 48 hours after CVC removal (see 
section 7.1 and Appendix C, D, E). 
  
• If an organism is cultured it is identified on the microbiology form.  Organisms 
cultured will be discussed with the microbiologist to identify whether they are 
skin or non skin organisms (Appendix D).  If a non skin organism is identified 
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then this is automatically a positive blood stream infection.  If a skin organism 
is identified then the microbiology form will be checked to identify whether the 
same skin organism has occurred again from any site within 48 hours (only 
one sample has to be within the correct timeframe for the primary outcome).  
This will be checked with the microbiologist and clinician endpoint review 
committee (Appendix G) to ensure the skin organisms are in fact the same.  If 
this is confirmed then this will be a positive blood stream infection.  Date and 
time of the samples are included on the microbiology form. 
• Timings will then be checked to ensure the sample was taken 48 hours post 
randomisation (insertion also used in a sensitivity analysis) and up to 48 hours 
after removal of the CVC.  These timings are included on form 1 section B 
(date and time of randomisation and date and time of successful insertion) 
and form 5 (date and time of CVC removal). The sample times are indicated 
on forms 9 and 10 (date and time sample taken). If no CVC removal date was 
recorded, date of transfer was used. For those with no time for removal but 
when the date is the same as randomisation, the time was set to 23.59. 
• Clinically indicated: defined in section 6.2.  The sampling form will then be 
checked to determine whether there were one or more clinical indices within 
48 hours of the sample being taken.  Clinical indication of infection is recorded 
on form 9 (sampling form: section A question 4 and section B question 1), 6 
(progress log) and on form 5 (CVC insertion follow up form: section A 
question 1 and section B question 3.  Note that there may be two reasons for 
removal) if the reason for removal is ‘CVC associated infection suspected’.  
Raised CRP and white blood cell counts alone will not be regarded as clinical 
indicators of infection. 
 
The number of positive blood stream infections taken more than 48 hours after 
randomisation and up to 48 hours after CVC removal will be presented split by 
treatment, the site of the sample (i.e. lumen, arterial, peripheral)  and whether the 
organisms cultured were skin or non-skin.   
 
Kaplan-Meier survival curves stratified by CVC will be presented.  A survival analysis 
will be performed using the Log rank test and Cox proportional hazard regression 
models if appropriate for heparin bonded or antibiotic impregnated CVCs (combined) 
compared with standard CVCs and adjusted for one the variables used for stratifying 
randomisation (elective and emergency participants).   In the design, the stratification 
of CATCH between emergency and elective was due to prognostic importance but 
centre and storage site were logistical.  ICH E9 states that “In some trials there may 
be no reason to expect the centres to have any influence on the primary or 
secondary variables because they are unlikely to represent influences of clinical 
importance. In other trials the limited number of subjects per centre will make it 
impracticable to include centre effects in the statistical model” (3).  Heterogeneity of 
treatment effects by centre will be considered in a graphical display.  
 
Since the hazard of infection may not be constant post CVC insertion, non-
proportional hazards survival models will also be investigated.  Results will be 
presented using Hazard Ratios and 95% confidence intervals. Survival times will be 
measured from the date and time of randomisation to the date and time of positive 
DOI: 10.3310/hta20180 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 18
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harron et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
83
Form prepared: 06/12/2013 v1.1 for CATCH Study  
blood stream infection as identified above.  For those not experiencing the primary 
outcome, they will be censored at death, 48 hours after CVC removal or for those 
with no CVC inserted, 48 hours after randomisation/attempted insertion. 
 
Differences between date and time of randomisation and date and time of insertion 
will be summarised using medians and IQR. 
 
A secondary analysis will compare each impregnated CVC against standard CVC 
i.e. i) heparin bonded versus standard and ii) antibiotic impregnated versus standard. 
 
Regression models will be used to further investigate the outcomes between the 
groups, including: type of admission (emergency clean, emergency dirty or elective); 
Immune compromised (yes/no); infection at admission (yes/no) and other devices in 
situ (4 or more in addition to CVC), age (as categorised within the baseline table), 
site (femoral vs other).  An interaction of elective and emergency will also be 
considered.   
 
A p-value of 0.05 or less will be used to declare statistical significance for all 
analyses.  
 
The number needed to treat (NNT) and 95% confidence intervals will be calculated 
(4). 
13.1 Analyses of missing data 
As much information as possible will be collected about the reasons for missing 
outcome data and this will be used to inform sensitivity analyses.   
 
If there are clinical indicators of infection but no microbiology report of blood cultures 
then no blood stream infection will be assumed, a sensitivity analysis will assess 
whether the conclusion differs if we assume there is an infection. Clinical indicators 
of infection will not be included where the clinical indicator that was on the sampling 
form was only for raised CRP or white blood cell counts or both.  The ICD-10 code 
reason for admission will also be considered. 
 
If the patients without microbiology reports are included in the denominator of the 
primary outcome then this assumes that there was no clinically indicated blood 
stream infection. The following classifications (Table 1) make use of all data 
available for each case and present reasonable assumptions on their primary 
outcome classification. Where there is uncertainty these cases are highlighted for 
sensitivity analysis. 
 
TABLE 1: ASSUMPTIONS FOR SENSITIVITY ANALYSIS 
Clinically indicated and samples taken  Include in numerator for sensitivity analysis  
Clinically indicated but no samples taken (taking 
into account ICD-10 code) 
Include in numerator for sensitivity analysis  
Not clinically indicated and no samples at 
removal  
Included in denominator only  
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Inserted for less than 48 hours/ attempted after 
12 hours after randomisation/not successfully 
inserted  
Included in denominator only  
 
‘None’ was not ticked for organisms and there 
were no other organisms noted.  
Included in denominator only  
 
 
13.2 Sampling frequency 
Samples will be descriptively summarised (numbers and percentages) for samples 
taken 48 hours after insertion and within 48 hours after removal that are clinically 
indicated. Table columns will be:  Standard; impregnated (heparin or antibiotic); 
antibiotic; heparin; and total. These tables will be produced across all sites and by 
site.  
a) Type of sample – arterial, peripheral or CVC  
b) Number with multiple samples from same cvc and different lumens  
c) Site (femoral, other) 
d) CVC tip sampled and paired CVC tip and blood culture within 48 hours 
e) PCR sampled  
 
14 Analysis of secondary efficacy outcomes 
The null hypothesis for each secondary outcome (in which statistical tests are being 
performed) will be that there is no difference in outcome between the standard and 
impregnated (antibiotic and heparin) groups. The alternative hypothesis is that there 
is a difference between the two groups. The stratification variable 
elective/emergency participants will be included as a covariate.  The outcomes will 
also be analysed with the groups separately. (Appendix C, D, E, F) 
14.1 Rate of blood stream infection during CVC insertion per 1000 CVC 
days  
Data obtained as per the primary outcome although the CVC must be in situ.  For a 
second infection the isolate needs to be a different strain (review conducted blind to 
allocation by a team of clinical professionals) and not within 48 hours to that 
identified in the primary outcome otherwise considered same infection. 
The analysis will involve the number of infections and the number of days the CVC is 
in situ.  This will be standardised to 1000 CVC days and the rate ratio and 95% 
confidence intervals will be presented based on poisson regression. 
14.2 Time to CVC thrombosis 
Data will be obtained from form 1 or 3 (Section B question 2: date and time of 
randomisation), 11 (difficulty withdrawing blood, episodes of flushing, swollen limb, 
ultrasound done – positive results obtained from sites), form 9 (section A, question 2: 
date and time sample taken and question 3: difficulty withdrawing blood), form 6 
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(thrombosis indicated, not bleeding back as a reason for no sample taken – to 
confirm unclear text with clinical team), form 5 (Section B, question 1: date and time 
of CVC removal and question 3: reason for removal ‘CVC blocked’). 
This will also be checked against the related adverse events form (form 12) to 
ensure all thrombosis events have been recorded on the thrombosis form and 
reviewed by a team of clinical professionals. There was no time on the progress log 
(form 6) or thrombosis form (form 11) therefore the time was set at 23.59. Patients 
with no event were censored at 48 hours after removal. 
The survival analysis will use the method of the Log rank test and Cox proportional 
hazard regression models if appropriate.  Results will be presented using Hazard 
Ratios and 95% confidence intervals.  Kaplan-Meier curves stratified by CVC will be 
presented.  Survival times will be measured from the date and time of randomisation   
to the date and time of CVC thrombosis. 
14.3 Time to a composite measure of blood stream infection based on 
the primary outcome or high bacterial DNA load or culture negative 
bloodstream infection based on clinical criteria 
Data used will include forms 1, 3 (date and time of randomisation), 5 (removal due to 
CVC infection), 6 (as per primary outcome), 7 (change in antibiotics), 9 (clinical signs 
of infection),10 and downloads (microbiology – culture negative and high DNA load, 
Appendix D).  A blood culture must have been taken. 
The date/ time of randomisation (form 1 and 3) and the date/time of first indication of 
a composite measure of clinically indicated blood stream infection will be used to 
calculate the time to a composite measure of clinically indicated blood stream 
infection. 
Antibiotics will be grouped by a clinical professional (Appendix F). Data will be 
reviewed by a team of clinical professionals (Appendix G). 
The survival analysis will use the method of the Log rank test and Cox proportional 
hazard regression models if appropriate.  Results will be presented using Hazard 
Ratios and 95% confidence intervals.  Kaplan-Meier curves stratified by CVC will be 
presented. Survival times will be measured from the date and time of randomisation 
to the date and time of the blood stream infection.  
14.4 A CVC related blood stream infection  
Data will be obtained as per the primary outcome although CVC tip is included and 
exit site infection (forms 5 and 12).  Differential positivity will be reviewed by a team 
of clinical professionals (Appendix G). 
 
The analysis will use the method of Fishers exact test to compare proportions in the 
standard group compared to the impregnated groups and relative risks will be 
presented with 95% confidence intervals.   
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14.5 Mortality by 30 days 
At the time of clinical analysis death will be taken as that recorded prior to discharge 
(form 16). ONS data will be obtained and reconciled with that held on form 16 and 
final analysis completed upon the reconciled data set.  
 
The analysis will use the method of Fishers exact test to compare proportions in the 
standard group compared to the impregnated groups and relative risks will be 
presented with 95% confidence intervals.   
14.6 Type of bacteria and fungi isolated from positive blood cultures 
The data will be taken from the microbiology form (form 10) and also obtained from a 
microbiology download from each site.  Line listings will be given to the 
microbiologist to specify the groupings (Appendix D and F).  
14.7 Resistance to minocycline or rifampicin of blood culture or CVC tip 
isolates 
The data will be obtained from a microbiology download from each site from positive 
blood cultures for the primary outcome and repeat bloodstream infections identified 
in Outcome 14.1 and CVC tipError! Reference source not found. and provided to 
the microbiologist to determine resistance (Appendix G). 
The analysis will use the method of Fishers exact test to compare proportions in the 
standard group compared to the impregnated groups and relative risks will be 
presented with 95% confidence intervals.   
14.8 Unexplained thrombocytopenia after insertion of CVC- detected by 
routine laboratory monitoring. 
The data will be obtained from the adverse event form (form 12 number 2 and 13).  
This will be measured from randomisation up to 48 hours after removal. 
The analysis will use the method of Fishers exact test to compare proportions in the 
standard group compared to the impregnated groups and relative risks will be 
presented with 95% confidence intervals.   
14.9 Time to randomised CVC removal 
The date and time of randomisation will be taken from form 1 and 3, section B, 
question 2.  The date and time of CVC removal will be taken from form 5, section B, 
question 1.  Note this does not have to be the randomised CVC, but rather the CVC 
inserted following randomisation. 
 
The survival analysis will use the method of the Log rank test and Cox proportional 
hazard regression models if appropriate. Survival times will be measured from the 
date and time of randomisation to the date and time of CVC removal. Results will be 
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presented using Hazard Ratios and 95% confidence intervals.  Kaplan-Meier curves 
stratified by CVC will be presented. 
14.10 Length of stay requiring PICU 
The length of stay will be measured from the date of randomisation to the date of 
transfer/discharge from PICU for the first stay in PICU (NICU and CICU will also be 
treated as PICU).  Date of randomisation (form 1 and 3 section B) or, date admitted 
to PICU (form 4) will be used as the start date and details of the ward will be used 
(form 1 and 3 section B question 7). Date and time of transfer/discharge from PICU 
is included on form 14 section A. A small number will need data from HES (those 
randomised at end of recruitment period) 
The analysis will use the method of the two sample t test or Mann Whitney U test 
depending on the distribution of the data.  Means will be presented with 95% 
confidence intervals or medians and interquartile range as appropriate. 
14.11 Total length of hospital stay for current episode (for up to 6 month 
post randomisation) 
The date/time of randomisation (form 1 and 3) and the date/time of transfer/ 
discharge (form 14) will be used.  A small number will need data from HES (those 
randomised at end of recruitment period). 
  
The analysis will use the method of the two sample t test or Mann Whitney U test 
depending on the distribution of the data.  Means will be presented with 95% 
confidence intervals or medians and interquartile range as appropriate. 
14.12 Cost effectiveness of heparin bonded vs. antibiotic-impregnated 
vs. standard CVCs 
The analysis will be undertaken by health economics using data downloaded from 
HES.  Please see health economics analysis plan. 
 
15 Setting results in context of previous research  
Once the trial has been completed the results of the trial will be set in context of the 
existing evidence base. This will compare the results of the trial with those reported 
within relevant systematic reviews. 
Generalisability of results  
Once the trial has been completed the results will be used in analyses that take into 
account trends in blood stream infection across all PICUs in the UK, in order to 
estimate the absolute risk difference associated with purchasing impregnated vs 
standard CVCs. The analysis will be undertaken by the team at UCL-ICH. Please 
see the generalizability study analysis plan.   
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Approval and agreement 
 
Two versions of the SAP should be approved. 
1. SAP version 1.0 should be created after it has been reviewed and signed-off to ensure all 
are in agreement with the planned analysis and no further changes are foreseen. 
 
2. The final SAP version should be converted to PDF and signed following the blinded 
review for protocol deviations and immediately prior to database lock as evidence of the 
analysis planned prior to unblinding of the study. 
 
SAP Version Number being approved:      
Trial Statistician 
 
Name            
Signed        Date     
 
Senior Statistician or Head of Statistics 
 
Name            
Signed        Date     
 
Chief Investigator 
 
Name            
Signed        Date     
OR Electronic approval attached    
 
Chair of Trial Steering Committee
 
Name            
Signed        Date     
OR Electronic approval attached    
OR TSC not reviewing SAP (ensure agreement is documented)    
 
Chair of Data Monitoring Committee 
Name            
Signed        Date     
OR Electronic approval attached    
OR IDSMC not reviewing SAP (ensure agreement is documented)    
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SAP APPENDIX A: CONSORT DIAGRAM 
CONSORT 2010 Flow Diagram  
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The A indicates that minocycline and rifampicin would be expected to be Active against the bug. The I 
indicates that the micocycline and rifampicin are less likely to be active.  NA indicates that this is not 
applicable. 
Neisseria meningitidis and Group B streptococci are very unlikely to be CVC associated infections.  
staphylococcus epidermis  Staphylocococcus capitis, Staphylococcus epidermidis  (skin) 
Staphylococcus spp. Gram +ve coccus  = Staphylococcus spp. (coagulase –ve)
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SAP APPENDIX E: STEPS TAKEN TO OBTAIN OUTCOME DATA 
 
Primary outcome: Time to first blood stream infection defined by a positive blood 
culture from a sample that was clinically indicated and taken more than 48 hours after 
CVC insertion and up to 48 hours after CVC removal. 
 
Step 1 
 
Identify those with microbiology blood sample taken (CVC tip is excluded) 
a. Results with no organisms cultured are classed as negative 
b. Those with organisms (bacteria or fungi) are categorised as either skin/non-
skin by microbiologist and a new variable created to indicate skin/non-skin 
classification. 
i. Non skin= positive blood culture 
ii. Skin 
1.  If a skin organism is identified, check whether any other skin 
organisms have been identified 
2. If so, check whether they are within 48 hours of each other. 
3. If so, check to see if this is the same organism based on 
clinician endpoint review 
4. If 1-3 = yes then this results in a positive blood culture all 
others are negative 
Note that this assumes those with missing microbiology are negative cultures.  However, the 
microbiology downloads will be checked if there is no microbiology CRF for a participant or if 
one skin organism within the time frame has been detected. 
Step 2 
 
Timepoints.  
For those with a positive blood culture identified from step 1 we check whether the 
sample was taken 48 hours after randomisation and within 48 hours after removal 
(This is done at this point as there are implications for skin organisms). For positive 
blood culture based on skin organisms at least one of the samples has to be within 
the above timeframe but not both. If timeframe is not that specified here then the 
result is coded as a negative blood culture.   
 
Positive blood cultures outside of the timeframe will be tabulated along with the time 
of occurrence. 
 
Step 3 
For each remaining positive blood culture need to determine whether this was clinically 
indicated based on one of the criteria a to c below:   
a. check whether the CVC was removed because a CVC associated infection 
was suspected (form 5 section B question 3, note that some participants have 
two reasons for removal) or whether there were signs of exit site infection 
(form 5, section A, question 1) 
b. check progress log (form 6) to see whether clinically indicated was marked as 
‘yes’ 
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c. check sampling form (form 9 section A question 4) to see whether one or 
more of the clinical indicators were present (WBC and/or CRP are not 
sufficient to clinically indicate infection) or whether there were signs of CVC 
infection prior to sampling (form 9 section B question 1) 
d. check that a clinical indicator (from step a-c) is present within 48 hours either 
side of the positive blood culture.  For positive cultures from a skin organism, 
the clinical indication has to be within 48 hours of the sample taken in the time 
window in step 2.   
e. If the positive blood culture is clinically indicated, this results in a positive 
blood stream infection.  
 
The time of randomisation and the time the sample of the positive blood culture was taken is 
used to calculate the time to first blood stream infection.  For positive blood cultures from two 
skin organisms, the first skin organism to occur in the specified time frame will be the 
organism used for first positive blood culture. 
 
Secondary outcomes: 
1. Rate of blood stream infection during CVC insertion per 1000 CVC days. 
Second episode of blood stream infection (defined as per primary outcome) will be defined 
by a positive blood culture of a different isolate (in terms of species) from a sample taken 
whilst the CVC is in situ. Any positive blood cultures of the same isolate will be regarded as 
the same episode regardless of time since the first sample.   
 Same as PO but not after removal 
 Data to be presented to the clinician endpoint review: first infection, second infection 
and the time between these who will decide how many separate blood stream 
infection each participant had.   
 
2. Time to CVC thrombosis - defined clinically by:  
a. 2 records of difficulty drawing back blood from one or more lumen (within 5 
days);  
b. 2 or more episodes of flushing to unblock (within 5 days);  
c.  an episode of swollen limb;  
d.  positive ultrasound;  
e.  removal of CVC because of clinical evidence of a blocked CVC. 
 
 To check thrombosis form (form 11) and AE form (form 12), sampling form (form 9) 
and progress log (form 6), follow up form (form 5) 
1. Create an indicator if there are 2 or more occasions of difficulty 
drawing back blood (form 9 and 11) 
2. Create an indicator if there are 2 or more occasions of an episode 
of flushing to unblock (form 11) 
3. Create an indicator if there was a swollen limb (form 11, form 12) 
4. Create an indicator if there was a positive ultrasound (form 11 and 
separate data received from sites) 
5. Note if removal of CVC was because of clinical evidence of a 
blocked CVC (form 5, note that there may be two reasons for 
removal)  
 If any of these (i to v) then a thrombosis has occurred.  
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 Check whether thrombosis was indicated on the progress log (form 6) 
 
The date/ time of randomisation (form 1 and 3) and the date/time of first indication of 
thrombosis will be used to calculate the time to CVC thrombosis. 
 
Extra information to check for thrombosis 
1) If indicated on the progress log that they have the corresponding entry on the 
thrombosis form (And vice versa); 
2) If indicated as text on the progress log i.e. not bleeding back , not sampling back – 
that there is a relevant entry on the progress log and thrombosis form (possibly form 
9  
depending on the interpretation); 
3)         On form 5 (not sampling back/ Not bleeding back) thrombosis event recorded on the  
progress log, thrombosis form and possibly form 9 depending on the interpretation;  
4)  CVC blocked/ not sampling back as reason for removal – corresponding thrombosis 
event on  progress log, Thrombosis form and Sampling Form (form 9 depending on 
the interpretation)  
5)  Any lumens on Form 9 not bleeding back – check entry on Thrombosis Form, 
Progress log and Sampling form ; 
6)  Thrombosis events are on the AE form and ensuring the corresponding events are 
on the thrombosis form – therefore the AE’s can be ignored; 
7) Progress log - the same event can continue during the trial however only one row of 
data would be indicated on the thrombosis form – check that each day with an event 
has a corresponding row of data. 
 
3. Time to a composite measure of clinically indicated blood stream infection based 
on the primary outcome or high bacterial DNA load or culture negative bloodstream 
infection based on clinical criteria defined as:  
a. Primary outcome as defined above 
b. Any of the clinical indicators of infection and (negative) blood culture taken and  
i. High bacterial DNA load from a PCR positive result or  
ii. change in antibiotic on same day or next day or 
iii. CVC removal for infection 
 As primary outcome 
 High bacterial DNA load from a PCR positive or negative result initially taken from 
microbiology downloads.  A positive will fulfil the high bacterial load criterion. 
 change in antibiotics (form 7 and Appendix F)  
 check form 5 as to whether removal of CVC was for infection (note that there may be 
two reasons for removal). 
 
The date/ time of randomisation (form 1 and 3) and the date/time of first indication of a 
composite measure of clinically indicated blood stream infection will be used to calculate the 
time to a composite measure of clinically indicated blood stream infection. 
4. A CVC related blood stream infection will be defined by: 
a. the same isolate (species) from the CVC tip and from a blood culture sample 
(one skin or one non skin) taken from any site more than 48 hours after CVC 
insertion and within 48 hours following CVC removal; 
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b. differential positivity of the same isolate in blood cultures taken from multiple 
CVC lumens (i.e. not all positive or negative at the same sampling or the 
same skin commensal isolated from the same lumen but not all lumens on 
multiple occasions). 
i. Non-skin and both negative =No 
ii. Non-skin and both positive =No 
iii. Non-skin and one negative and one positive =Yes 
iv. Skin and one negative and one positive on two occasions 
(otherwise, as primary outcome criteria) =Yes 
c. OR positive BSI AND CVC removed for infection (and two skin organisms) 
d. OR positive BSI AND CVC exit site infection (and two skin organisms) 
 Organisms cultured sent to clinical review team to decide if they are the same isolate. 
 Note positivity of isolates  
 Positive BSI as noted for primary outcome and reason for removal is infection (form 
5) 
 Positive BSI and reason for removal is exit site infection (form 5) 
 If a-d is yes then CVC related BSI 
 
5. Mortality by 30 days 
 Check death form (form 16) 
 Date/time of death (form 16) 
 Date/time of randomisation (form 1 and 3) 
 Data will also come from HES 
 
6. Type of bacteria and fungi isolated from positive blood cultures 
 Line listings will be given to the microbiologist to specify what the groupings for each 
are. (CRF 10 and downloads) 
 
7. Resistance to minocycline or rifampicin of blood culture or CVC tip isolates 
 Microbiologist to classify based on organisms listed (CRF 10) for positive blood 
cultures only (see primary outcome (main analysis) and secondary outcome 1) 
between 48 hours after insertion and within 48 hours after removal. 
8. Unexplained thrombocytopenia after insertion of CVC- detected by routine 
laboratory monitoring 
 AE form (12 number 2 and 13) 
 From randomisation up to 48 hours after removal. 
 
9. Time to randomised CVC removal 
 Date/ time of randomisation (form 1 and 3) 
 Date/ time of removal (form 5) 
 Note this does not have to be the randomised CVC, but rather the CVC inserted 
following randomisation. 
 
10. Length of stay requiring PICU (for first episode) 
 Date/time admitted to PICU (form 1, 3 and 4) 
 Date/ time discharged from PICU/ transferred (form 14) 
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 A small number will need data from HES (those randomised at end of recruitment 
period) 
 
11. Total length of hospital stay for current episode (for up to 6 month post 
randomisation) 
 Date/ time admitted (form 1 and 3)  
 Date/ time discharged (form 14) 
 Data will come from HES 
 
12. Cost effectiveness of heparin bonded vs. antibiotic-impregnated vs. standard 
CVC 
 see health economics plan 
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SAP APPENDIX F: ANTIBIOTIC 
GROUPING 
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SAP APPENDIX G: CLINICAL ENDPOINT REVIEW 
 
 
Randomisation 
number 
Date 
of 
birth 
Age 
(years) 
Initials Date/time of 
randomisation 
Date/time 
of 
removal 
Time from 
randomisation 
to removal 
(hours) 
       
Date/time 
of sample 
Time from 
randomisation 
(hours) 
Time 
from 
removal 
(hours) 
Blood/ 
CVC 
tip 
Isolate 
(skin) 
ICD-10 
code for 
primary 
reason for 
admission* 
Committee 
decision 
(same 
isolate/not 
the same 
isolate) 
       
       
       
*This has been inserted to determine the status of those with no microbiology for the sensitivity analyses 
Date/time of 
sample 
Time from 
randomisation 
(hours) 
Blood/ 
CVC tip 
Isolate  Skin/ non-
skin 
Committee 
decision: 
number of 
separate 
bloodstream 
infections 
      
      
      
Note microbiology profile comes from patient uploads: sensitive/ resistant/ intermediate 
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Appendix 2 Clinical effectiveness study
additional data
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TABLE 24 Recruitment by site
Centre
Date site
initiated
Date of first
randomisation
Target
recruitment
Number
randomised
and consented
Prospective
consent
Deferred
consent
Great Ormond Street
Hospital PICU/CICU
10/02/2011 15/04/2011 200 362 27 335
Evelina London
Children’s Hospital
(Guy’s and St Thomas’)
25/11/2010 06/01/2011 100 161 43 118
Royal Brompton
Hospital
17/06/2011 24/08/2011 100 49 29 20
St Mary’s Hospital,
London
01/02/2012 07/02/2012 100 26 0 26
Southampton
General Hospital
27/06/2011 11/07/2011 100 200 140 60
Bristol Royal Hospital
for Children
20/06/2011 24/06/2011 100 109 61 48
Alder Hey Children’s
Hospital
05/07/2011 11/07/2011 100 113 69 44
Birmingham Children’s
Hospital
22/08/2011 01/09/2011 100 150 34 116
Glenfield Hospital 13/10/2011 22/10/2012 100 65 48 17
Leicester Royal Infirmary 13/10/2011 11/01/2012 15 3 12
Royal Victoria Infirmary 25/01/2012 03/02/2012 50 41 0 41
Freeman Hospital 26/01/2012 10/02/2012 18 13 5
Leeds General Infirmary 14/12/2010 22/12/2010 100 149 32 117
Queen’s Medical Centre 11/05/2012 16/05/2012 50 27 2 25
Total 1200 1485 501 984
CICU, cardiac intensive care unit.
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TABLE 26 Threats to validity
Threats to validity
Standard
(n= 502)
Antibiotic
(n= 486)
Heparin
(n= 497)
Total
(n= 1485)
n % n % n % n %
CVC inserted 481 95.8 465 95.7 464 93.4 1410 94.9
Internal validity
Randomised multiple times 15 3.0 12 2.5 11 2.2 38 2.6
Clinical indication 48 hours after randomisation, no sample
taken in primary outcome time windowa
183 38.0 196 42.2 196 42.2 575 40.8
External validity
Child aged > 16 years 2 0.4 4 0.8 0 0.0 6 0.4
CVC inserted but removed before 48 hoursa,b 94 19.5 96 20.6 96 20.7 286 20.3
CVC inserted > 12 hours after randomisationa 1 0.2 1 0.2 4 0.9 6 0.4
Line not required following randomisation (post 12 hours); randomisation pack returned to the CTU
CVC attempted but not inserted 15 3.0 14 2.9 24 4.8 53 3.6
CVC insertion not attempted 6 1.2 7 1.4 9 1.8 22 1.5
Incorrect randomisation envelope used 4 0.8 8 1.6 9 1.8 21 1.4
CTU, Medicines for Children Clinical Trials Unit.
a Based on any clinical indicator, including abnormal C-reactive protein or white cell count, which were not considered
sufficient clinical indication on their own.
b Of whom five were transferred before the CVC had been inserted (n= 2 standard, n= 2 heparin and n= 1 antibiotic);
follow-up data were missing for one participant.
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TABLE 27 Primary outcome: sensitivity analysis assuming the presence of a BSI in patients with clinical indicators
for infection who had no blood culture sample taken in the primary outcome time window
Group Total randomised
Primary
outcome
Clinical
indication but
no sample
taken in time
window
Total
included in
sensitivity
analysis
HR vs. standarda
(95% CI) p-valuen % n % n %
Standard 502 18 3.6 8 1.6 26 5.2
Any impregnated 983 24 2.4 9 0.9 33 3.4 0.67 (0.39 to 1.15) 0.15
Antibiotic 486 7 1.4 6 1.2 13 2.6 0.54 (0.29 to 1.02) 0.06
Heparin 497 17 3.4 3 0.6 20 4.1 0.83 (0.47 to 1.49) 0.54
Total 1485 42 2.8 17 1.1 59 4.0
a HR for antibiotic vs. heparin= 0.64 (95% CI 0.32 to 1.27; p= 0.20).
TABLE 28 Indicators of the composite outcome of BSI
Indicator
Standard
(n= 502)
Antibiotic
(n= 486)
Heparin
(n= 497)
Total
(n= 1485)
n % n % n % n %
Primary outcome only 2 0.4 0 0.0 4 0.8 6 0.4
Clinical indication, blood culture, plus
Bacterial DNA detected by PCR only 2 0.4 1 0.2 1 0.2 4 0.3
Change in antibiotic on the same day or next day only 79 15.7 71 14.6 64 12.9 214 14.4
CVC removal for infection only 6 1.2 12 2.5 7 1.4 25 1.7
Primary outcome and CVC removal for infection 1 0.2 0 0.0 0 0.0 1 0.1
Primary outcome and antibiotic change 8 1.6 6 1.2 6 1.2 20 1.3
CVC removal for infection and antibiotic change 7 1.4 11 2.3 13 2.6 31 2.1
PCR positive and antibiotic change 1 0.2 1 0.2 0 0.0 2 0.1
Primary outcome, CVC removal for infection and
antibiotic change
6 1.2 1 0.2 6 1.2 13 0.9
CVC removal for infection, PCR positive and
antibiotic change
0 0.0 0 0.0 0 0.0 0 0.0
Primary outcome, bacterial DNA detected by PCR,
CVC removal for infection and antibiotic change
1 0.2 0 0.0 1 0.2 2 0.1
Totala 113 22.5 103 21.2 102 20.5 318 21.4
a Overall number of indicators in an exclusive descending hierarchy: BSI= 42; PCR positive= 5; CVC removed for
infection= 56; change or start of antibiotics same or next day= 214.
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TABLE 29 Type of bacteria and fungi isolated from positive blood cultures
Organism group Organism Standard Antibiotic Heparin Total
Gram positive Staphylococcus aureus 1 1 3 5
Streptococcus spp. 1 0 0 1
Methicillin-resistant S. aureus 1 0 0 1
Enterococcus spp. 2 0 4 6
Streptococcus mitis 1 0 1 2
Streptococcus parasanguis and
Streptococcus salivarius
0 1 0 1
Gram negative Serratia marcescens 1 1 0 2
Pseudomonas aeruginosa 2 1 1 4
Gram-negative bacillus 1 0 1 2
Escherichia coli 0 1 0 1
E. coli and coliform 0 1 0 1
Coliform 1 0 0 1
Klebsiella spp. 0 0 1 1
Cellulomas spp. 0 0 1 1
Raoultella panticola and Enterobacter spp. 1 0 0 1
Gram positive and
Gram negative
Enterococcus spp. and Klebsiella pneumoniae 0 0 1 1
Fungi Candida spp. 2 0 2 4
Candida albicans 0 0 1 1
Skin bacteria and
Gram positive
Coagulase-negative staphylococcus and
enterococcus spp.
1 0 0 1
Skin bacteria Coagulase-negative staphylococcus spp. 3 1 1 5
Total 18 7 17 42
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TABLE 30 Causes of death recorded on CRFs as adverse eventsa
Related/unrelated Cause of death
Standard
(n= 533)
Antibiotic
(n= 451)
Heparin
(n= 479)
Total
(n= 1463)
n % n % n % n %
Unrelated Related to comorbidities at admission 58 10.9 37 8.2 35 7.3 130 8.9
Cerebral haemorrhage 0 0.0 0 0.0 1 0.2 1 0.1
Multiorgan failure as a result of
calcification of the arteries
1 0.2 0 0.0 0 0.0 1 0.1
Pneumonitis and multiorgan failure 1 0.2 0 0.0 1 0.2 2 0.1
Pseudomonas septicaemia second
to peritonitis
0 0.0 1 0.2 0 0.0 1 0.1
Severe birth asphyxia 1 0.2 0 0.0 0 0.0 1 0.1
Complication of treatment 1 0.2 0 0.0 0 0.0 1 0.1
Cerebral bleeding by ventricular
assist device
1 0.2 0 0.0 0 0.0 1 0.1
Group B streptococcus infection/sepsis 1 0.2 0 0.0 0 0.0 1 0.1
Multiorgan failure and systemic
inflammatory response syndrome
0 0.0 0 0.0 1 0.2 1 0.1
Multiorgan failure 0 0.0 1 0.2 0 0.0 1 0.1
Exact cause not known 0 0.0 1 0.2 0 0.0 1 0.1
Pulmonary haemorrhage 1 0.2 0 0.0 0 0.0 1 0.1
Unlikely to be related Related to comorbidities at admission 0 0.0 2 0.4 0 0.0 2 0.1
Missing 1 0.2 2 0.4 0 0.0 3 0.2
Total 66 12.4 44 9.8 38 7.9 148 10.1
a n= participants by CVC received or attempted to be inserted, i.e. safety analysis.
TABLE 31 Antibiotic resistance to minocycline or rifampicin by CVC allocation
CVC allocation Organism
Etest result
Minocycline Rifampicin
Standard Coliform bacilli Resistant Resistant
Enterococcus faecalis Resistant Resistant
Serratia marcescens Resistant Resistant
Staphylococcus aureus Sensitive Sensitive
Methicillin-resistant S. aureus Sensitive Sensitive
Antibiotic Escherichia coli Resistant Resistant
Staphylococcus spp. Resistant Resistant
Heparin Klebsiella pneumoniae Resistant Resistant
K. pneumoniae Resistant Resistant
S. aureus Sensitive Sensitive
Coagulase-negative staphylococcus spp. Sensitive Sensitive
Enterococcus hirae and coagulase-negative
staphylococcus spp.
Resistant,
sensitive
Sensitive,
resistant
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TABLE 32 Positive PCR detection of bacterial DNA
CVC allocation Primary outcome PCR value (pg of DNA/µl)
Antibiotic No 0.011
No 0.023
No 0.05
Heparin No 0.006a
No 0.008a
No 0.05
Yes 0.16375
Standard No 0.013
No 0.02
No 0.02
No 0.024
Yes 0.36
a Samples from the same child.
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Appendix 3 Cost-effectiveness study
additional data
TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
LB08Zb Ureter Major Endoscopic
Procedure
1379.00 5 2468.00 12 301.00
PA03Zb Febrile Convulsions 928.00 1 661.00 3 304.00
PA14Ab Lower Respiratory Tract
Disorders without Acute
Bronchiolitis with CC
3215.00 13 2473.00 14 222.00
CZ06Nb Minor Throat Procedures
with CC
1431.00 3 3222.00 24 281.00
FZ03Bc Diagnostic and
Intermediate Procedures
on the Upper GI Tract
≤ 18 Years
852.00 5 1267.00 5 223.00
GB04Ac Endoscopic/Radiology
Category 1 with
Major CC
1879.00 8 6347.00 54 228.00
AA16Z Intracranial Procedures
except Trauma with
Non-Transient Stroke
or Cerebrovascular
Accident, Nervous
System Infections or
Encephalopathy –
Category 1 or 2
4255.00 24 7371.00 66 210.00
EA24Z Complex Congenital
Surgery
9631.00 21 14,934.00 46 205.00
EA25Z Intermediate Congenital
Surgery
9571.00 19 13,009.00 58 205.00
PA14C Lower Respiratory Tract
Disorders without Acute
Bronchiolitis with Length
of Stay ≥ 1 Day with CC
3602.00 22 2301.00 15 291.00
DZ07B Fibreoptic Bronchoscopy
≤ 18 Years
1146.00 5 1394.00 5 190.00
VA11D Multiple Trauma
Diagnoses Score ≥ 51
with Interventions
Score 1–8
5246.00 94 5246.00 94 232.00
PA16A Major Infections with CC 1719.00 8 2856.00 22 291.00
QZ15B Therapeutic Endovascular
Procedures with
Intermediate CC
1523.00 5 5389.00 49 227.00
continued
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TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea (continued )
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
DZ37B Non-Invasive Ventilation
Support Assessment
≤ 18 Years
927.00 5 927.00 5 190.00
PA23B Cardiac Conditions
without CC
1420.00 5 1427.00 5 291.00
PA15B Acute Bronchiolitis
without CC
1066.00 8 910.00 8 291.00
PA23A Cardiac Conditions
with CC
1956.00 5 3638.00 16 291.00
EA23Z Major Complex
Congenital Surgery
12,638.00 36 19,436.00 66 205.00
PA14E Lower Respiratory Tract
Disorders without Acute
Bronchiolitis with Length
of Stay 0 Days
561.00 5 434.00 5 291.00
FZ11A Large Intestine – Major
Procedures with
Major CC
5441.00 33 8053.00 68 228.00
PA63B Head, Neck and Ear
Disorders with Length of
Stay ≥ 1 Day with CC
2514.00 9 972.00 6 291.00
PA48A Blood Cell Disorders
with CC
1474.00 8 2335.00 10 291.00
PB02Z Minor Neonatal
Diagnoses
1041.00 14 1041.00 14 291.00
FZ07A Major Small Intestine
Procedures with CC
4569.00 19 8028.00 62 228.00
VA15D Multiple Trauma
Diagnoses Score ≥ 51
with Interventions
Score ≥ 45
20,844.00 143 20,844.00 143 232.00
HC12Z Intradural Spine Minor 1 571.00 5 739.00 5 231.00
PA12Z Asthma or Wheezing 563.00 5 622.00 5 291.00
FZ06A Very Major Small
Intestine Procedures
with CC
7781.00 40 8308.00 63 228.00
PA25B Major Gastrointestinal or
Metabolic Disorders
without CC
949.00 5 1177.00 8 291.00
AA21Z Intracranial Procedures
except Trauma with
Other Diagnoses –
Category 1 or 2
1096.00 5 5346.00 42 210.00
HB99Z Other Procedures for
Non Trauma
331.00 5 331.00 5 231.00
GA05B Hepatobiliary Procedures
Category 5 without CC
5598.00 17 5980.00 35 221.00
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TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea (continued )
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
PA47Z Sickle-Cell Anaemia
with Crisis
494.00 8 1587.00 9 291.00
QZ15A Therapeutic Endovascular
Procedures with
Major CC
9835.00 86 10,258.00 107 227.00
AA02Z Intracranial Procedures
for Trauma with
Intermediate Diagnosis
6738.00 40 6738.00 40 210.00
EA26Z Standard Congenital
Surgery
5615.00 15 5615.00 15 205.00
QZ14A Vascular Access except
for Renal Replacement
Therapy with CC
548.00 5 1353.00 8 227.00
PA02A Epilepsy Syndrome
with CC
1043.00 5 942.00 5 291.00
PA15A Acute Bronchiolitis
with CC
2254.00 15 1962.00 14 291.00
PA25A Major Gastrointestinal or
Metabolic Disorders
with CC
1715.00 5 2583.00 14 291.00
QZ13A Vascular Access for Renal
Replacement Therapy
with CC
1287.00 5 1571.00 8 227.00
VA14D Multiple Trauma
Diagnoses Score ≥ 51
with Interventions
Score 30–44
11,259.00 129 11,259.00 129 232.00
DZ06Z Minor Thoracic
Procedures
729.00 5 1063.00 5 190.00
DZ03A Major Thoracic
Procedures with CC
3371.00 14 6985.00 39 190.00
AA20Z Intracranial Procedures
except Trauma with
Muscular, Balance,
Cranial or Peripheral
Nerve Disorders or
Epilepsy – Category 1
or 2
1957.00 10 3883.00 32 210.00
CZ07O Exteriorisation of Trachea
with Major CC
8640.00 98 7363.00 95 250.00
PB01Z Major Neonatal
Diagnoses
1511.00 16 1511.00 16 291.00
HB16B Minor Hip Procedures for
Non Trauma Category 1
with CC
1267.00 33 1267.00 33 231.00
FZ05A Major Stomach or
Duodenum Procedures
≥ 2 Years with CC
3591.00 16 6539.00 57 228.00
continued
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TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea (continued )
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
FZ05C Major Stomach or
Duodenum Procedures
≤ 1 Year
5402.00 16 4582.00 11 228.00
PA44Z Neoplasm Diagnoses with
Length of Stay 0 Days
541.00 5 527.00 5 291.00
FZ12A General Abdominal –
Very Major or Major
Procedures with
Major CC
5070.00 29 6963.00 54 228.00
PA18A Minor Infections with CC 843.00 5 1204.00 8 291.00
AA09Z Intracranial Procedures
except Trauma with
Other Diagnoses –
Category 4
2396.00 5 8293.00 49 210.00
HB63Z Minor Shoulder and
Upper Arm Procedures
for Non Trauma
1401.00 5 1401.00 5 231.00
EA20Z Other Complex Cardiac
Surgery and Re-do’s
10,511.00 26 12,806.00 57 205.00
EA14Z Coronary Artery Bypass
Graft (First Time)
7358.00 16 9055.00 39 205.00
EA12Z Implantation of
Cardioverter –
Defibrillator Only
5556.00 5 7248.00 34 205.00
DZ02A Complex Thoracic
Procedures with
Major CC
8271.00 31 9426.00 54 190.00
VA11B Multiple Trauma
Diagnoses Score 24–32
with Interventions
Score 1–8
3864.00 24 3864.00 24 232.00
PA26A Other Gastrointestinal or
Metabolic Disorders
with CC
1603.00 5 1076.00 5 291.00
PA59C Major Congenital
Conditions under 1 Year
with CC
2444.00 8 3609.00 31 291.00
PA59E Major Congenital
Conditions ≥ 1 Year
with CC
1148.00 5 3142.00 13 291.00
PA08B Intermediate Injury
without Intracranial Injury
without CC
790.00 5 757.00 5 291.00
PA28A Feeding Difficulties and
Vomiting with CC
2136.00 10 1012.00 5 291.00
HB23B Intermediate Knee
Procedures for Non
Trauma with CC
2342.00 29 2342.00 29 231.00
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TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea (continued )
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
PA19B Viral Infections with
Length of Stay ≥ 2 Days
1255.00 5 1255.00 5 291.00
PA06Z Head Injury with
Intracranial Injury
1689.00 9 1689.00 9 291.00
PA67Z Diabetes Mellitus with
Ketoacidosis or Coma
954.00 6 954.00 6 291.00
PA45Z Febrile Neutropenia
with Malignancy
8858.00 51 3894.00 13 291.00
LB10Z Bladder Major Open
Procedures/
Reconstruction
5348.00 24 7019.00 52 215.00
PA17A Intermediate Infections
with CC
1067.00 5 1274.00 9 291.00
PA03B Febrile Convulsions
≥ 1 Year
705.00 5 595.00 5 291.00
QZ05A Miscellaneous Vascular
Procedures with CC
1687.00 5 3733.00 30 227.00
VA13D Multiple Trauma
Diagnoses Score ≥ 51
with Interventions
Score 19–29
8858.00 117 8858.00 117 232.00
AA10Z Intracranial Procedures
except Trauma with
Non-Transient Stroke or
Cerebrovascular Accident,
Nervous System Infections
or Encephalopathy –
Category 3
7598.00 74 11,733.00 74 210.00
JC01A Major Multiple Skin
Procedures with
Major CC
9610.00 62 9608.00 79 223.00
GA05A Hepatobiliary Procedures
Category 5 with CC
6767.00 26 7488.00 57 221.00
EA52Z Repair or Replacement of
More Than One Heart
Valve
12,196.00 31 15,633.00 84 205.00
DZ03B Major Thoracic
Procedures without CC
2429.00 9 3884.00 20 190.00
QZ04Z Extracranial or Upper
Limb Arterial Surgery
3567.00 7 5606.00 34 227.00
EA39Z Pacemaker Procedure
without Generator
Implant (Includes Resiting
and Removal of Cardiac
Pacemaker System)
2748.00 5 5302.00 33 205.00
PA38D Renal Disease with Renal
Failure with Length of
Stay ≥ 1 Day
3800.00 9 3184.00 15 291.00
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TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea (continued )
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
PA07B Head Injury without
Intracranial Injury
without CC
539.00 5 506.00 5 291.00
VA10D Multiple Trauma
Diagnoses Score ≥ 51
with No Interventions
3712.00 93 3712.00 93 232.00
PA21A Infectious and
Non-Infectious
Gastroenteritis with CC
1855.00 8 810.00 5 291.00
PA16B Major Infections
without CC
696.00 5 1659.00 11 291.00
FZ01C Complex Oesophageal
Procedures ≤ 18 Years
14,175.00 63 14,175.00 63 228.00
QZ01A Aortic or Abdominal
Surgery with CC
6487.00 27 7307.00 53 227.00
HB13Z Intermediate Hip
Procedures for Non
Trauma Category 2
5194.00 26 5194.00 26 231.00
HC08Z Intradural Spine Major 1 4992.00 31 4992.00 31 231.00
AA11Z Intracranial Procedures
except Trauma with
Haemorrhagic
Cerebrovascular Disorders –
Category 3
6166.00 50 8917.00 50 210.00
PA01A Nervous System Disorders
with CC
1146.00 5 2368.00 15 291.00
PA34A Musculoskeletal or
Connective Tissue
Disorders with CC
1112.00 5 1246.00 8 291.00
LB02D Kidney Major Open
Procedure ≤ 18 Years
4289.00 7 8972.00 36 215.00
HB16C Minor Hip Procedures for
Non Trauma Category 1
without CC
969.00 5 969.00 5 231.00
VA12D Multiple Trauma
Diagnoses Score ≥ 51
with Interventions
Score 9–18
7012.00 102 7012.00 102 232.00
CZ01S Minor Mouth or Throat
Procedures ≤ 18 Years
with CC
1551.00 5 3137.00 8 250.00
HB14B Intermediate Hip
Procedures for Non
Trauma Category 1
with CC
3509.00 61 3509.00 61 231.00
PA63A Head, Neck and Ear
Disorders with Length of
Stay 0 Days
540.00 5 383.00 5 291.00
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TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea (continued )
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
PA60C Other Congenital
Conditions under 1 Year
with CC
945.00 5 1336.00 9 291.00
VA10C Multiple Trauma
Diagnoses Score 33–50
with No Interventions
3453.00 47 3453.00 47 232.00
HB15F Minor Hip Procedures for
Non Trauma Category 2
≤ 18 Years with CC
1725.00 23 1725.00 23 231.00
FZ20C Appendicectomy
Procedures ≤ 18 Years
2367.00 5 2292.00 7 228.00
FZ27D Endoscopic or
Intermediate General
Abdominal Procedures
≤ 18 Years
1216.00 5 1729.00 8 228.00
LA05Z Renal Replacement
Peritoneal Dialysis
Associated Procedures
1138.00 5 1195.00 5 215.00
LB05D Kidney Intermediate,
Endoscopic and
Percutaneous
Interventions ≤ 18 Years
2372.00 5 4973.00 25 215.00
AA04Z Intracranial Procedures
except Trauma with
Non-Transient Stroke or
Cerebrovascular Accident,
Nervous System Infections
or Encephalopathy –
Category 4
7936.00 74 11,733.00 74 210.00
PA19A Viral Infections with
Length of Stay ≤ 1 Day
446.00 5 444.00 5 291.00
PA21B Infectious and
Non-Infectious
Gastroenteritis
without CC
705.00 5 520.00 5 291.00
EA11Z Percutaneous Congenital
Interventions: Other
Including Septostomy,
Embolisations,
Non-Coronary Stents
and Energy Moderated
Perforation
1934.00 5 4417.00 33 205.00
FZ25B Therapeutic Endoscopic
or Intermediate Stomach
or Duodenum Procedures
≤ 18 Years
996.00 5 996.00 5 228.00
FZ04A Very Major Stomach or
Duodenum Procedures
with Major CC
8135.00 44 11,299.00 84 228.00
AB04Z Major Pain Procedures 570.00 5 2624.00 24 210.00
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TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea (continued )
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
LB11B Urinary Diversion without
Cystectomy without
Malignancy
5913.00 30 9562.00 71 215.00
VA12C Multiple Trauma
Diagnoses Score 33–50
with Interventions,
Score 9–18
6487.00 61 6487.00 61 232.00
VA11A Multiple Trauma
Diagnoses Score ≤ 23
with Interventions,
Score 1–8
1965.00 10 1965.00 10 232.00
SA14Z Plasma Exchanges 2–9 2385.00 13 7293.00 55 237.00
AA19Z Intracranial Procedures
except Trauma with
Cerebral Degenerations
or Miscellaneous
Disorders of Nervous
System – Category 1 or 2
1843.00 8 5014.00 25 210.00
VA11C Multiple Trauma
Diagnoses Score 33–50
with Interventions
Score 1–8
4513.00 45 4513.00 45 232.00
PB03Z Healthy Baby 0.00 5 0.00 5 0.00
PA49Z Coagulation Disorders 666.00 5 691.00 5 291.00
PA35A Skin Disorders with CC 1103.00 5 1187.00 8 291.00
PA42Z Brain Tumours with
Length of Stay ≥ 1 Day
2660.00 9 2830.00 9 291.00
GB03A Endoscopic/Radiology
Category 2 with CC
1020.00 5 6235.00 53 221.00
GB01Z Endoscopic/Radiology
Category 4
2366.00 9 4813.00 58 221.00
PA68Z Diabetes Mellitus without
Ketoacidosis or Coma
941.00 5 941.00 5 291.00
QZ15C Therapeutic Endovascular
Procedures without CC
1178.00 5 3091.00 26 227.00
SA15Z Plasma Exchanges 10–19 4892.00 13 7293.00 55 237.00
PA51Z Child Safeguarding
(Welfare and Protection)
854.00 5 854.00 5 291.00
GA03A Hepatobiliary Procedures
Category 7 with CC
10,784.00 49 14,235.00 71 221.00
DZ02B Complex Thoracic
Procedures with CC
6356.00 18 6729.00 26 190.00
PA14D Lower Respiratory Tract
Disorders without Acute
Bronchiolitis with
Length of Stay ≥ 1 Day
without CC
2286.00 16 1035.00 6 291.00
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TABLE 33 A list of all bundled HRGs, costed for inpatient stays using the national tariff guidancea (continued )
HRG HRG name (inpatient)
Elective spell
tariff (£)
Elective
long-stay
trim point
(days)
Non-elective
spell tariff (£)
Non-elective
long-stay trim
point (days)
Per-day long-stay
payment (for
days exceeding
trim point) (£)
CZ04Q Complex Major Mouth or
Throat Procedures
without CC
7565.00 39 7565.00 39 250.00
AA17Z Intracranial Procedures
except Trauma with
Haemorrhagic
Cerebrovascular Disorders –
Category 1 or 2
2794.00 12 6852.00 64 210.00
QZ11B Amputations without
Major CC
8011.00 53 10,771.00 95 227.00
HC11Z Intradural Spine Minor 2 3138.00 18 3138.00 18 231.00
EA10Z Percutaneous Congenital
Interventions: Balloon
Valve Intermediate
Interventions and Arterial
Duct Closure
4111.00 6 8275.00 48 205.00
FZ02Z Very Major Oesophageal
Procedures
3802.00 11 6158.00 39 228.00
FZ11B Large Intestine – Major
Procedures without
Major CC
2643.00 14 4640.00 32 228.00
AA15Z Intracranial Procedures
except Trauma with
Other Diagnoses –
Category 3
2396.00 5 8293.00 49 210.00
QZ05B Miscellaneous Vascular
Procedures without CC
1035.00 5 2402.00 14 227.00
EA43Z Implantation of Prosthetic
Heart or Ventricular
Assist Device
42,583.00 90 42,583.00 90 205.00
FZ07B Major Small Intestine
Procedures without CC
3134.00 15 4551.00 28 228.00
CC, comorbidity; GI, gastrointestinal.
a 2012–13 tariff unless stated otherwise.
b 2010–11 tariff.
c 2011–12 tariff.
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TABLE 34 A list of all bundled HRGs, costed for outpatient attendances using the national tariff guidance
Treatment
function
Treatment
function name
(outpatient)
WF01B First
Attendance –
Single Professional
(£)
WF02B First
Attendance – Multi
Professional (£)
WF01A Follow Up
Attendance – Single
Professional (£)
WF02A Follow Up
Attendance – Multi
Professional (£)
100 General Surgery 191.00 207.00 101.00 101.00
101 Urology 177.00 196.00 96.00 99.00
103 Breast Surgery 154.00 154.00 84.00 85.00
104 Colorectal Surgery 131.00 157.00 72.00 105.00
105 Hepatobiliary and
Pancreatic Surgery
166.00 166.00 102.00 102.00
106 Upper
Gastrointestinal
Surgery
140.00 140.00 82.00 82.00
107 Vascular Surgery 234.00 234.00 116.00 116.00
110 Trauma and
Orthopaedics
137.00 137.00 83.00 83.00
120 Ear, Nose and
Throat
114.00 141.00 63.00 73.00
130 Ophthalmology 115.00 138.00 67.00 75.00
140 Oral Surgery 130.00 185.00 80.00 126.00
143 Orthodontics 186.00 285.00 83.00 129.00
144 Maxillo-Facial
Surgery
115.00 190.00 70.00 99.00
160 Plastic Surgery 117.00 131.00 67.00 85.00
170 Cardiothoracic
Surgery
227.00 227.00 142.00 162.00
171 Paediatric Surgery 191.00 241.00 109.00 163.00
172 Cardiac Surgery 293.00 293.00 171.00 171.00
173 Thoracic Surgery 260.00 260.00 159.00 159.00
190 Anaesthetics 98.00 98.00 95.00 95.00
191 Pain Management 181.00 195.00 91.00 119.00
211 Paediatric Urology 182.00 196.00 111.00 111.00
214 Paediatric Trauma
and Orthopaedics
154.00 163.00 100.00 113.00
215 Paediatric Ear Nose
and Throat
116.00 141.00 74.00 74.00
216 Paediatric
Ophthalmology
156.00 172.00 89.00 125.00
217 Paediatric
Maxillo-Facial
Surgery
154.00 190.00 116.00 116.00
219 Paediatric Plastic
Surgery
182.00 182.00 98.00 98.00
251 Paediatric
Gastroenterology
279.00 279.00 158.00 158.00
252 Paediatric
Endocrinology
305.00 352.00 172.00 185.00
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TABLE 34 A list of all bundled HRGs, costed for outpatient attendances using the national
tariff guidance (continued )
Treatment
function
Treatment
function name
(outpatient)
WF01B First
Attendance –
Single Professional
(£)
WF02B First
Attendance – Multi
Professional (£)
WF01A Follow Up
Attendance – Single
Professional (£)
WF02A Follow Up
Attendance – Multi
Professional (£)
253 Paediatric Clinical
Haematology
414.00 464.00 218.00 247.00
257 Paediatric
Dermatology
49.00 168.00 107.00 108.00
258 Paediatric
Respiratory
Medicine
315.00 315.00 172.00 172.00
263 Paediatric Diabetic
Medicine
353.00 353.00 119.00 119.00
300 General Medicine 210.00 251.00 105.00 121.00
301 Gastroenterology 265.00 265.00 83.00 116.00
302 Endocrinology 230.00 230.00 106.00 116.00
303 Clinical
Haematology
268.00 288.00 106.00 106.00
306 Hepatology 224.00 290.00 139.00 151.00
307 Diabetic Medicine 242.00 321.00 99.00 147.00
320 Cardiology 210.00 251.00 105.00 121.00
321 Paediatric
Cardiology
289.00 289.00 170.00 170.00
329 Transient
Ischaemic Attack
477.00 477.00 – –
330 Dermatology 112.00 168.00 69.00 108.00
340 Respiratory
Medicine
223.00 244.00 105.00 128.00
341 Respiratory
Physiology
189.00 189.00 122.00 122.00
350 Infectious Diseases 255.00 255.00 195.00 195.00
360 Genitourinary
Medicine
133.00 148.00 82.00 82.00
361 Nephrology 299.00 454.00 124.00 219.00
370 Medical Oncology 228.00 290.00 98.00 115.00
410 Rheumatology 246.00 246.00 102.00 102.00
420 Paediatrics 231.00 288.00 129.00 159.00
430 Geriatric Medicine 303.00 303.00 139.00 139.00
501 Obstetrics 119.00 154.00 60.00 60.00
502 Gynaecology 138.00 142.00 81.00 99.00
503 Gynaecological
Oncology
154.00 271.00 90.00 132.00
560 Midwife Episode 119.00 154.00 60.00 60.00
800 Clinical Oncology 228.00 290.00 98.00 115.00
812 Diagnostic Imaging 0.00 0.00 0.00 0.00
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TABLE 35 A list of all bundled HRGs, costed for A&E attendances using the national tariff guidance
HRG code HRG name (A&E) Band
24-hour A&E
units tariff (£)
Non-24-hour A&E
units and minor
injury units tariff (£)
VB01Z Any Investigation with Category 5 Treatment 1 235.00 54.00
VB02Z Category 3 Investigation with Category 4 Treatment 1 235.00 54.00
VB03Z Category 3 Investigation with Category 1–3 Treatment 2 151.00 54.00
VB04Z Category 2 Investigation with Category 4 Treatment 2 151.00 54.00
VB05Z Category 2 Investigation with Category 3 Treatment 2 151.00 54.00
VB06Z Category 1 Investigation with Category 3–4 Treatment 3 81.00 54.00
VB07Z Category 2 Investigation with Category 2 Treatment 4 112.00 54.00
VB08Z Category 2 Investigation with Category 1 Treatment 4 112.00 54.00
VB09Z Category 1 Investigation with Category 1–2 Treatment 3 81.00 54.00
VB10Z Dental Care 5 54.00 54.00
VB11Z No Investigation with No Significant Treatment 5 54.00 54.00
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Appendix 4 Generalisability study additional data
Predictive model identifying children most likely to require a
central venous catheter in the paediatric intensive care unit
The PICANet database does not record insertion or removal of CVCs. However, through the use of CVC
audit data from two PICUs, it was possible to create a predictive model to identify admissions in the
PICANet data set most likely to have required a CVC.
Methods
Central venous catheter audit data
Central venous catheter audit data were obtained from four PICUs. Data from PICUs 1 and 2 consisted of
individual-level information and data from PICUs 3 and 4 consisted of aggregate data. At PICU 1, the
insertion and duration of insertion of CVCs were recorded for 6 months between July and December
2009. At PICU 2, the number of CVCs present for each patient was recorded on a daily basis between
December 2005 and March 2012. At PICU 3, the total number of patients admitted and the number of
patients with one or more CVCs was recorded by month between January 2011 and February 2012.
At PICU 4, the total number of patients admitted, the number of patients with one or more CVC and the
total number of CVCs in place were recorded each day between December 2009 and June 2012.
A predictive model for central venous catheter use
Central venous catheter use was identified within the PICANet data set using the PICANet ID and hospital
number from the audit data. Multivariable logistic regression was then used to model the probability of
CVC use dependent on a set of predictors:
log
π i
1−π i
=α + β1xi1+β2xi2+⋯β jxi j=βxi, (3)
where πi is the probability of CVC use for patient i, a is the constant term and β1. . .βj are the set of
predictors. To identify the best-fitting set of predictors, all possible regression models were tested, ranging
from the model including only the intercept to the model including all possible predictor variables. Models
were compared using the BIC.
Evaluating the performance of the predictive model
To quantify the performance of a predictive model, two measures are typically used:83
l discrimination (the ability of predicted probabilities to correctly classify children by CVC use)
l calibration (agreement between observed CVC use and predicted probability of CVC use)
To measure the discrimination of the predictive model, the c-index [equivalent to the area under the
receiver operating characteristic (ROC) curve] was calculated. The c-index corresponds to the chance that
the predicted probability of CVC use in someone who did require a CVC is greater than the predicted
probability of CVC use in someone who did not require a CVC. The greater the c-index, the more
discriminative the model.
To measure the calibration of the predictive model, observed CVC use and predicted probabilities were
compared using the calibration slope (or linear predictor), as described in Steyerberg et al.83 The calibration
slope is the regression coefficient β in the logistic regression of observed CVC use (binary variable) with
predicted CVC use (probability) as the only predictor. Predicted CVC use is calculated as the linear
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combination of regression coefficients as estimated from the predictive model. In a perfectly calibrated
model, the regression coefficient β in the following model would be equal to 1:
Observed CVC use=α+β (predicted CVC use). (4)
By definition, when the model is developed and tested in the same sample, the calibration slope will be
equal to 1. However, when predictive models are tested with new data, the calibration slope is often < 1
as most models provide predictions that are too extreme. The closer the β coefficient to 1, the better the
calibration of the model.
Internal validation
When predictive models are derived and tested within the same sample of data, measures of predictive
ability (e.g. calibration/discrimination) are likely to be overoptimistic. This is because of model overfitting,
in which the ‘apparent’ performance in the model derivation data set is likely to be better than the
performance in a new set of data. Bootstrapping is an approach that addresses this problem and makes
use of all available data, producing more stable results.83,84 The method involves repeatedly sampling from
the original data, a process that simulates sampling from the underlying population from which the
original data were drawn. An estimate of the ‘optimism’ in the predictive ability of the model is made by
comparing model performance in bootstrap samples with ‘apparent’ performance in the derivation sample.
Bootstrapping was used to estimate the optimism in the predictive ability of the model as measured in the
derivation sample of data (i.e. the ‘apparent’ performance in the CVC audit data). The optimism reflects
the difference between model performance in the derivation data set and model performance in a
separate but similar data set drawn from the same underlying population. Optimism was estimated as
the difference between the apparent performance of a model derived in a bootstrap sample and ‘test’
performance when the same model was applied to the derivation sample (CVC audit data).
Finally, apparent model performance (as measured in the derivation sample) was adjusted for optimism/
overfitting by subtracting the estimate of optimism from the measure of predictive ability (calibration slope
or c-index). The resulting measure of performance is said to be ‘internally validated’.85
Choosing a probability cut-off
A probability cut-off is required to classify children as either requiring a CVC or not requiring a CVC.
Higher probability cut-offs result in greater specificity; lower probability cut-offs results in greater sensitivity.
A visualisation of the trade-off between sensitivity and specificity was provided by the ROC curve. Two
main criteria are used for finding the optimal cut-off based on maximising the area under the ROC curve,
and probability cut-offs according to both of these criteria were calculated:86,119
1. the minimum distance criterion assumes that the optimal cut-off minimises the distance between the
point (0,1) and the ROC curve, that is, the minimal value of (17 – sensitivity)2+ (1 – specificity)2
2. the Youden Index criterion assumes that the optimal cut-off maximises the vertical distance between
the ROC curve and the line of equality where sensitivity= 1 – specificity, that is, the maximum value
of sensitivity+ specificity – 1.
External validation
Aggregate CVC audit data from PICUs 3 and 4 were not used for development of the predictive model
(individual-level data were not available) but could provide estimates of the average proportion of children
requiring a CVC in the PICU. To externally validate the predictive model, the actual numbers of admissions
and bed-days with CVCs in the audit data from PICUs 3 and 4 were compared with the results of the
predictive model (with shrinkage factor applied).
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Results
A predictive model for central venous catheter use
The best-fitting model included length of stay, vasoactive agent, admission from ward, renal support and
invasive ventilation. No significant first-order interactions were found. The predicted probability of CVC use
for each admission (πi) was derived from the logistic model:
π i=
eβxi
1+eβxi
, (5)
where βxi was the linear predictor of the BIC model. Model coefficients are provided in Table 37.
Evaluating the performance of the predictive model
Discrimination
The c-index of the predictive model in the original sample was estimated as 0.778. The average c-index in
100 bootstrap samples was 0.778 and, on average, the c-index as measured in the derivation sample
was 0.004 higher than when measured in the test sample. Subtracting this estimate of optimism from
the apparent performance in the derivation sample produced an internally validated c-index of
0.778 – 0.004= 0.774. This indicated that the model performed reasonably well at classifying children as
requiring a CVC.
Calibration
By definition, the calibration slope (β coefficient) for the regression of observed CVC use and predicted
CVC use in the original sample was 1, as the model was developed and tested in the same sample:
Observed CVC use= (2:02×10−9)+1(predicted CVC use). (6)
The average calibration slope in 100 bootstrap samples was 0.967 and, on average, the calibration slope
in the derivation data set was 0.033 higher than when measured in the test data set. Subtracting this
estimate of optimism from the apparent performance in the derivation sample produced an internally
validated calibration slope of 1 – 0.033= 0.967. This indicated close agreement between observed CVC
use and CVC use as predicted in the model.
The coefficients in the original model were multiplied by the shrinkage factor of 0.967 to provide a final
model, adjusted for overfitting.85
Choosing a probability cut-off
The Youden Index indicated that the optimal probability cut-off was 0.57. With this cut-off, the sensitivity
of the predictive model for capturing admissions requiring a CVC was 61%, the specificity was 82%,
the positive predictive value was 82% and the negative predictive value was 61%.
External validation
Compared with the aggregate CVC data, the model predicted that 54.6% and 63.5% of admissions in
the Newcastle PICU and Birmingham PICU, respectively, required a CVC, compared with true values of
49.4% and 54.6% respectively. The predictive model identified 80% of the CATCH admissions as having
a CVC.
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TABLE 36 Survey results on type of CVC used prior to the CATCH trial and percentage of admissions requiring a CVC
PICU trust
Type of CVC used prior to the CATCH
2009 survey Admissions requiring a CVC, 2012 survey
Emergency admissions Elective admissions
Emergency admissions
(%)
Elective admissions
(%)
1 Not surveyed Not surveyed 75 25
2 Standard/heparin Standard/heparin 57 93
3 Not surveyed Not surveyed < 5 < 5
4 Standard/heparin Standard 80 90
5 Standard Standard 85 50
6 Standard Standard No response No response
7 Standard/antibiotic Standard 60–100 60–90
8a Standard Standard 80 80
9a Heparin Heparin 60 30
10 Standard Standard 30 50
11 Standard Standard 50 50
12 Standard Standard No response No response
13 Standard Standard No response No response
14 Standard Standard 75 No response
15 Heparin Heparin 87 18
16 Standard Standard 60 20
17 Standard Standard 70 80
18 Standard Standard No response No response
19 No response No response No response No response
20 Standard Antibiotic 50 50
21 Heparin Standard/heparin 50 30
22a Not surveyed Not surveyed No response No response
23a Not surveyed Not surveyed 60 50
Average 60 50
a No data in linked data set.
Shaded boxes correspond to the 12 NHS trusts participating in the CATCH trial (14 PICUs).
TABLE 37 Independent predictors of CVC use in CVC audit data (basis for the predictive model)
Predictor Odds ratio (95% CI) p-value
Length of stay (hours) 1.003 (1.000 to 1.004) < 0.0001
Vasoactive agent 4.443 (3.600 to 5.513) < 0.0001
Admission from ward 1.428 (1.200 to 1.738) < 0.0001
Renal support 3.952 (2.000 to 7.822) < 0.0001
No ventilation or non-invasive ventilation only 1
Invasive ventilation 2.547 (1.900 to 3.350) < 0.0001
Invasive and non-invasive ventilation 2.278 (1.500 to 3.395) < 0.0001
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TABLE 38 Characteristics of admissions during the 23-month trial period (December 2010–November 2012) in all
PICUs in England
Characteristic
CATCH participantsa
(n= 1398)
Admissions
expected to require
a CVC (n= 20,199)
All admissions
during the trial
period (n= 53,897)
n % n % n %
Length of stay (hours)
1 to < 4 3 0.2 186 0.9 1482 2.7
4 to < 12 18 1.3 438 2.2 3764 7.0
12 to < 24 101 7.2 1699 8.4 9647 17.9
24 to < 48 175 12.5 2959 14.6 10,919 20.3
48+ 1101 78.8 14,917 73.9 28,085 52.1
Age (years)
< 1 815 58.3 11,775 58.3 27,323 50.7
1–4 327 23.4 4473 22.1 13,405 24.9
5–10 144 10.3 2023 10.0 6837 12.7
11–15 112 8.0 1926 9.5 6328 11.7
Unknown 0.0 2 0.0 4 0.0
Vasoactive agents 1054 75.4 17,081 84.6 18,792 34.9
Renal support 148 10.6 1469 7.3 1684 3.1
PIM2
< 1% 150 10.7 1857 9.2 13,855 25.7
1 to < 5% 744 53.2 10,332 51.2 25,840 47.9
5 to < 15% 354 25.3 5472 27.1 10,520 19.5
15 to < 30% 103 7.4 1486 7.4 2290 4.2
30%+ 47 3.4 1052 5.2 1392 2.6
Ventilation status
Neither 33 2.4 442 2.2 12,652 23.5
Non-invasive only 10 0.7 159 0.8 2620 4.9
Invasive only 1017 72.7 16,170 80.1 32,882 61.0
Both 337 24.1 3424 17.0 5625 10.4
Unknown 1 0.1 4 0.0 118 0.2
Type of admission
Planned 572 40.9 9015 44.6 21,844 40.5
Unplanned 826 59.1 11,180 55.3 31,992 59.4
Unknown 0.0 4 0.0 61 0.1
Source of admission
Same hospital 729 52.1 11,713 58.0 32,966 61.2
Other hospital 667 47.7 8374 41.5 20,210 37.5
Unknown 2 0.1 112 0.6 721 1.3
continued
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TABLE 38 Characteristics of admissions during the 23-month trial period (December 2010–November 2012) in all
PICUs in England (continued )
Characteristic
CATCH participantsa
(n= 1398)
Admissions
expected to require
a CVC (n= 20,199)
All admissions
during the trial
period (n= 53,897)
n % n % n %
Primary diagnosis at admission
Cardiac 707 50.6 10,687 52.9 16,818 31.2
Respiratory 273 19.5 3751 18.6 14,295 26.5
Infection 100 7.2 1078 5.3 2333 4.3
Other 318 22.7 4683 23.2 20,451 37.9
Care area of admission
A&E 242 17.3 2379 11.8 9422 17.5
HDU 72 5.2 878 4.3 2410 4.5
ICU/PICU/NICU 222 15.9 3802 18.8 8112 15.1
Other intermediate
care area
8 0.6 466 2.3 1315 2.4
Recovery only 3 0.2 39 0.2 155 0.3
Theatre and recovery 565 40.4 8422 41.7 20,566 38.2
Unknown 9 0.6 165 0.8 919 1.7
Ward 273 19.5 3889 19.3 10,417 19.3
Radiography/
endoscopy/CT
4 0.3 159 0.8 581 1.1
Retrieval, yes 596 42.6 7464 37.0 18,230 33.8
Retrieval team
Non-specialist team 19 1.4 721 3.6 2031 3.8
Other specialist team 306 21.9 4358 21.6 9681 18.0
Own team 263 18.8 2339 11.6 6388 11.9
Unknown 8 0.6 46 0.2 130 0.2
Sex
Male 811 58.0 11,363 56.3 30,428 56.5
Female 587 42.0 8830 43.7 23,449 43.5
Unknown 0.0 6 0.0 20 0.0
PICU type
General 59 4.2 2831 14.0 15,828 29.4
Mixed 1286 92.0 16,997 84.1 37,386 69.4
Cardiac 53 3.8 371 1.8 683 1.3
PICU size (admissions per year)
< 650 59 4.2 2373 11.7 14,255 26.4
650–1000 620 44.3 3227 16.0 8731 16.2
> 1000 719 51.4 14,599 72.3 30,911 57.4
CT, computerised tomography.
a Consenting to linkage with the PICANet data set.
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Appendix 5 Statistical analysis report
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Due to the nature of the trial, information could not be collected regarding eligible emergency participants who were not 
randomised.  
No patients were withdrawn after randomisation 
502 allocated to Standard: 
 
Received allocated CVC            
                                           468   
Received other CVC: 
    Heparin                           12 
    Antibiotic                           1 
 
Did not receive a CVC:  
    insertion attempted         15 
    not attempted                   6 
486 allocated to Antibiotic: 
 
Received allocated CVC               
                                            437   
Received other CVC: 
     Standard                          23 
     Heparin                              5 
 
Did not receive a CVC:  
     insertion attempted          14 
     not attempted                    7 
497 allocated to Heparin: 
 
Received allocated CVC          
                                        440  
Received other CVC: 
    Standard                      22 
    Antibiotic                        2 
 
Did not receive a CVC: 
    insertion attempted        24 
    not attempted                  9 
1859 randomised  
(501 prospective consent 
and 1358 deferred consent) 
374 deferred consent not obtained:        
                                       St (122)      An (126)      He (126) 
Received allocated CVC        90               89                 92 
Received other CVC           7              8                 12 
Did not receive a CVC:       
   insertion attempted             13                21               13 
    not attempted         10                  6                 8 
    missing                        2                  2           1 
Randomised 
Allocation 
Blood cultures 
≥ 1 sample taken               415 
 
Clinically indicated and in 
primary outcome time window    
                                          213 
 
Blood cultures 
 
≥ 1 sample taken               389 
 
Clinically indicated and in 
primary outcome time window      
                                           190 
Blood cultures 
 
≥ 1 sample taken             412 
 
Clinically indicated and in 
primary outcome time 
window                            190 
Unblinded              1 
Reason: safety concern 
Unblinded               1 
Reason: safety concern 
Unblinded                2 
Reasons:To determine eligibility 
for another trial & in error, not 
related to treatment of patient 
Analysis 
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169 allocated to Standard: 
 
Received allocated CVC  167      
 
Received other CVC       0       
 
 
 
Did not receive a CVC:  
    insertion attempted          0      
    not attempted          2       
166 allocated to Antibiotic: 
 
Received allocated CVC    149     
 
Received other CVC: 
    Standard        13 
    Heparin          2      
 
Did not receive a CVC:  
    insertion attempted           0      
    not attempted                  2      
166 allocated to Heparin:
 
Received allocated CVC  151  
 
Received other CVC: 
    Standard       10 
    Antibiotic         1  
 
Did not receive a CVC: 
    insertion attempted         1   
    not attempted                  3   
501 randomised  
Randomised 
Allocation 
Blood cultures 
 
≥ 1 sample taken            134  
 
Clinically indicated and in 
primary outcome time 
window   69 
                                           
Blood cultures 
 
≥ 1 sample taken        128       
 
Clinically indicated and in 
primary outcome time 
window  43    
                                           
Blood cultures 
 
≥ 1 sample taken      136      
 
Clinically indicated and in 
primary outcome time 
window   51 
Unblinded       0        Unblinded        0                 Unblinded    0        
Analysis 
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333 allocated to Standard: 
 
Received allocated CVC    301    
 
Received other CVC:  
    Heparin         12 
    Antibiotic                1 
                 
 
Did not receive a CVC:  
    insertion attempted           15   
    not attempted                     4    
320 allocated to Antibiotic: 
 
Received allocated CVC     288  
 
Received other CVC:  
    Standard          10 
    Heparin           3     
 
 
Did not receive a CVC:  
    insertion attempted            14   
    not attempted                      5    
331 allocated to Heparin: 
 
Received allocated CVC  289    
 
Received other CVC: 
    Standard       12   
    Antibiotic         1    
 
 
Did not receive a CVC: 
    insertion attempted         23   
    not attempted                 6     
1358 randomised  
374 deferred consent not obtained:        
                                       St (122)      An (126)      He (126) 
Received allocated CVC        90                89                92 
Received other CVC           7               8                12
  
Did not receive a CVC:       
insertion attempted                13             21               13 
not attempted          10               6                  8 
missing             2             2           1 
Randomised 
Allocation 
Blood cultures 
 
≥ 1 sample taken               281 
 
Clinically indicated and in 
primary outcome time window 
144   
Blood cultures 
 
≥ 1 sample taken     261           
 
Clinically indicated and in 
primary outcome time window  
147  
Blood cultures 
 
≥ 1 sample taken           276     
Clinically indicated and in 
primary outcome time 
window   139 
Unblinded          1     
Reason: safety concern
Unblinded         1  
Reason: safety concern
             Unblinded     2  
Reasons:To determine eligibility 
for another trial & in error, not 
related to treatment of patient 
Analysis 
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1 Randomisation checking 
Checks to be conducted  
Randomisation numbers are sequential by date randomised  
No missing randomisation numbers  
Treatments balanced across strata where required  
Site Randomisation numbers not used N Reason 
Leeds General 
Infirmary 
0030-1-2-020  
 
1 Patient was randomised 
and the CVC was not 
inserted. CRF’s were not 
completed.  The patient 
was re-randomised (0030-
1-2-024). 
Leicester Royal 
Infirmary 
0031-1-1-014 1 File note to state that 
envelope was missing or 
opened in error 
Southampton 
General Hospital 
0114-1-1-024 1 File note to state that 
envelope was missing or 
opened in error 
Bristol Royal 
Hospital for Children 
0116-1-1-060 1 File note to state that 
envelope was missing or 
opened in error 
Nottingham General 
Hospital 
0213-1-1-009 1 File note to state that 
envelope was missing or 
opened in error 
St Mary’s Hospital 
London 
0214-1-1-028, 0214-1-1-038 2 File note to state that 
envelope was missing or 
opened in error 
Alder Hey Children’s 
Hospital 
0243-1-1-044, 0243-1-2-004, 0243-1-2-017, 
0243-1-2-019 
4 File note to state that 
envelope was missing or 
opened in error 
Great Ormond Street 
Hospital for Sick 
Children PICU/CICU 
0249-1-5-048, 0249-1-5-167, 0249-1-5-239, 
0249-1-5-259, 0249-1-5-295 
5 File note to state that 
envelope was missing or 
opened in error 
Evelina (Guy’s & St. 
Thomas’s) 
5840-1-1-056, 5840-1-1-108, 5840-1-1-111, 
5840-1-1-123 
4 File note to state that 
envelope was missing or 
opened in error 
Great Ormond Street 
Hospital for Sick 
Children Childrens' 
Acute Transport 
Service 
7470-1-6-200  1  No file note 
7470-1-6-026, 7470-1-6-037, 7470-1-6-040, 
7470-1-6-087, 7470-1-6-120,  7470-1-6-150, 
7470-1-6-152, 7470-1-6-158, 7470-1-6-160, 
7470-1-6-167, 7470-1-6-176, 7470-1-6-187 
12 File note to state that 
envelope was missing or 
opened in error 
Birmingham 
Children’s Hospital 
0133-1-2-001, 0133-1-2-002, 0133-1-2-003, 
0133-1-2-004, 0133-1-2-005, 0133-1-2-006, 
0133-1-2-007, 0133-1-2-008, 0133-1-2-009, 
0133-1-2-010, 0133-1-2-011, 0133-1-2-012, 
0133-1-2-013, 0133-1-2-014, 0133-1-2-015, 
0133-1-2-016, 0133-1-2-017, 0133-1-2-018, 
0133-1-2-019, 0133-1-2-020 
20 Incorrect batch of 
envelopes sent to site, 
0133/1/2/001 - 
0133/1/2/020 never sent 
0133-0-1-034, 0133-1-1-064 2 File note to state that 
envelope was missing or 
opened in error 
Total 55 
Site Randomisation numbers used out of N Reason 
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sequence* 
Great Ormond Street 
Hospital for Sick 
Children PICU/CICU 
0249-1-5-237 1 File not states missing 
rather than out of 
sequence 
0249-1-5-070, 0249-1-5-074, 0249-1-5-146, 
0249-1-5-238, 0249-1-5-147, 0249-1-5-280, 
0249-1-5-299 
7 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
Southampton 
General Hospital 
0114-0-1-101, 0114-1-1-007, 0114-1-1-008, 
0114-1-1-031, 0114-1-1-032, 0114-1-1-060, 
0114-1-1-063 
7 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
Bristol Royal 
Hospital for Children 
0116-1-1-010, 0116-1-1-011, 0116-1-1-014, 
0116-1-1-015, 0116-1-1-026, 0116-1-1-027, 
0116-1-1-038, 0116-1-1-043, 0116-1-1-044, 
0116-1-1-049, 0116-1-1-050 
11 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
Birmingham 
Children’s Hospital 
0133-1-1-103, 0133-1-1-104, 0133-1-1-109, 
0133-1-1-110, 0133-1-1-112, 0133-1-1-113  
6 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
Royal Brompton 
Hospital 
0211-1-1-008, 0211-1-1-009 2 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
Nottingham General 
Hospital 
0213-1-1-020, 0213-1-1-021, 0213-1-1-029, 
0213-1-1-030 
4 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
St Mary’s Hospital 
London 
0214-1-1-011, 0214-1-1-012, 0214-1-1-013, 
0214-1-1-042 
4 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
Evelina (Guy’s & St. 
Thomas’s) 
5840-1-1-013, 5840-1-1-014, 5840-1-1-033, 
5840-1-1-088, 5840-1-1-089, 5840-1-1-091, 
5840-1-1-105, 5840-1-1-106, 5840-1-1-127, 
5840-1-1-131, 5840-1-1-139, 5840-1-1-144, 
5840-1-1-146 
13 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
Alder Hey Children’s 
Hospital 
0243-0-1-010 1 Due to the partial date and 
time indicated in 0243-0-1-
010 patients notes this is 
why it looks out of 
sequence  
0243-0-1-009, 0243-0-1-026, 0243-0-1-044, 
0243-1-2-003, 0243-1-2-005, 0243-1-2-006, 
0243-1-2-010, 0243-1-2-011, 0243-1-2-012, 
0243-1-2-013, 0243-1-2-014 
11 File note received from site 
indicating they were used 
out of sequence.  Training 
needs discussed 
Total 67 
*CATS patients have not been listed here. They are randomised out of sequence due to the way the 
retrieval teams go out to a patient and take an envelope which may not be used while another team go 
out and take the next in sequence
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Resistance to minocycline or rifampicin of blood culture or CVC tip isolates 
Samples taken between randomisation and 48 hours after removal are included in this table. Testing 
for antibiotic resistance varied by centre. Only 12 (13 organisms) of the 42 children with the primary 
outcome had minocycline and rifampicin resistance reported using etest strips; 8/12 were resistant, in 
each case to both antibiotics (3/5 standard; 2/2 antibiotic; 3/5 heparin). Resistant organisms by trial 
arm are provided in Table.
Table 51: Resistance to minocycline or rifampicin of blood culture by CVC allocation 
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Organisms resistant to Minocycline and Rifampicin 
Standard 
• Colifom bacilli  
• Colifom bacilli  
• Coag Neg Staph    (Rifampicin only) 
• Coag Neg Staph    
• Enterococcus faecalis 
• Coagulase (Rifampicin only)  
• S. epi (Rifampicin only) 
• Mixed coagulase negative Staphylococci (Rifampicin only) 
• Enterococcus (minocycline only) 
• S. viridans (minocycline only) 
• Coagulase (Rifampicin only)  
• P.aeruginosa (Rifampicin only)  
• S.marcescens 
 
 
Antibiotic 
• Staph 
• E. coli   
• Enterococcus sp,Mixed coagulase negative Staphylococci (Rifampicin only)  
• Mixed coagulase negative Staphylococci (Rifampicin only) 
• Mixed coagulase negative Staphylococci,Enterococcus sp,Pseudomonas aeruginosa 
(Rifampicin only) 
• Coag Neg Staph. 2 (Rifampicin only), Enterococcus (minocycline only) 
• Enterococcus (minocycline only) 
• Coag Neg Staph. (Rifampicin only) 
• E.cloacae 
 
Heparin 
• Klebsiella pneumonia 
• Enterococcus hirae (minocycline only), Enterococcus faecalis and CNS (Rifampicin only) 
• K Pneumoniae & Ent Cloacae 
• Coag Neg Staph    (Rifampicin only)  
• Coag Neg Staph    (Rifampicin only)  
• Pseudomonas aeruginosa 
• Klebsiella spp 
• Mixed coagulase negative Staphylococci (Rifampicin only) 
• Coagulase negative Staphylococcus (minocycline only) 
• Staphylococcus capitis (minocycline only) 
• Enterococcus, P.aeruginosa, Coag Neg Staph. (Rifampicin only) 
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3.5.8 Unexplained thrombocytopenia after insertion of CVC- detected by routine 
laboratory monitoring 
There were two occurrences of unexplained thrombocytopenia which were recorded as adverse 
events and are included in the adverse event table (Section 0). 
 
3.5.9 Time to randomised CVC removal 
Table 52: Time to randomised CVC removal
Analysis Treatment Number 
randomised 
Number of participants 
with a successful CVC 
insertion 
Hazard ratio (95% 
confidence interval) 
p-
value 
Baseline comparator: standard 
- Standard 502 481 - - 
Primary Antibiotic or 
Heparin 
983 929 1.04 (0.93, 1.16) 0.53 
Secondary Antibiotic 486 465 1.02 (0.90, 1.17) 0.67 
Secondary Heparin 497 464 1.05 (0.92, 1.19) 0.51 
Baseline comparator: heparin 
Secondary Antibiotic 486 465 0.99 (0.87, 1.13) 0.87 
25 patients did not have a CVC removal date, of these, 16 had died and the line was left in and 9 
were transferred.   These dates were used in the analysis and patients were censored at these dates. 
Table 53: Length of CVC insertion (post hoc) 
Treatment Number 
randomised 
Number of participants with a 
successful CVC insertion 
Length of CVC insertion in 
days, Median (IQR) 
Standard 502 481 4.28 (2.30, 6.97) 
Antibiotic or 
Heparin 
983 929 4.25 (2.19, 6.97) 
Antibiotic 486 465 4.31 (2.13, 7.0) 
Heparin 497 464 4.20 (2.24, 6.97) 
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